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Allergic asthma is a chronic inflammatory disease of the lung. It is thought 
to arise as a result of aberrant type-2 immune responses to environmental allergens 
in susceptible individuals. Among the allergens, sensitization to house dust mite 
(HDM) is one of the major risk factors for the onset of asthma. However, the 
mechanisms driving the initiation of such inappropriate type-2 immune responses 
following allergen exposure remain unclear. Recent studies have shown that the 
release of the cytokine interleukin 33 (IL-33) from airway epithelial cells following 
allergen recognition by pattern recognition receptors (PRRs) expressed on these 
cells dictates the nature and magnitude of the immune responses. However, the 
allergen-induced signals regulating the release of IL-33 remain to be fully 
established. Based on recent evidence that asthma is associated with increased 
glycolysis activity in the lungs, we hypothesized that HDM exposure induces 
increased glycolysis in airway epithelial cells, facilitating the secretion of IL-33 and 
allergic airway responses. We report for the first time that HDM induces immediate 
increases in glycolytic flux in airway epithelial cells that is associated with the early 
release of IL-33. Mechanistically, we confirm that HDM-induced IL-33 release is 
mediated by cytoskeletal rearrangement, which results in rapid deprivation of 
intracellular ATP. Such energy deprivation leads to activation of the homeostasis 
regulator AMP-activated protein kinase (AMPK), resulting in increased glycolysis 
and production of glycolytic ATP that in turn, facilitates the translocation of IL-33 to 





abrogates HDM-induced allergic airway responses likely via inhibition of IL-33 
release, which in turns inhibits type-2 cytokine IL-13 production from its potent 
early innate source, type-2 innate lymphoid cells (ILC2s). 
  Collectively, these results suggest that allergic asthma may arise due to 
allergen-driven changes in airway epithelial cell metabolism that facilitates early, 
immediate release of IL-33 and the initiation of type-2 inflammation through 
recruitment and activation of ILC2s. Prevention of allergen-driven metabolic 
changes in the airway epithelium may provide a means to mitigate the initiation of 
type-2 immune response-mediated inflammation and the onset of asthma, offering a 
promising new therapeutic avenue for combating this disease. 
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Chapter 1: Introduction and background 
 
1.1  Asthma 
1.1.1 Disease characteristics 
1.1.1.1 Definition 
The Global Initiative for Asthma (GINA) characterizes asthma as “chronic 
airway inflammation and a history of respiratory symptoms such as wheeze, 
shortness of breath, chest tightness, and cough that vary over time and in intensity, 
together with variable expiratory airflow limitation” (GINA, 2015) [1]. Clinically, this 
disease is commonly defined by the presence of reversible airflow obstruction, 
airway hyperresponsiveness (AHR), and airway inflammation [2]. It is believed that 
the pathological outcomes of asthma arise as a result of underlying inflammation of 
the airways caused by inappropriate immune responses to common allergenic 
stimuli in genetically susceptible individuals [3]. Asthma is also recognized as a 
complex disease varying in clinical manifestation, severity, the degree of 
reversibility, and the responsiveness to current therapies [4].  
 
1.1.1.2 Prevalence and public health impact 
Asthma is a common global public health problem. The World Health 
Organization (WHO) estimated that, conservatively as many as 300 million people of 
all ages and ethnic backgrounds were suffering from asthma by the year 2006 [5]. In 





increased in parallel with an increase in atopic sensitization [6]. It is estimated that 
an additional 100 million people will be diagnosed with asthma by 2025 [6]. 
Asthma prevalence in the United States (U.S.A.) has also rapidly increased 
over the last few decades. According to the Centers for Disease Control and 
Prevention (CDC), asthma prevalence increased from 3.1% in 1980 to 5.5% in 1996 
and 7.3% in 2001 (20.3 million persons diagnosed). However, it increased to 8.2% 
(24.6 million persons diagnosed) in 2009, representing an increase of 12.3% in 
those eight years alone. Among those individuals affected by this disease, the 
prevalence among children (aged under 18 years) was highest compared to other 
age groups and reached 9.6% in 2009 [7]. A more recent report from the CDC noted 
that 13% of adults aged 18 and over were diagnosed with asthma in 2012 [8]. 
Significant health disparities associated with socioeconomic and racial status were 
observed, as women, minorities, and those unemployed or living below the poverty 
line were more affected [7, 8]. 
Asthma has caused great economic burden to the society as well. It resulted 
in a total indirect cost (e.g., productivity loss) of $8.2 billion and a total direct cost of 
$7 billion (e.g., hospital admission) in 1997 in the US [9]. A recent CDC report 
suggested that the financial burden of disease reached $56 billion in 2009, with an 
annual increase of $1.5 billion [10]. Thus, asthma remains a major public health 
concern, resulting in an urgent need for the development of more effective 
prevention and control approaches. 
 





(1) Genetic susceptibility 
Although asthma is known as a heterogeneous disorder of unknown 
etiology [3], susceptibility to asthma is thought to result from the interaction 
between intrinsic genetic predisposition and extrinsic environmental factors [11]. 
Children whose parents have atopic diseases are more likely to develop allergic 
asthma [12, 13], indicating a heritable component of the disease. This hypothesis is 
further supported by multiple twin studies showing that there is a significant 
concordance in monozygotic twins as compared with dizygotic twins [14-16]. 
There have been numerous studies focusing on identifying genetic risk 
factors for allergic asthma utilizing genome-wide approaches and candidate gene 
association studies [17]. In early genome-wide linkage studies of asthma, more than 
20 distinct chromosomal regions were implicated in susceptibility to a diagnosis of 
asthma or the related traits (See review in [17]). Collectively, these previous studies 
suggested that certain chromosomal regions such as 2p (cytotoxic T-lymphocyte-
associated protein 4 (CTLA4)), 5q23-31 (cytokine gene cluster, cluster of 
differentiation 14 (CD14), B-adrenergic receptor), 6p24-21 (the major 
histocompatibility complex (MHC)), 11q13-21 (near the B chain of the high affinity 
receptor for IgE), 12q21-24 (stem cell factor (SCF), interferon-γ, and signal 
transducer and activator of transcription-6 (Stat6), etc.) might harbor asthma 
susceptibility genes [17]. The application of advanced genome-wide association 
studies (GWAS) has allowed more comprehensive discoveries of asthma 
susceptibility genes. For example, a large scale GWAS in Europeans (GABRIEL 





significantly associated with allergic asthma [18]. Another recent meta-analysis of 
GWAS datasets (EVE Consortium) showed that four loci within/near IL1RL1, TSLP 
and IL33, and one locus within PYHIN1 were significantly associated with allergic 
asthma across various ethnic populations [19]. 
In addition to the genome-wide analyses, candidate gene studies account for 
the majority of genetic identifications for asthma determinants. These studies test 
whether the frequencies of particular specific genetic variants are more prevalent in 
asthmatic patients (cases) than in healthy individuals (controls) [17]. These genetic 
variants were mainly selected based on prior hypothesis-driven studies that sought 
to identify an association between variants in pathways influencing allergic asthma 
or relevant phenotypes [20]. It was concluded that most allergic asthma risk genes 
were involved in innate immunity and antigen presentation, Th2 polarization, and 
epithelial cell function (see review in [20]). 
(2) Allergens. 
The generational interval necessary to introduce a genetic predisposition to 
allergic asthma, along with lack of 100% concordance in twin studies suggest that 
the recent rise in asthma prevelance cannot be exaplined by genetics alone, and that, 
environmental factors play significant roles in the development of allergic asthma as 
well. In fact, environmental factors such as allergens [21], pollutants [22] and 
viruses [23] have been reported to play pivotal roles in asthma and allergy. Among 
these factors, allergic asthma is more likely induced by allergens [24], and it is 
believed that exposure of genetically predisposed individuals to environmental 





Allergens are derived from a variety of sources including plants, insects, 
fungi, mold, and mammals [26]. Among different allergens, aeroallergens derived 
from the house dust mite (HDM) are known to be powerful inducers of allergic 
responses in children [27]. Epidemiological studies have shown that at least 60% of 
asthmatics are sensitized to HDM [28], and this number is closer to 80% among 
children [29]. Further prospective cohort population studies [30] and data derived 
from experimental murine models [31] have confirmed that HDM exposure is 
sufficient to induce the onset of allergic asthma. Although it is widely accepted that 
environmental exposures lead to dysregulated immune responses and subsequent 
pathological changes in the host, the underlying mechanisms by which 
environmental factors such as allergens induce allergic airway responses are not 
well understood [32].  
 
1.1.2 Pathophysiology 
  Patients with allergic asthma (i.e., the most common form of asthma) 
generally have higher levels of circulating IgE antibody and are skin test positive to 
common allergens. Such IgE antibody is produced via a tightly regulated, complex 
network of cellular and molecular events necessary for the development of asthma 
pathophysiological manifestations. Specifically, it was reported that during an 
asthma attack, the presence of inflammatory cells in the bronchoalveolar lavage 
(BAL), sputum and lung biopsies is normally observed [33-35]. Thus, it is believed 
that inflammation is probably one major underlying cause of allergic asthma. 





that in susceptible individuals, airway inflammation arises due to inappropriate 
immune responses to common aeroallergens following recognition and 
presentation of antigens by airway epithelium and antigen presenting cells (APC) to 
CD4+ T cells in the draining lymph nodes. These allergen specific T cells polarize to 
a T helper (Th) 2 phenotype and produce the Th2 associated cytokines IL-4, IL-5 
and IL-13. Collectively, these cytokines activate a series of events leading to IgE 
antibody production as well as recruitment and activation of a variety of 
downstream effector cells such as eosinophils, mast cells, and basophils [36]. Upon 
re-exposure to sensitizing allergens, sensitized individuals develop both early and 
late phase responses [37]. During an early phase response, allergens crosslink with 
IgE and induce mediator release from mast cells that result in bronchoconstriction 
and edema [38], while eosinophils and lymphocytes dominate the late phase allergic 
responses [39]. Continued chronic exposure to allergens results in the migration of 
inflammatory cells into local tissues, and pathological structural and functional 
changes such as fibrosis, goblet cell hyperplasia, excessive mucus production, as 
well as smooth muscle cell layer thickening and contraction are observed in the 
airways [40] (Fig.1).  
 
1.1.2.1 Cellular inflammatory responses in allergic asthma 
As previously mentioned, inflammatory cell infiltration of the lung is a 
major hallmark of asthma pathology. Cells that infiltrate the airways of asthmatic 
individuals include eosinophils, mast cells, and basophils [41]. These cells are 





in the bone marrow [42, 43]. Following allergen exposure, cytokines and 
chemokines are produced locally in the lung, which recruit these cells and initiate 
allergic responses.  
(1) Eosinophil 
Eosinophils are multifunctional leukocytes involved in initiation and 
progression of diverse inflammatory responses including parasitic infection and 
allergic responses [44]. They are granulocytes that develop in the bone marrow and 
are released into the peripheral blood in their mature state, and they can be 
activated and recruited into local tissues by appropriate stimuli such as the cytokine 
IL-5 [45]. Human eosinophil granules contain proteins including eosinophil 
peroxidase, major basic protein (MBP), ribonucleases and eosinophil-derived 
neurotoxins. The granules also store numerous cytokines, enzymes and growth 
factors [45]. In allergic asthma, eosinophils undergo degranulation and release these 
proteins that cause epithelial cell damage, inflammation and airway remodeling 
[46]. It was also reported that activated eosinophils release reactive oxygen species 
[47] and important lipid inflammatory mediators including leukotrienes, 
prostaglandins, and thromboxanes [48, 49]. These mediators are shown to recruit 
and activate other inflammatory leukocytes like T cells and monocytes [50], 
resulting in vascular edema [51], smooth muscle contraction [52], and AHR [53]. 
Eosinophil infiltration to the airway is one of the first noted pathological 
changes in the asthmatics [54]. As the most predominant inflammatory cell involved 
in allergic asthma, eosinophils are observed in the peripheral blood or BAL among 





inflammation is correlated with asthma severity and a decline in pulmonary 
function [56]. Eosinophilic inflammation in clinical practice is also a reliable 
indicator of those patients who will benefit from treatment with inhaled 
corticosteroids. It was observed that asthmatics with eosinophilic inflammation 
respond better to steroids compared to those with non-eosinophilic inflammation 
[57]. However, the causal relationship between eosinophils and allergic asthma is 
conflicting. Studies using several approaches to suppress eosinophils including 
antibody against CCR3 (a chemokine receptor whose ligands are specific for 
eosinophils) for ablation of eosinophils in mice [58], IL-5 deficient mice [59] and 
eosinophil deficient mice [60, 61] have shown remarkable reductions in allergic 
inflammation and airway remodeling, but not complete inhibition. Overall, as one of 
the most important leukocytes in allergic asthma pathogenesis, eosinophils 
contribute to the disease progression, however, blockade of eosinophils may not be 
sufficient to improve disease outcome. 
(2) Mast cell and basophil 
Mast cells and basophils are important leukocytes in allergic inflammation. 
Mast cells are tissue-based inflammatory cells of hematopoietic origin [42], and 
basophils are basophilic granulocytes circulating in the peripheral blood [62]. While 
these cells differ in many aspects, they also share several similarities, including 
expression of the high-affinity IgE receptor FcεRI on their surface, and the release of 
inflammatory mediators such as leukotriene and histamine in response to various 





Both mast cells and basophils are reported to contribute to allergic asthma 
[64, 65]. In asthmatics, they are activated by IgE antibody crosslinking of their high 
affinity IgE receptor upon allergen re-exposure, leading to degranulation of these 
cells and release of inflammatory mediators such as tryptase, chymase, 
carboxypeptidase A, histamine, prostaglandins, and leukotrienes [66-68]. As 
previously discussed, these mediators result in vascular edema, smooth muscle 
contraction, and AHR. Other than releasing these mediators, both mast cells and 
basophils are also known to contribute to the development of Th2 immune 
responses. It was reported that mast cell derived tumor necrosis factors (TNF) may 
enhance cytokine production by Th2 cells [69], and basophils were noted in 
multiple studies for their capability to secrete large amounts of IL-4 and IL-13 after 
FcɛR1 crosslinking [70-73]. 
Although both mast cells and basophils are present during allergic 
inflammation, studies using in vivo mouse models devoid of mast cells indicate that 
these cells are not sufficient to drive asthma pathogenesis [74-77]. 
(2) Neutrophil 
Neutrophils are known as the first responders to inflammatory stimuli such 
as bacterial infections [78]. However, their role in asthma is not clear. Excessive 
neutrophils in the airway have been reported in certain asthmatics as early as 1986 
[79]. This type of asthma was referred to as non-eosinophilic asthma, a subtype of 
the disease based on neutrophilic airway inflammation, possibly triggered by 
exposure to bacterial endotoxin, air pollutants, and ozone, as well as viral infections 





positively correlated with asthma severity [81, 82]. This non-eosinophilic asthma is 
often associated with a Th17 immune response rather than classical Th2 immunity 
[83, 84]. These patients exhibit significant resistance to corticosteroid treatment 
[84, 85]. 
The mechanisms by which neutrophils are recruited to the airways during 
allergic inflammation and the mechanisms by which they may induce the symptoms 
of asthma are not clear. Earlier studies suggest that neutrophilic inflammation is 
likely mediated by IL-8 [80], IL-1β, TNF-α, and leukotriene B4 [86]. Recent evidence 
shows that IL-17A is an important regulator of neutrophil recruitment, which might 
provide a mechanism for the recruitment of neutrophils in severe asthmatics [87]. 
  Neutrophils are known to release cytotoxic mediators and proteolytic 
enzymes that contribute to inflammation and tissue remodeling [88]. Neutrophils 
may also contribute to the processing of interleukin 33 (IL-33), a major epithelial 
cytokine mediating the pathogenesis of allergic asthma [89]. In summary, 
neutrophils are likely to play an important role in certain aspects of asthma, but 
their exact role in asthma is yet to be determined. 
 
1.1.2.2 Lung function alterations in allergic asthma 
(1) Airway hyperresponsiveness (AHR) and lung function 
The most common clinical manifestations of allergic asthma are increased 
airway reactivity to bronchoconstrictor stimuli and decreased lung function. AHR is 
defined as the excessive response of the airway to a variety of stimuli such as 





AHR by different stimuli may differ, but also share common pathways. For example, 
methacholine is known to bind and activate cholinergic receptors expressed by 
airway smooth muscle cells, resulting in airway smooth muscle contraction [91]. 
Other stimuli such as cold air and exercise have been observed to cause AHR [92].  
Together with AHR, a decline in lung function (FEV1/FVC) due to airway 
obstruction has also been observed in allergic airway response. The most common 
approach of measuring lung function is using spirometry to determine the forced 
expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) [93]. In an 
earlier study examining lung physiology of asthmatic patients, the mechanical 
function of the lung assessed with this approach showed a 50% to 60% reduction of 
predicted normal values due to persistent airflow obstruction in asthmatic 
peripheral airways [94]. With this observation, lung function measurement has been 
used as a clinical indicator for asthma, and a FEV1/FVC ratio less than 70% is 
considered an indicator of airway obstruction. Generally, both methacholine 
challenge test (AHR) and FEV1/FVC measurements (airway obstruction) are utilized 
in the clinical diagnosis of asthma. 
(2) Airway remodeling 
Besides the functional changes of the airways observed in asthmatics, 
structural alterations in the lung are also common in asthma patients [95]. The 
pathological changes reflecting airway remodeling, especially the altered bronchial 
epithelial barrier, were first described nearly 100 years ago [54]. In general, airway 
remodeling has been extensively studied and defined by series of structural cell and 





thickening, increased smooth muscle mass, mucus metaplasia, and subepithelial 
fibrosis [95].  
Airway wall thickening is one of the most obvious pathological observations 
reported in almost all patients with asthma [96, 97]. However, it differs in fatal and 
non-fatal asthmatics: the airway thickening is most marked in the small 
cartilaginous and large membranous airways in fatal asthma, while it occurs more 
frequently in small membranous airways and mid-sized airways in non-fatal asthma 
[98]. The level of thickness was also found to be associated with the severity of the 
disease [96].  
Airway thickening is due to several features including an increase in airway 
smooth muscle, edema, inflammatory cell infiltration, glandular hypertrophy and 
connective tissue deposition [95]. Airway thickening enhances airway lumen 
narrowing [97], and more importantly, it may uncouple the airway from the 
distending and tethering forces of surrounding lung parenchyma, leading to greater 
smooth muscle contraction and AHR [99]. As a main contributor to AHR, airway 
smooth muscle has been reported to undergo hypertrophy in asthmatics [100]. 
There are also studies speculating that the sensitivity of smooth muscle cells to 
contractile mediators might be higher in asthmatic patients [101].  
Excessive mucus production by goblet cells is another important 
manifestation of asthma attacks [102]. Mucus is secreted by goblet cells in the 
airway epithelium and plays an important role in host defense [103]. However, in 
the remodeled airways of asthmatics, the mucus occupies a large percentage of the 





[102]. Studies have also shown that the area of mucous glands is increased in 
asthmatics [104]. Increases in mucus viscosity can also increase the surface tension 
at the air-liquid interface of the airways, thereby adding to the forces that tend to 
constrict the airways [105].  
Increased deposition of extracellular matrix proteins such as collagen I, III, 
V, and fibronectin, referred to as subepithelial fibrosis, has been shown in 
asthmatics [106]. Subepithelial fibrosis is associated with a decline in FEV1 [107],  
increased sensitivity to methacholine challenge [108, 109], and correlates with 
disease severity. However, subepithelial fibrosis was reported to be protective in 
some patients with severe asthma [110] probably due to its mechanical protection 
against smooth muscle contraction by providing adverse parenchymal pressure 
[105]. This indicates that the role of subepithelial fibrosis in asthma is more 
complicated than originally hypothesized. 
In conclusion, although the exact mechanisms underlying asthma are not 
well understood, airway remodeling likely contributes to the airway narrowing 
observed during asthma attacks and exacerbations. Such constriction can be 
induced by neuro-transmitters such as acetylcholine from parasympathetic nerves 
[111], inflammatory mediators like histamine and leukotrienes from mast cells [65] 
and basophils [112], or by T cell cytokines such as IL-13 [113].  
 
1.2  Immune responses in allergic asthma  





Allergic asthma is thought to arise as a result of inappropriate immune 
responses to inhaled aeroallergens in susceptible hosts, and aberrant T cell 
responses are observed in asthmatic patients [3]. In particular, CD4+ T cells which 
orchestrate specific immune responses are thought to play an important role in 
asthma [114].  
T cells originate from the bone marrow and are derived from T-lymphoid 
progenitor cells in the thymus through highly regulated subsequent differentiation 
processes [115]. These differentiation processes yield T cells expressing CD4 and 
CD8 on their surfaces [115, 116]. CD8+ T cells are primarily involved in the 
recognition and clearance of pathogens [117], but their roles in allergic asthma are 
rather controversial as studies have reported both protective [118] and pathogenic 
[119] outcomes after CD8+ T cell depletion.  
Despite the unclear roles of CD8+ T cells in allergic asthma, CD4+ T cells are 
known to play a major role in the pathogenesis of allergic asthma. They were first 
shown to be elevated in acute severe asthmatics. Significantly increased expression 
of activated CD4+ T cell surface proteins (interleukin-2 receptor, class II 
histocompatibility antigen, and "very late activation" antigen) was observed in the 
serum of asthmatics compared to healthy individuals, which is decreased in patients 
with improved symptoms after treatment [120, 121]. The numbers of CD4+ T cells 
in BAL fluids and bronchial biopsies are increased in asthmatics as compared to 
healthy individuals [3, 122-124]. Also, CD4+ T cells are actively recruited to the 
airways following allergen challenge as a simultaneous drop in their number is 





asthmatics, depletion of CD4+ T cells with anti-CD4 antibody prior to antigen 
sensitization and challenge resulted in diminished allergic airway responses in mice 
[126]. Taken together these data supports a role for CD4+ T cells in disease 
pathogenesis. 
CD4+ T cells are characterized by their distinct abilities to produce 
cytokines and function in the control of specific pathogens or immune responses. It 
is concluded that: Th1 cells are programmed through the transcription factor, T-bet. 
They produce interferon (IFN) γ in defense against intracellular pathogens. Th2 cells 
are programmed through GATA-3 and produce IL-4, IL-5, and IL-13 to defend against 
extracellular parasites. The newly identified Th9 cells, mediated by the transcription 
factor PU.1, produce IL-9 and play important roles in the regulation of cancer. Th17 
cells are regulated by RORγt and produce IL-17 and IL-22 to mediate autoimmunity 
and immune responses to fungi. Lastly, regulatory T cells (Tregs) are induced by the 
transcription factor FOXP3, and they produce cytokine IL-10 and TGF-β to regulate 
priming and function of other T cells (see recent review [127]). Overall, these CD4+ 
T cells are highly regulated and play essential roles in all aspects in immunity. These 
specific CD4+ T cell subtypes play differential roles in allergic asthma [125, 128, 
129], which will be discussed below in detail. 
 
1.2.1.1 Th2 
Th2 cells are known to play a central role in allergic asthma. It was initially 
observed that asthmatics displayed the pattern of cytokines that mirrors a Th2 





and IL-5 producing CD4+ T cells in the BAL and biopsies from mild to moderate 
asthma patients compared to biopsies from non-asthmatic individuals [125]. 
Elevated levels of Th2 cytokines IL-4, IL-5 and IL-13 have also been confirmed in 
peripheral blood and BAL [114]. Later studies found that GATA-3 expression was 
higher in the airways of allergic asthmatics compared to healthy individuals [130]. 
Also, genetic analyses in humans have shown associations of polymorphisms in IL-
13, IL-4 and Stat6 with asthma [131-133].  
In addition to the evidence in human disease, studies in mouse models of 
disease have also provided definite support for the role of Th2 cells in asthma. 
Studies with genetic manipulation of IL-4 showed that depletion of IL-4 resulted in 
attenuation of allergic airway inflammation caused by OVA [134], while 
overexpression of IL-4 led to enhanced allergic responses [135]. Although it appears 
that IL-4 is playing a major role in allergic inflammation, antibody neutralization of 
IL-4 cannot effectively diminish allergic airway responses if given only during the 
allergen challenge. Furthermore, blockade of IL-4 has little effect on eosinophilia 
even if given during the systemic immunization period [136]. IL-5 is known to play a 
major role in the induction of eosinophilia. However, IL-5 antibody blockade in mice 
showed significant reduction of eosinophils, but no reduction in AHR [137].  
Although both IL-4 and IL-5 play crucial roles in allergic inflammation, it 
was interesting to observe that blockade of the IL-4 receptor (IL-4R) at the time of 
allergen challenge was effective in inhibition of allergic phenotype [138], which 
seemed inconsistent with the earlier IL-4 antibody neutralization study. This led to 





important role in generating the allergic airway responses. And indeed, IL-13, 
another Th2 cytokine, shared a receptor with IL-4 (i.e. composed of the IL-4Rα and 
the IL-13Rα1) [139]. Later studies suggested that IL-13 was the central player in 
allergic asthma [113, 140] by mediating the effector phase of allergic airway 
responses. In vivo blockade of IL-13 reversed allergen-induced allergic airway 
responses in mice, and administration of recombinant IL-13 or the overexpression 
of IL-13 in the lung was sufficient to induce allergic airway responses such as AHR, 
eosinophilia, and excessive mucus production [113, 140, 141]. In humans, candidate 
gene studies also identified SNPs in IL-13 as strongly associated with the risk of 
development of allergic asthma [133, 142]. Clinical trials using monoclonal 
antibodies to IL-13 have shown improved lung function in allergic asthma patients 
[143], and targeting the IL-4 receptor α complex also led to diminished allergic 
asthma symptoms [144, 145].  
IL-13 is believed to act on resident airway cells to induce the pathological 
features of allergic asthma. It regulates mucus production via direct induction of 
mucin gene expression and mucus secretion in vitro in epithelial cell lines [146] and 
is likely mediated by Stat6 signaling [147]. Further studies confirm that IL-13 plays a 
pivotal role in mucus cell metaplasia, mucin gene induction, mucus packaging and 
release, and viscosity changes of the mucus produced in vivo [148]. IL-13 also 
contributes to sub-epithelial fibrosis [141], probably through induction of arginase 1 
and TGF-β production by alternatively activated macrophages (M2 macrophages) 
and myeloid cells [149-151], as well as Stat6-mediated myofibroblasts proliferation 





cells. Although the exact mechanism is not clear, it is generally believed that IL-13 
directly enhances force generation and contractile function of airway smooth muscle 
cells in response to stimulation [153], and indirectly promotes airway smooth 
muscle cell proliferation and thus the muscle mass [154]. Despite the effects on 
airway smooth muscle cells, IL-13 also acts on bronchial epithelial cells and induces 
a series of signaling pathways that lead to the narrowing of the airways [148]. In 
conclusion, experimental data and clinical trials to date suggest that Th2 immune 
responses are a major driver in allergic asthma inflammation. 
 
1.2.1.2 Th17 
Th17 cells are a distinct lineage of CD4+ effector T cells that express IL-17A 
and IL-17F and play pivotal roles in tissue inflammation [155, 156]. They 
differentiate in response to IL-6, TGF-β and IL-23 through activation of Stat3, RORγt 
and RORα [157]. Despite their significant roles in autoimmune diseases, they are 
also associated with severe, neutrophilic, corticosteroid resistant asthma [158-160]. 
Asthmatics with severe, persistent disease exhibit neutrophilic infiltration rather 
than eosinophilic inflammation [161-163]. Further murine studies have shown that 
IL-17A drives neutrophil recruitment and AHR [164, 165]. Likewise, a study of 
allergic responses in RORγt transgenic mice confirmed a role for Th17 cells in the 
pathogenesis of severe asthma [166]. Specifically, RORγt transgenic mice had greater 
AHR and neutrophilic inflammation compared to wild type (WT) controls in 
response to OVA [166]. More importantly, such responses could only be ameliorated 





Th17 cells also contribute to airway remodeling. Th17 cells release IL-17A, 
IL-17F and IL-22 that promote proliferation of human airway smooth muscle cells 
[167]. Moreover, adoptive transfer of Th17 cells into allergen-exposed mice resulted 
in increased mucus production, airway smooth muscle mass, and peribronchial 
collagen deposition, which were abrogated by IL-17 neutralization [168].  
Although it is possible that IL-17A alone drives allergic disease, it has also 
been reported that IL-17A is only capable of driving allergic asthma synergistically 
with IL-13 in allergen-exposed mice [169]. Another study also showed that IL-23 
and Th17 cells could enhance Th2 cells-mediated allergic airway responses such as 
eosinophilia and AHR [170]. Together, these studies suggest that Th17 cells, rather 
than driving asthma pathogenesis, exacerbate established Th2 inflammation and 
asthma pathology. However, several studies also indicate protective roles of Th17 
cells in allergic asthma pathology [171, 172]. Further studies are needed to elucidate 
the exact role of Th17 cell derived cytokines in allergic asthma. 
  
1.2.1.3 Th1 and Treg 
Besides Th2 cells and Th17 cells, other subtypes of CD4+ T cells also play a 
role in allergic asthma. Th1 cells, which are known to mediate immune response 
against intracellular pathogens [173], are generally thought to be protective in 
allergic asthma pathogenesis [174]. Th1 cells produce IFNγ, and their differentiation 
requires IL-12 [175]. It is believed that the transcription factor T-bet is the main 
regulator of Th1 cell differentiation by mediating expression of Th1 cell hallmarks 





Th1 cells were thought to play protective roles in asthma pathogenesis as 
identified by murine model studies [177]. The protective role of Th1 in allergic 
asthma is thought to be conferred via inhibitory effects on Th2 cell differentiation 
[174]. Studies show that T-bet inhibits the action of GATA3, the Th2 cell 
transcription factor [178]. Adoptive transfer of allergen specific Th1 cells also result 
in suppression of allergen-induced allergic airway inflammation [179]. However, 
contradictory results are also reported that Th1 cells could even enhance Th2 
dominant lung inflammation [180]. Several human studies indicated that IFNγ levels 
correlate with asthma severity [181]. Moreover, in a longitudinal birth cohort study, 
it was reported that IFNγ levels were positively correlated with both atopic and 
non-atopic AHR [182]. In a murine model of asthma, adoptive transfer of antigen-
specific Th1 cells was shown to mediate development of steroid–resistant AHR upon 
subsequent allergen and endotoxin lipopolysaccharides (LPS) challenge [183]. 
Indeed, a clinical study in which IFNγ was instilled into the lungs of asthmatics had 
no beneficial effect [184], indicating that Th1 cells are unlikely a good therapeutic 
target for allergic asthma. 
As another important subtype of CD4+ T cells, Tregs were discovered and 
noted in many immunological disorders for their potent regulatory effects on 
multiple immune responses [185]. There are several subsets of Tregs, but they are 
generally recognized by the expression of the transcription factor Foxp3 which 
plays an important role in the differentiation and function of these cells, and release 





the other CD4+ T cells, and studies found that attenuation of Foxp3 expression in 
these cells results in their conversion to Th1 or Th2 cells [187]. 
It is commonly accepted that Tregs represent the major mechanism of 
peripheral tolerance through the secretion of the anti-inflammatory cytokine IL-10 
[188]. Reduced or altered function of Treg cell populations has been observed in 
asthmatics, and an inverse association between IL-10 levels and the severity of 
allergic asthmatic has been reported [189]. Multiple studies reported that transfer 
of Tregs attenuates allergen-induced allergic airway responses [190-192]. On the 
other hand, depletion of Tregs leads to exacerbation of experimental asthma [193]. 
The protective actions of Tregs against allergic inflammation are mediated by both 
direct and indirect mechanisms (see review [194]). They produce the anti-
inflammatory cytokines, IL-10 and TGF-β, which significantly inhibit the 
inflammatory programming mainly by dendritic cells (DC) and T cells. They also 
express inhibitory molecules such as CTLA4 that could significantly reduce the 
activity of antigen presenting cells [195]. Indirectly, they may form direct cell contact 
with DCs via lymphocyte function-associated antigen 1 (LFA1) and CTLA4, leading to 
the down-regulation of dendritic cell derived co-stimulatory molecules [196]. 
Several studies have shown that the ability of Tregs to suppress Th2 cells is impaired 
in asthma patients, highlighting the role of Tregs in allergic asthma [129, 197, 198].  
 
1.2.2 Initiation and amplification of type-2 immune responses  
  Although Th2 cells play a pivotal role in allergic asthma, their activation and 





[36]. The direct regulators of Th2 cell development are APCs, which control the 
phenotype and magnitude of resultant adaptive responses by interaction of the 
expressed MHC II molecules with T cell receptors (TCR). 
   Several cell types are recognized as APCs, including “professional” APCs 
such as DC, macrophages and B cells. These cells constitutively express major 
histocompatibility complex class II (MHC II) molecules and function readily upon 
taking up antigens [199]. Several “non-professional” APCs have also been reported 
according to their expression of MHC II including mast cells [200], basophils [201], 
epithelial cells [202] and innate lymphoid cells (ILC) [203]. Although MHC II is 
considered necessary for antigen presentation, cells must be able to take up and 
process antigens, migrate to secondary lymphoid organs, and express co-stimulatory 
molecules in order to effectively activate naïve T cells, making the “professional” 
APCs main effective presenters of antigens [199]. 
  Antigen presenting cells are normally present in the lung and sample 
antigens from both the airway epithelium and the environment directly by uptake 
and transport of macromolecule antigens to the lymph nodes [204]. Taking DCs as 
an example, several activation signals are required for them to act as antigen 
presenting cells such as the expression of maturation markers [205] and activation 
of surface pattern recognition receptors (PRRs) [206]. Specifically, in the event of 
inflammation, immature DCs in the periphery are quickly recruited to the site of 
inflammation by chemokines produced by local tissues. These immature DCs are 
then exposed to antigens that can be recognized by their PRRs. Antigen uptake and 





stimulatory molecules such as CD80/86 [208], CD40 [209], and Ox40L [210]. These 
activated DCs then migrate to the draining lymph nodes where they interact with 
naïve T cells [211].  
  At this time, the antigens are presented to CD4+ T cells by DCs with the 
expression of MHC II molecules. MHC II proteins are encoded by three polymorphic 
genes HLA-DR, HLA-DQ, and HLA-DP in humans [212]. They bind the antigen 
peptide that is generated in the endosome of antigen presenting cells and 
transported to the plasma membrane [213, 214]. This process is referred to as the 
MHC II loading of antigens. DCs then interact via these loaded MHC II molecules with 
antigen-specific TCRs expressed by naïve T cells. Another signal required at this 
stage is the expression of co-stimulatory signals [215]. It has been reported that 
certain co-stimulatory molecules such as OX40/OX40L and CD40/CD40L are 
implicated in the induction of Th2 responses [216, 217]. 
  After the activation and migration of DCs to the lymph node, the third signal 
required for effective T cell polarization is a Th2 cytokine promoting rich 
environment. Interestingly, DCs only produce required cytokines for Th1 (IFNγ/IL-
12) and Th17 (IL-6/IL-23) differentiation [218], but not those required for Th2 
differentiation. Previously, it has been proposed that the induction of Th2 immunity 
was a result of the absence of Th1 and Th17 polarizing signals [219]. This theory 
was proven incorrect as later studies suggested that basophils would provide the 
required co-stimulation as well as IL-4, for the induction of Th2 immunity [201]. 
However, a recent study suggested that it was in fact a subtype of inflammatory DCs 





perpetuate Th2 allergic immune responses in a model of HDM-induced 
experimental asthma [220]. Our knowledge of the factors required for the initiation 
of Th2 immunity has rapidly grown over the last few years, as type-2 innate 
lymphoid cells (ILC2s) have been found to be recruited early to the lung in response 
to papain exposure and provide IL-13 to boost DC function (mainly migration) and 
promote Th2 cell responses [221]. Moreover, eosinophils recruited into tissues and 
lymph nodes can also be a source of IL-4 and can promote DC-driven immunity 
[222]. As a result, basophils, eosinophils, and ILC2s all contribute to the initiation of 
Th2 immunity. This adds to the complexity of Th2 cell induction, and initiating 
events resulting in specific recruitment and activation of these cells following 
antigen exposure remain to be identified. 
   
1.2.3 Epithelial cell regulation of the allergic response 
Recent evidence suggests that airway epithelial cells are important players 
in allergic asthma. They lie at the interface between the host and the environment, 
and represent the first barrier of defense against external environmental stimuli 
[223]. Beyond their role as a passive physiological barrier, the airway epithelium is 
now perceived as an active interface between the immune system and the outside 
environment that shapes and regulates immune responses to external stimuli, e.g., 
type-2 immune responses against allergens and parasitic infections.  
First, it was proposed that environmental factors causing disruption of the 
airway epithelium barrier might contribute to allergic inflammation [224]. As 





is mainly because of the loss of epithelial barrier integrity through suppressed 
expression of E-cadherin, a major component of adherent junctions and airway 
epithelium [223]. Studies suggest that the loss of the epithelial barrier is a result of 
epithelial-to-mesenchymal transition (EMT) [225], a phenomenon in which mature 
epithelial cells change into a mesenchymal phenotype following morphogenic 
pressure from injured tissue [226]. This process not only contributes to airway 
epithelium associated remodeling, but may also promotes DC activation and allergic 
inflammation by allowing efficient DC encounter of antigens, and following antigen 
presentation [227].  
Another more important mechanism by which the airway epithelium 
regulates the initiation of immune responses is via production of chemokines and 
cytokines that recruit and activate APCs for induction of Th2 immunity. The main 
epithelial-derived factors playing important roles in the downstream allergic 
response include: granulocyte macrophage-colony stimulating factor (GM-CSF), 
CCL20, IL-33, IL-25, and thymic stromal lymphopoietin (TSLP) [227]. GM-CSF is 
released from epithelial cells in response to environmental stimuli such as diesel 
exhaust [228], particulate matter [229] and HDM [230]. It was found to effectively 
induce DC development in vitro [231] and was associated with Th2 polarized airway 
inflammation in vivo [230, 232]. CCL20 was also induced by HDM [233] and was 
shown to guide the accumulation of immature DCs expressing it receptor CCR6 
[234]. IL-33, IL-25, and TSLP are mainly involved in the recruitment and differential 
activation of ILC2s [235], the newly identified important players in the initiation of 





promote Th2 responses, as IL-33-treated DCs have been shown to induce robust IL-5 
and IL-13 production by co-cultured T cells [237]. 
 
1.2.3.1 The epithelial-cell derived factor, IL-33 
  IL-33 is a cytokine belonging to the IL-1 family [238]. It has a β-trefoil fold in 
its carboxy-terminus similar to the other IL-1 members, allowing its binding to the 
orphan IL-1 receptor (IL-1R) family member ST2/IL1RL1 (ST2) [238]. It has been 
shown to activate Myd88-dependent signaling pathways in target cells expressing 
the ST2/IL-1RAcP receptor complex [238, 239] and induce subsequent production 
of pro-inflammatory mediators. IL-33 is constitutively expressed and located mainly 
in the nuclei of tissue structural cells including epithelial cells, endothelial cells and 
fibroblasts [240]. It was originally thought to function as an “alarmin” as it is 
released during cell necrosis, while cleaved and inactivated by caspases during 
apoptosis [240-242]. It was also found to be cleaved by calpain as well as neutrophil 
elastase and cathepsin G to generate its mature forms from the full-length protein 
with enhanced biological activity [243]. The regulation of IL-33 remains poorly 
identified, but recent evidence suggests that besides its alarmin properties, it is also 
released upon environmental exposures to allergens, virus and mechanical stress 
[244-247]. 
(1) Regulation of IL-33 release 
  Although IL-33 has been recognized as a major player in type-2-mediated 
allergic inflammation, the exact pathways regulating its production, transport within 





to function as an alarmin following cellular damage/injury [248], extracellular 
danger signals or environmental stimuli can also induce live cells to release pre-
formed IL-33 within minutes by airway epithelial cells and fibroblasts from both the 
nuclei and other vesicular compartments where this cytokine is located [244-247]. 
This was confirmed in vivo, as the increase of IL-33 protein in extracellular fluids is 
associated with reduced staining for IL-33 protein in the nucleus [249]. 
Initially, researchers attempted to identify a signaling peptide within the IL-
33 protein. Signaling peptides are specific peptide sequences within a protein 
molecule, allowing the protein to be recognized by the shuttling machinery within 
conventional endoplasmic reticulum (ER) and Golgi cisternae-mediated secretory 
pathways [250]. However, IL-33 does not have a traditional signal sequence [251]. 
Recently, researchers found that IL-33 was located both in the nucleus and in 
membrane-bound cytoplasmic vesicles in fibroblasts [247]. They determined 
through fluorescent pulse-chase fate-tracking experiments that there was dynamic 
nuclear-cytoplasmic flux of IL-33, which was reduced after cytoskeleton disruption 
with latrunculin B [247]. These studies indicated that IL-33 translocation between 
intracellular organelles is mediated by cytoskeleton rearrangement. Another two 
groups found that endogenously produced ATP and its autocrine activation of 
purinoceptor-dependent signaling and calcium mobilization was required to 
translocate IL-33 to extracellular milieu [244, 245]. They further showed that the 
elevated intracellular calcium resulted in dual oxidase-1-mediated activation of 
calpainin, a protease thought to process IL-33 [243, 245]. Taken together, these 





epithelial cells is dependent upon cytoskeletal rearrangement and calcium signaling. 
However, to date, no direct evidence for the regulation of IL-33 live cell release or 
translocation has been provided.  
(1) Regulation of IL-33 activity 
Another level of IL-33 regulation is its processing by caspases and 
proteases. IL-33 was found to contain a cleavage site for caspase-3, which could 
cleave IL-33 and generate two biologically inactive products [252]. This was 
probably a protective mechanism to avoid unnecessary activation of its downstream 
immune responses. However, the role of caspases in inactivating IL-33 remains 
controversial, as another study found that the release and activity of IL-33 from 
macrophages and mast cells is independent of caspases [252]. 
However, as the knowledge of IL-33 processing has evolved, evidence has 
accumulated to suggest that the mature form of IL-33 is formed through enzymatic 
cleavage [89, 243, 245]. Specifically, the cleaved forms of IL-33 (IL-3395–270, IL-3399–
270 and IL-33109–270) generated by neutrophil elastase and cathepsin G in vitro and in 
vivo have 10 fold more biological activity compared to the full-length protein in their 
capability to induce granulocytes and monocyte production of pro-inflammatory 
cytokines [89]. However, the roles of proteases derived from granulocytes in IL-33 
activity regulation remain controversial, as the mast cell chymase is able to degrade 
IL-33 [253], and neutrophil proteinase 3 (PR3) cleavage of IL-33 actually results in 
the generation of two inactive truncated forms of IL-33 in vitro [254]. Taken 
together, these data suggests a complex balance of maturation and inactivation of IL-






1.2.3.2 IL-33 and type-2 immune response 
IL-33 plays a pivotal role in allergic inflammation. Current studies have 
suggested a role for IL-33 the regulation of both innate and adaptive arms of type-2 
immune responses.  
(1) DCs 
  Accumulating evidence suggests that DCs express the IL-33 receptor ST2 
[237, 255, 256]. As professional antigen presenting cells, DCs are critical in 
controlling adaptive T helper cell responses. Initial studies demonstrated that IL-33 
treated DCs polarize naïve CD4+ T cells into Th2 cells which produce IL-5 and IL-13 
but not IL-4, while IL-33 treatment of CD4+ T cells alone is not sufficient to induce 
these Th2 cytokines [237, 255]. In the meantime, ST2 knockout (ST2 -/-) mice 
exhibit attenuated allergic inflammation in the lung after allergen exposure, 
probably through diminished activation and migration of DCs in these animals [255]. 
Interestingly, DCs can be driven to express IL-33 upon stimulation by allergen-IgG 
immune complexes [257] or TLR ligands [258]. In one study using HDM as the 
stimulus, delivery of IL-33 restores the attenuated allergic inflammation in FcγR-
/- mice, and the same group reveals that DC Il33 expression is dependent on FcγR, 
TLR4, and PI3K signaling [259]. 
(2) Macrophages 
  As previously discussed, macrophages also play a role in allergic asthma. M2 
macrophages that are generated in the presence of IL-4 and IL-13 are known to 





macrophage associated TLR signaling [261], as well as polarization into the M2 
subset and airway inflammation [262]. Thus, IL-33 enhances the function of M2 
macrophages in Th2 promoting environments. However, despite regulation of 
macrophage function, recent evidence also shows that macrophages may be an 
important source of IL-33 [263, 264]. The exact mechanism that drives macrophage 
expression of Il33 is not clear, but it is probably an important driver of M2 
macrophage-mediated pulmonary fibrosis in acute lung injury induced by bleomycin 
[263], suggesting that it may also contribute to the airway remodeling in allergic 
airway inflammation where fibrosis is also implicated [95].  
(3) Mast cells 
  Mast cells are critical effector cells in allergic asthma. Acute IL-33 exposure 
potently activates ST2 expressing mast cells both dependent upon and 
independently of IgE [265, 266]. In the IgE independent activation of mast cells, IL-
33 binds ST2 and leads to activation of NF-κB and p38 MAPK signaling [267, 268], 
resulting in expression of Th2 cytokines IL-4, IL-5 and IL-13 [269, 270]. As a result, 
IL-33 enhances the capacity of mast cells to intensify type-2 immune responses 
within the tissue. In the IgE dependent activation of mast cells, IL-33 synergizes with 
IgE to cause enhanced mast cell degranulation and cytokine synthesis [266, 268]. IL-
33 also increases IgE synthesis from plasma cells [269], leading to further 
intensified mast cell activation. Additionally, IL-33 promotes mast cell proliferation, 
survival or maintenance upon allergic inflammation. For example, an early study 





of wild type controls following helminth parasite infection [271]. These findings 
suggest another mechanism through which IL-33 might magnify mast cell activity.  
  The crosstalk between IL-33 and mast cells is rather bi-directional, as mast 
cells are also critical regulators of IL-33. Mast cells express IL-33, and their 
activation causes increased Il33 mRNA expression [272] and release that is 
detectable in the in vitro culture supernatants [273, 274]. Such a phenomenon 
demonstrates a potential autocrine mechanism through which inflammatory cell-
release of IL-33 may in fact cause further activation of these cells via activation of 
ST2, resulting in an even greater magnitude of the inflammatory response. Besides 
being a source of IL-33, mast cells may also control the duration and potency of IL-
33 protein activity. For example, mast cell degranulation leads to the release of 
serine proteases, trypase, and chymase, which are shown to cleave and process full-
length IL-33 protein, resulting in sub-forms with greater biological activities that 
contribute to allergic airway inflammation [275, 276].  
  However, IL-33 doesn’t always lead to greater activity of mast cells. Long-
term IL-33 exposure impairs downstream signaling of FcεRI activation, which down-
regulates mast cell degranulation [277]. Whether the Th2 cytokine release can be 
suppressed after long-term IL-33 exposure remains unknown. 
(4) Eosinophils, basophils, and neutrophils 
  Eosinophils are the “classical” magnifier of type-2 immune responses. A 
recent study shows that eosinophils also express ST2, and are rapidly activated by 
IL-33 to degranulate and release Th2 cytokine [278]. This is likely caused by NF-κB-





activation of eosinophils by IL-33 is likely more effective than that by IL-4 [279]. IL-
33 also facilitates eosinophil migration mediated by ICAM-1 [280]. Together, the 
data suggest that IL-33 enhances eosinophil recruitment and activation in allergic 
inflammation. Similar to eosinophils, IL-33 also binds ST2 and enhances IgE 
initiated basophil degranulation and release of pro-inflammatory mediators [281]. 
By activation of PI3K/Akt pathway, IL-33 could promote basophil expansion and 
survival [282, 283].  
  While neutrophils are implicated only in certain subtypes of asthmatics, 
they also interact with IL-33 and are potentially linked to allergic inflammation. 
Neutrophils could generate proteases, elastase and cathepsin G, which are known to 
process full-length IL-33 into more potent forms [89]. IL-33 may also enhance 
neutrophil recruitment by driving release of neutrophil chemotactic factors from 
mast cells [284] and macrophages [285]. This indicates that neutrophils recruited in 
asthmatics may enhance IL-33 activity and contribute to disease pathogenesis. 
(5) ILC2s 
  ILC2s are key activators of type-2 immune responses that are recruited and 
activated by IL-33. They are defined based on: (1) their lack of lineage markers in 
combination with expression of cell surface markers including ST2 [286, 287], (2) 
the production of type-2 cytokines in response to epithelial-derived IL-25, IL-33, and 
TSLP [288-293], and (3) their dependency on the transcription factors RORα and 
GATA-3 for their proper development and function [294-297]. More specifically, they 





CD4), NK cells (CD49b), B cells (B220), DCs (CD11b, CD11c) and macrophages 
(CD11b, F4/80) [298].  
ILC2s are hematopoietic in origin and are developed under the regulation of 
Interleukin-7 (IL-7), transcription factors inhibitor of DNA binding 2 (ID2), and 
nuclear factor IL-3 (NFIL3) as well as transcription factors GATA-3 and RORα [299, 
300]. ILC2s are known to produce the Th2 cell-associated cytokines IL-5 and IL-13, 
but not IL-4, and to mediate allergen-driven airway inflammation [301]. As 
previously mentioned, these cells express ST2, and IL-33 has been shown to be a 
potent inducer of their expansion and secretion of Th2 cytokines. The induction of 
Th2 cytokines is mediated through the activation of numerous signaling molecules 
such as nuclear factor-κB (NF-κB), extracellular signal-regulated kinase 1 (ERK1), 
ERK2, p38 and JUN N-terminal kinase-1 (JNK1) downstream of ST2 ligation [288, 
302, 303].  
As a newly identified cell type, little is understood about the clinical 
relevance of ILC2 cells in human asthma. However, they are increased in the nasal 
polyps of a subset of severe asthmatics that often have comorbidity with chronic 
rhinosinusitis (CRS) and do not respond well to steroids [304, 305]. The IL-33/ILC2 
axis has been widely implicated in mouse models of allergic airway inflammation 
[221, 306-308]. More importantly, ILC2s serve as potent innate producers of Th2 
cytokines in that they constitute the majority of cells expressing IL-5 and IL-13 in 
the lung after HDM exposure or IL-25 and IL-33 administration [301]. Further 
studies reveal that pulmonary resident ILC2s responding to IL-25, TSLP, and in 





of the adaptive immune response [306-308]. Depletion of ILC2s abolished both viral 
and allergen-induced AHR, while adoptive transfer of purified ILC2s reconstituted 
AHR [307, 308]. All these studies suggest that ILC2s play a role in the early, innate 
response to environmental stimuli, providing an early source of Th2 cytokines and 
driving allergic inflammation. Besides, ILC2s also interact with other immune and 
structural cells by acting as MHC II-dependent antigen presenting cells in vitro to 
stimulate T cell responses [309], by driving Th2 cytokine secretion by CD4+ T cells 
via direct contact [310], by promoting B cell IgE production [311], and by 
contributing to pathological airway remodeling via amphiregulin production [312].  
(6) CD4+ T cells 
  As discussed earlier, CD4+ Th2 cells facilitate the pathophysiology of allergic 
asthma. Although naïve T cells and resting Th2 cells have very low-level expression 
of ST2, it can be induced by cytokines such as IL-2 in the presence of IL-33 [313]. 
These effects are likely direct as in the presence of antigen, IL-33 induces the 
production of IL-5 and IL-13, but not IL-4, by murine Th2 cells, which is sufficient to 
induce allergic airway inflammation [314]. Further studies suggest that IL-33 may 
also mediate the migration of Th2 cells: ex vivo studies show that IL-33 increases 
migration of Th2 cells isolated from human and mouse, but not in ST2 deficient Th2 
cells [315].  
  In summary, IL-33 plays a crucial role in promoting type-2 immune 
responses and allergic asthma pathogenesis. It forms highly interconnected 
interactions with other drivers and effectors of the disease. As a result, 





inflammation. The capacity of IL-33 to promote IL-13 production by immune cells, 
particularly ILC2s, is crucial for pathogen responses, but also detrimental in asthma 
pathogenesis.  
 
1.2.3.3 Epithelial cell recognition of environmental allergens 
As airway epithelial cells play important roles in the regulation of type-2 
immune responses through the secretion of IL-33, the recognition of such 
environmental stimuli leading to IL-33 release most likely plays a critical role in the 
initiation of allergic inflammation. Airway epithelial cells respond to environmental 
stimuli through many PRRs, and the environmental stimuli recognized are termed 
pathogen-associated molecular patterns (PAMP) and danger-associated molecular 
patterns (DAMP) such as macromolecules with cabonhydrate moieties 
(lipopolysaccharide, peptidoglycan), proteins (flagellin), and nucleotide sequences 
(bacterial or viral DNA and RNA) [316]. 
There are many types of PRRs, which recognize a wide variety of stimuli 
[316]. PRRs are categorized according to their cellular locations, as membrane 
bound, secreted and/or intracellular. Membrane bound PRRs include Toll like 
receptors (TLRs), C-type lectin receptors (CLRs), protease-activated receptors 
(PARs), and a variety of scavenger receptors. Secreted PRRs include serum amyloid a 
(SAA), C-reactive protein (CRP), and mannose-binding lectin (MBL). Intracellular 
PRRs include nucleotide oligomerization domain (NOD)-like receptors (NLRs) and 
retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) [317]. PRR ligation results 





(NF-κB) and mitogen-activated protein kinase (MAPK) that result in the secretion of 
proinflammatory cytokines and chemokines [318].  
Depending on the nature of the antigens, different PRRs initiate distinct 
immune responses. The identification of PRRs involved in the regulation of type-2 
immune responses is lacking. As a major aeroallergen exhibiting great complexity of 
its contents, HDM is thought to activate multiple PRRs that together contribute to 
the activation of multiple innate immune pathways [319]. Indeed, several studies 
have attempted to identify the allergenic component(s) of HDM responsible for the 
induction of allergic asthma. For example, the HDM allergen, Der p 2, was found to 
interact with the TLR4 signaling complex by mimicking the structure of MD2, the 
lipid binding component of TLR4 signaling complex, to augment adaptive allergic 
responses [320]. However, this study did not explore the role of TLR4 in HDM 
induced IL-33 release from airway epithelial cells. In fact, there are few studies 
addressing this question except for one showing the involvement of the P2 
purinergic receptor that recognizes extracellular ATP [244]. As a result, identifying 
the PRRs recognizing HDM allergens that lead to the release of the type-2 immune 
response regulators IL-33 remains a major priority. 
Overall, disruption of the epithelial cell barrier function and activation of 
PRRs lead to epithelial cell activation and subsequent changes including secretion of 
soluble factors [227]. These soluble factors include cytokines such as IL-33, IL-25, 
TSLP, GM-CSF, CCL20, as well as DAMPs such as ATP, uric acid, and reactive oxygen 
species (ROS) [227]. Among these cytokines, IL-25, TSLP and IL-33 all play 





major players. Understanding the HDM specific signaling that leads to IL-33 
production by airway epithelial cells not only advances the current understanding of 
allergic asthma pathogenesis, but also provides future directions for the disease 
prevention and treatment. 
 
1.3  Cellular glucose metabolism regulation of immune cell function  
1.3.1 Cellular glucose metabolism 
Cellular glucose metabolism has long been recognized as one of the most 
important physiological processes. Recent emerging evidence shows that cellular 
glucose metabolism regulates vital pathways for cell survival and activation [321, 
322], extending the recognition of this old concept into new fields, such as its roles 
in the regulation of immune responses. The crosstalk between glucose metabolism 
and the immune system has provided great insights into the development, function 
and regulation of immune cells. Specifically, cell metabolism has been shown to 
regulate the synthesis and release of certain mediators and cytokines, conferring 
importance in pathological conditions and immune homeostasis [323-326]. 
   The main purpose of cellular glucose metabolism is to produce energy and 
substrates for various cellular processes [327]. The major form of energy for cellular 
activities is ATP. To generate ATP, cells utilize primarily glucose, and sometimes 
fatty acids in the presence of oxygen [328]. Basically, glucose is taken up by cells via 
glucose transporters (GLUT). There are 12 members of the GLUT family proteins. 
While the primary glucose transporter expressed on mammalian cells is GLUT1, 





functions such as glucose sensing, insulin responses and fructose uptake [329]. After 
cellular uptake, glucose is first metabolized to pyruvate via glycolysis catalyzed by a 
set of enzymes (Fig. 2). During oxygen deprivation, pyruvate can be converted to 
lactic acid (1 molecule of lactate and 1 molecule of proton) by lactate dehydrogenase 
(LDH) in the cytosol. This process is referred to as anaerobic glycolysis. During this 
process, a total of four molecules of ATP are formed from ADP in glycolysis. 
However, two ATP molecules are consumed during earlier steps of this pathway as 
shown in Fig. 2, resulting in the net production of 2 molecules of ATP per each 
molecule of glucose. When sufficient oxygen is available, pyruvate can also be fully 
oxidized to CO2 and H2O via the tricarboxylic acid (TCA) cycle in the mitochondria. 
This process involves reduction of O2 to H2O and activity of ATP synthase in the 
electron transport chain in the mitochondria, generating a total of 36 molecules of 
ATP [330]. These two processes are interrelated and integrated when pyruvate is 
converted into acetyl-CoA to enter the TCA cycle, and the balance of these two 
processes is regulated by the availability of oxygen and/or the energy demand for 
cellular events [330]. 
  As discussed above, in the presence of sufficient O2, ATP is mostly generated 
by oxidative phosphorylation (OXPHOS). Under hypoxic conditions cells mainly 
generate ATP via glycolysis. However, in some cases, cells may preferentially use 
glycolysis for ATP generation even in the presence of sufficient oxygen. This process 
is referred to as aerobic glycolysis or Warburg metabolism [331]. Moreover, it has 
been proposed that certain cellular events might use ATP from different sources 





membrane-associated actions (those related to channels and transporters) in a 
timely manner compared to OXPHOS derived ATP [332]. This is probably explained 
by the fact that the immediate energy source for ATP synthesis in the mitochondria 
is provided by the proton-motive force across a membrane [328], which may not be 
as “convenient” as the substrate-level phosphorylation that is catalyzed by water-
soluble enzymes in the cytosol independent of membranes and ion gradients [328]. 
As a result, glycolysis derived ATP is proposed to be generated physically in greater 
proximity to membrane compartments in a timely manner [332]. In addition, 
glycolysis and OXPHOS generate different intermediates, meeting different needs of 
cells through several key pathways such as the pentose phosphate pathway (PPP) 
for synthesis of pentose sugars, fatty acid synthesis, and lipid ligands production 
[325]. 
 
1.3.2 Glucose metabolism and immune cell activities 
  Crosstalk between cellular glucose metabolism and immune cell activities 
has been widely implicated. In the immune system, most cells cycle between a 
quiescent state and an activated state in response to perturbations of the host. 
During such transitions, large numbers of cellular events take place including gene 
expression and post-translational modifications, resulting in the production of 
cytokines, inflammatory mediators, tissue remodeling factors, as well as physical 
actions of migration and proliferation [325]. 
Cell metabolism has been shown to regulate activation of many immune 





cells [321, 341, 342] and B cells [343, 344]. For example, neutrophils and 
eosinophils are highly dependent on glucose for ATP production via aerobic 
glycolysis [334]. Upon activation by TLR agonists or cytokines, they exhibit 
increased consumption of glucose and metabolic activities [333, 335]. Similar 
observations were made with antigen presenting cells. Studies on cell metabolism in 
DCs found that while resting immature DCs rely mainly on OXPHOS as most tissue 
cells. TLR stimulation reprograms their metabolism and they become dependent on 
aerobic glycolysis and Warburg metabolism [337]. A recent study further showed 
that DCs undergo rapid induction of glycolysis activity that drives cytokine 
production and MHC molecule loading [338]. Similar to DCs, glycolytic flux is also 
very important for macrophage activation [339], while altered balance between 
OXPHOS and glycolysis is thought to regulate macrophage polarization between 
classic and alternative activations [345]. In T cells, the role of glucose metabolism is 
more extensively studied. Firstly, T cells engage Warburg metabolism upon 
activation for their extensive and rapid proliferation [321]. Studies have shown that 
molecules such as the mammalian target of rapamycin (mTOR), phosphoinositide 3-
kinase (PI3K), protein kinase B (Akt), Myc, and hypoxia-inducible factor (HIF) are all 
playing roles in the crosstalk between immune signals and metabolic cues for the 
activation, development, function, and maintenance of T cells [341]. In fact, mTOR 
signaling was shown to direct naïve T cell differentiation into Th2 cells, further 
confirming that metabolic alterations in T cells contribute to allergic asthma [346]. 





other immune cells, such as their increased glucose uptake and induction of 
glycolysis after activation [343, 344].  
  While the most common hypothesis for the role of cell metabolism in 
immune cell activation is via satisfaction of the energy needs for immune cell 
activation, other studies have also explored potential mechanisms by which certain 
metabolites can be involved. For example, there are many G-protein coupled 
receptors (GPCR) that serve as receptors for metabolic intermediates and energy 
substrates [347]. Among these receptors, GPR81 recognizes lactate and has been 
shown to promote cancer cell survival [348], and GPR91 ligates succinate to 
promote chemotaxis and activation of DCs [349]. Moreover, the A2B and A2A 
adenosine receptors, when activated, are shown to strongly promote IL-4 driven 
alternative activation in macrophages [350]. Besides inducing signaling pathways in 
cells, metabolites may also stimulate immune cell responses. One example is 
extracellular ATP, which is released at the mucosal surface following tissue damage 
[351]. ATP was shown to act as a DAMP to induce IL-33 release from epithelial cells 
[244], and was found to be associated with allergic airway inflammation [352].  
 
1.3.3 Regulation of glucose metabolism 
  As mentioned previously, glucose metabolism has been shown to play an 
important role in the activation and function of multiple cell types. Extensive studies 
have explored the potential pathways linking immune cell activation and altered 
glucose metabolism. It has been shown that activation of the AMP-activated protein 





1α (HIF-1α), etc.) may contribute to the glucose metabolism phenotypes in activated 
immune cells. 
(1) AMP-activated protein kinase (AMPK) 
AMPK is a key regulator of cellular metabolism. It promotes ATP 
conservation and production in times of ATP deficiency. Therefore, pathways 
producing ATP (glycolysis, fatty acid oxidation, etc.) are turned on, and pathways 
consuming ATP (gluconeogenesis, glycogen synthesis, etc.) are decreased [353]. 
AMPK also increases the activity of GLUT1, the major glucose transporter, to 
enhance glucose uptake [354]. AMPK is mainly activated in times of energetic 
deprivation, in which there is an increased AMP: ATP ratio in the cells [355]. During 
cell activation, the rapid increased demand of energy may result in activation of 
AMPK signaling. For example, AMPK is rapidly activated in T cells following TCR 
stimulation [354], leading to the previously described metabolic alterations in 
activated T cells. 
(2) mTOR 
  mTOR signaling is shown to mediate cell metabolic alterations during cell 
activation and contribute to the activation process. mTOR exists as two complexes, 
mammalian target of rapamycin complex 1 (mTORC1) and mammalian target of 
rapamycin complex 2 (mTORC2), and integrates extrinsic and intrinsic signals 
related to nutrient levels, energy status, and stress to induce changes in cellular 
metabolism, growth, and proliferation [356]. Extracellular stimuli activate PI3K, 
which recruits 3-phosphoinositide–dependent protein kinase-1 (PDPK1) and Akt. 





mTORC1 [356]. Both Akt and mTOR promote aerobic glycolysis by regulating 
nutrient transport and phosphorylation of glycolytic enzymes [357]. mTORC1 could 
also increase protein translation [356] and lipid synthesis [358]. mTOR activation is 
implicated in effector T cell differentiation, growth, and function [359]. Specifically, 
Th1, Th2, and Th17 cells strongly engage glycolysis via mTOR signaling, whereas 
Treg cells depend more on the oxidation of lipids [360]. Other studies suggest that 
mTOR also play important roles in activation of DCs by TLR agonists [360]. 
(3) Others 
  Besides the above two master regulators of cell metabolism, many other 
pathways contribute to metabolic regulation of cell activation in a transcription- 
dependent fashion. For example, up-regulation of transcription factors c-Myc, 
estrogen-related receptor α (ERRα), and HIF-1α coordinately drives the expression 
of genes involved in metabolism alterations that fuel the rapid proliferation of 
effector T cells during clonal expansion [361]. In dendritic cell activation, mTOR 
could target HIF1α and mediate DC activation [362]. HIF1α induces the expression 
of many enzymes in the glycolysis pathway and promotes glycolysis in several 
systems [363]. However, in more immediate activation of DCs, the induction of 
glycolysis depends totally on post-translational modification. In this condition, TLR 
agonists activate TANK-binding kinase 1 (TBK1) and Akt, leading to a rapid increase 
of glycolysis and then DC activation [338]. 
  Alterations in cell metabolism contribute to many aspects of cell activation. 





on immune cells leads to the activation of metabolic-related signaling pathways, 
which either induce or promote the activation and function of cells.  
 
1.3.4 Glucose metabolism changes in Asthma 
Based on the potential role that cellular metabolism plays in immune cell 
function, the role that altered glucose metabolism plays in allergic asthma 
pathogenesis has been recently explored.  
Although studies have shown that metabolic alterations occur in cells 
relevant to asthma, it is not clear whether there is a correlation between such 
metabolic phenotypes and asthma in humans. The earlier reports about metabolism 
in asthmatics focused on lactic acidosis during asthma attacks, in which people 
found increased serum lactate levels in acute severe asthmatics despite normal 
oxygenation [364-369], which was thought to be attributed to increased cellular 
metabolism during asthma attacks as well as medication-related sympathetic 
effects. However, in the recent study conducted by Ostroukhova et al., they found 
that isolated CD4+ T cells from asthmatics produce more lactate than those from 
normal individuals, suggesting metabolic reprogramming in these cells. 
Interestingly, they observed that lactate treatment significantly increased T cell 
proliferation in vitro. When treated with a glycolysis inhibitor, cytokine production 
and proliferation of purified CD4+ T cells were significantly reduced, although there 
was no direct evidence for specific inhibition of Th2 cell activities. This study 
established a correlation between enhanced glycolysis and allergic inflammation in 





sensitized to ragweed, and observed that while ragweed treatment significantly 
induced allergic airway responses in those mice, inhibition of glycolysis significantly 
reduced airway resistance, remodeling, and Th2 cytokine (IL-5, IL-13) levels in the 
lung [370].  
Intriguingly, another study conducted at the same time attempted to 
understand the biological mechanisms involved in the early asthmatic responses 
following allergen exposure. Xu and colleagues treated rats with OVA, and harvested 
the lungs 14 days later to determine the protein expression profiles associated with 
allergic responses. They found that the rats exposed to OVA had significantly greater 
pulmonary resistance, and proteomic analyses of the lung proteins revealed an 
increased expression of proteins related to glycolysis (glucose transporter, pyruvate 
kinase, etc.), calcium signaling, and mitochondrial activities [371]. Another 
metabolomic study also found that OVA-sensitized mice had greater lactate levels in 
the BAL [372]. These studies provided further evidence that glycolytic activities are 
involved in asthma pathogenesis. Collectively, these data support the hypothesis 
that enhanced glycolysis is prevalent in allergic asthma, indicating that alterations in 
the balance of cell metabolism may be associated with the development of allergic 
asthma. In support of this concept, cell metabolism has recently been found to be 
involved in the activity and function of important cells for type-2 immune 
responses. For example, naïve T cell differentiation into Th2 cells is dependent on 
mTOC-mediated metabolic reprogramming [346]; glycolysis has been found to play 





survival [373]; B cells require metabolic reprogramming and rely on glycolysis for 
its proliferation and antibody production [374].  
However, despite the accumulating evidence that changes in cellular 
metabolism may play a role in allergic inflammation, little is known about the cell 
metabolic phenotypes of residential structural cells in human asthma, and few 
studies have investigated whether metabolic reprogramming regulates type-2 
immune responses. Considering that cell metabolism has been implicated as an 
important mechanism for immune cell activation and associated with allergic 
asthma, further analyses for its role in regulating initiation of the aberrant immune 
responses in allergic asthma are needed.  
Airway epithelial cells play pivotal roles in regulating type-2 immune 
responses by the secretion of IL-33. As such, we propose to address the following 
questions in the current study: (1) does the common aeroallergen HDM induce 
metabolic alterations in airway epithelial cells? (2) Does cellular glucose 
metabolism contribute to IL-33 secretion by airway epithelial cells? (3) Does 
modulation of cellular glucose metabolism affect HDM-induced allergic 
inflammation in vivo? By answering these questions, we hope to advance our 
current understanding of the mechanisms driving the initiation of allergic asthma 
caused by the major allergen HDM, in order to provide insights into the 
development of novel asthma prevention and therapies. 
 





Allergic asthma is a chronic disease of the lung, whose prevalence has 
increased dramatically over the last few decades. Although the etiology of asthma is 
not well understood, both genetic and environmental influences are known to 
contribute to its pathogenesis. Indeed asthma is thought to arise as a result of 
inappropriate immune responses to innocuous environmental allergens. 
Sensitization and challenge with allergens such as HDM results in aberrant type-2 
immune responses that lead to the functional and pathological features of the 
disease including AHR, eosinophilic inflammation and elevated IgE synthesis. 
Recently studies have shown that the release of the cytokine IL-33 from bronchial 
epithelial cells is an important driver of type-2 immune responses and allergic 
asthma.  
The mechanism(s) by which epithelial cells secrete IL-33 following 
exposure to environmental stimuli remain unknown. Recent studies suggest that 
asthma is associated with an imbalance between glycolysis and oxidative 
phosphorylation in the lungs, and cell metabolism related pathways are thought to 
play pivotal roles in early responses of immune cells to external stimuli. As IL-33 is 
rapidly released upon environmental exposure, it is likely that allergen-induced 
changes in epithelial cell metabolism also mediate IL-33 production. In this thesis, 
we propose the novel hypothesis that environmental allergen exposure 
induces changes in glucose metabolism in airway epithelial cells, which 
modulates secretion of the Th2-promoting cytokine IL-33 and the 
development of allergic asthma. To address this hypothesis, we propose the 





1. To determine whether HDM-induced metabolic changes in bronchial 
epithelial cells drive IL-33 secretion. 
2. To delineate the mechanism(s) of HDM-induced glycolysis in bronchial 
epithelial cells. 
3. To determine whether modulating glycolytic metabolism affects allergic 





1.5  Figures 
Figure 1: An integrated view of allergic asthma initiation. This figure presents 
an overview of the cell types and cytokines involved in the initiation of allergic 
asthma. Briefly, allergic sensitization results from aeroallergen exposure and 
recognition of allergenic components by PRRs expressed on the epithelium. This 
leads to the release of soluble mediators such as IL-33, IL-25, TSLP, GM-CSF, and 
CCL20 that play different roles in the recruitment of inflammatory cells such as DCs 
and ILC2. ILCs release Th2 cytokines IL-5 and IL-13 that contribute to recruitment 
of additional inflammatory cells such as epsinophils, and contribute to DC-mediated 
Th2 cell polarization. DCs process and present the allergens to the naïve CD4+ T 
cells in the draining lymph nodes. In the presence of MHC II molecule, co-
stimulatory molecules (co-stim) and Th2 cytokine, Th2 cells are differentiated. Th2 
cells then interact with B cells, in combination with IL-13, leading to the production 
of IgE. IgE can then bind to the surface receptors on mast cells and basophils, 
leading to release of lipid mediators. In the meantime, IL-13 signals on 
macrophages, airway smooth muscle cells, and the airway epithelium to result in 
allergic asthmatic phenotype, marked by airway narrowing, airway 
hyperresponsiveness, mucus production, and elevated levels of the Th2 cytokines 














Figure 2: Glucose catabolism overview with a focus on steps involving ATP and 
the regulation by mTOR and AMPK. When glucose enters a cell from the 
bloodstream, it is immediately converted to glucose 6-phosphate by hexokinase 
(HK) and trapped within the cells for subsequent catabolism. It is then converted to 
fructose 6-phosphate that is converted to Fructose-1,6-biphosphate by phospho 
fructokinase (PFK). Both HK and PFK require ATP. Following these steps, the 
molecule with 6 carbons are then split into two molecules of 3 carbons that are 
converted to 2 molecules of pyruvate, generating 4 molecules of ATP, resulting in a 
net production of 2 molecules of ATP. The further reactions of pyruvate depend on 
metabolic conditions and on the nature of the organism. In normal mammalian 
tissue cells, pyruvate is converted to either lactic acid in the cytosol by lactate 
dehydrogenase, or converted to acetyl-CoA by pyruvate dehydrogenase in the 
mitochondria. Acetyl-CoA undergoes further series of reactions that make up the 
TCA cycle. Altogether, these acetyl-CoA and acetyl-CoA derived from catabolism of 
amino acid and fatty acid are oxidized and carbon dioxide is yielded. Moreover, the 
TCA cycle also provides protons and electrons to the electron transport chain in the 
mitochondria, facilitating its ATP and water production. The TCA cycle generates 34 
molecules of ATP, which together with the 2 molecules generated during glycolysis, 
providing a total of 36 molecules net production of ATP. Activation of receptor 
tyrosine kinase leads to activation of the PI3K/Akt/mTOC1 signaling cascade that 
enhances the activity of the glucose transporter, HK and PFK, whereas energy 





Figure 2: Overview of glucose catabolism with a focus on steps involving ATP 






Chapter 2: Materials and Methods 
 
2.1  Epithelial cell cultures 
2.1.1 BEAS-2B and NHBE cells 
Transformed BEAS-2B human bronchial epithelial cells were purchased 
from ATCC and normal human bronchial epithelial cells (NHBE) were purchased 
from Lonza. Cells were maintained in bronchial epithelial cell growth media (BEGM, 
Lonza) supplemented with bovine pituitary extract (BPE), hydrocortisone, h-EGF, 
epinephrine, transferrin, insulin, retinoic acid, triiodothyronine, and 
gentamycin/ampicillin (BEGM SingleQuot Kit Lonza). Cells were grown on 
collagen/fibronectin coated tissue culture flasks. Cells were passaged when 70-80% 
confluent using 0.05% trypsin. For experiments, cells were plated at 20,000 
cells/well and grown until confluent. Prior to stimulations, cells were starved by 
culturing them overnight in BEGM devoid of bovine pituitary extract.  
 
2.1.2 16HBE cells 
16HBE human bronchial epithelial cells (California Pacific Medical Center, 
San Francisco, CA) were maintained in Dubeco’s minimum essential medium 
(DMEM, Corning) supplemented with 10% fetal bovine serum (FBS), 2 mmol L 
glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin (c-DMEM). Cells were 
grown on collagen/fibronectin-coated tissue culture flasks and passaged by means 
of trypsinization when 80-90% confluent (0.05% Trypsin-EDTA, Gibco). For 





to stimulations, cultures were serum starved overnight with DMEM supplemented 
with 0.1% fetal bovine serum (FBS), 2mmol L-glutamine, 100 U/mL penicillin and 
100 μg/mL streptomycin. 
 
2.2  Allergen extracts and inhibitors 
2.2.1 Allergen extracts 
HDM extract, peanut extract, Alternaria alternata (Alternaria) cell filtrate 
and cockroach extract were all ordered from Greer and re-suspended in PBS at 2.5 
mg/mL based on protein content. Cells were stimulated with HDM (100 μg/mL), 
Alternaria (25 μg/mL), cockroach (25 μg/mL) and peanut (100 μg/mL) for 2 hours.  
 
2.2.2 Inhibitors 
In experiment using inhibitors, cells were pretreated with DCA (Sigma), 
oxamate (Sigma), lactic acid (Sigma) for 1 hour before allergen stimulation, or 
dimethyloxalylglycine (DMOG) (1 mM, Sigma) for approximately 16 hours before 
allergen treatment, or cycloheximide (0.5 μM, Santa Cruz), NSC23766 (Rac1i, 
Tocris), EDTA (0.5 mM, Gibco), Exo1 (20μM, Tocris), oligomycin (4 μM, Tocris), 
compound C (AMPKi, Calbiochem), Pepinh-MYD (10 μM, Invivogen), Pepinh-Control 
(10 μM, Invivogen), BX795 (5 μM, Tocris), ATP (50 µM, Sigma), Suramin (100 µM, 
Sigma) and WRW4 (20 μM, Tocris) for 30 minutes before allergen exposure. 
Experiments were performed with either H2O or DMSO controls according to the 
solvent used for specific inhibitors. In the energy source exchange experiment, cells 





supplemented with 2.5 mM pyruvate (Thermo Fisher Scientific) for approximately 
16 hours before allergen treatment. 
 
2.3  Cell metabolism measurement 
Live cell respiration was measured using XF extracellular flux analyzer 
(Seahorse Bioscience). Cell respiration was quantified by oxygen consumption rate 
(OCR). Glycolysis was measured by extracellular flux acidification rate (ECAR). 
Specifically, BEAS-2Bs were seeded at 12,000 cells/well (50% confluent) in 
Seahorse specialized cell culture plate (Seahorse Bioscience), attached and grew 
overnight. On the next day, cells were washed and switched to buffer free DMEM 
(Seahorse Bioscience) supplemented with BEGM SingleQuot Kit and calibrated for 1 
hour in a CO2 free incubator. Allergen extracts and inhibitors were prepared and 
loaded into the Seahorse sensor cartridge (Seahorse Bioscience) at 20 μL per 
injection port. The concentrations were adjusted so that final concentrations after 
injection into cells were consistent with the other assays. Then cells were loaded 
into the analyzer and calibration was performed per the manufacture’s manual. 
After a stable baseline respiration was achieved, OCR and ECAR were measured 
every 7 minutes for 70 minutes. For lactate secretion, cell culture supernatants or 
BAL were collected and lactate concentration in them was determined with 
colorimetric assay (BioVision). For glucose uptake, 10 μL supernatant was taken 
from each well before and after the allergen and inhibitor treatment. Glucose 
concentration in them was measured using the colorimetric assay (BioVision) and 





between conditions. Extracellular ATP levels were determined using the ATP 
determination kit (Invitrogen) following manufacture’s manual. 
 
2.4  Cell viability 
Cell viability was assessed for BEAS-2B cells as the live cell numbers post 
the treatment with inhibitors. In each condition after allergen and inhibitor 
treatment, live cell numbers were determined using trypan blue or Cell Counting Kit 
– 8 (Sigma). 
 
2.5  IL-33 subcellular translocation measurement 
BEAS-2B cells were treated as described with media or 20 mM DCA for one 
hour followed by 15 minutes with media or HDM (100 μg/mL). Then proteins from 
cytosolic, nuclear and cytoskeleton-attached compartments were extracted using 
the subcellular fractionation kit (Pierce) following the manufacture’s manual. IL-33 
in the supernatant and various subcellular fractions was measured by ELISA. 
 
2.6  siRNA transfection 
Rac1 and AMPK siRNA tranfection was conducted to validate the effects of 
inhibitors. BEAS-2Bs were plated at 15,000 cells/well in flat-bottom 96-well plates 
and allowed to attach and grow overnight. The next day, cells were washed 3× with 
100 μL sterile PBS. DharmaFECT 1 (Dharmacon) was diluted in BEGM media 
(Lonza) without supplements at 2 μL/well. In separate eppendorf tubes, scrambled 





siRNA dilutions were incubated for 5 minutes at room temperature. They were then 
combined and the mixtures were incubated for 20 minutes at room temperature 
before addition to cultures. Cells were then transfected for 48 hours, starved for 
approximately 16 hours, followed by media or HDM stimulation as described. 
Supernatants were harvested and cells were suspended in Trizol for RNA isolation. 
 
2.7  Cell culture supernatant IL-33 Western Blot 
2 ml of BEAS-2B culture supernatants after exposure to HDM with and 
without the presence of DCA were collected and concentrated using Amicon Ultra-
0.5 mL Centrifugal Filters (EMD Millipore). The concentrated 20 μL protein solution 
plus loading dye were boiled for 5 min and resolved on NuPage 12% Bis-Tris gels 
(Invitrogen). Gels were wet transferred to nitrocellulose membranes (Invitrogen) 
and then blocked in Odyssey Blocking Buffer (LI-COR Biosciences) overnight at 4 °C. 
Anti-human IL-33 antibody (R&D) was diluted in Odyssey blocking buffer TO 0.1 
µg/mL and incubated overnight at 4 °C with medium agitation. Blots were washed 
three times in PBST for 10 min and then incubated with IRDye secondary antibody 
(LI-COR Biosciences) in Odyssey blocking buffer plus 0.5% Tween 20 and incubated 
with gentle shaking for 1 hour (protected from light), and the blots were scanned 
and quantified on an Odyssey imaging system. 
 
2.8  Extracellular acidity manipulation 
Acetic acid was added into BEGM cell culture media at the concentration of 





of the BEGM media were determined using the Mettler Toledo S220 SevenCompact 
pH meter (Fisher). 
 
2.9  Mice 
For airway responses, WT BALB/c males were ordered from Jackson 
Laboratories (Bar Harbor, ME) between 6 and 8 weeks of age. All mice were housed 
in a specific pathogen free facility and used one week after delivery. Mice were 
provided autoclaved food (Lab diet 5010) and water ad libitum. This study was 
performed in strict accordance with recommendations in the Guide for the Care and 
Use of Laboratory Animals of Johns Hopkins Bloomberg School of Public Health 
(JHSPH). The protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC) of JHSPH (Permit Number MO12H97). All surgery was 
performed under ketamine/xylazine anesthesia, and all efforts were made to 
minimize suffering. 
 
2.10 Allergen sensitization and challenge 
In early time point experiments, mice received intra-tracheally (i.t.) a single 
dose of HDM (100 μg/40 μL per mouse) or HDM plus intra-peritoneal (i.p.) injection 
of DCA (5 mg/50 μL per mouse) at 1 hour before and once every 8 hours after HDM 
challenge. The mice were sacrificed 18h after HDM treatment. To induce allergic 
asthma, mice were treated as described above on days 0 and 14 with HDM, or HDM 
plus DCA at 1 hour before and once every 8 hours after HDM challenge for the first 





recombinant IL-33 (rIL-33) experiment, mice received intra-nasally (i.n.) a dose of 
rIL-33 (0.5 μg/50 μL per mouse, ebioscience) on days 0, 3 and 6 with or without 
DCA as described, and were sacrificed on day 7. Control mice received PBS (i.t. or 
i.n.) and H2O (i.p.) in all experiments. Mice were anesthetized with 100 μL 
Ketamine/Xylazine (Ketamine: 13.6 mg/mL, Zylazine: 2.12 mg/mL) followed by 
terminal exsanguination. 
 
2.11 Airway responsiveness measurement 
For analysis of AHR, mice were anesthetized by IP administration of 
Ketamine/Xylazine. Mice were then tracheotomized followed by insertion of an 18-
gauge cannula into the trachea. Mice were paralyzed with suxamethonium chloride 
(3 mg/kg), intubated, and respirated at a rate of 120 breaths per minute with a 
constant tidal volume (0.2 mL). After a stable baseline was achieved, methylcholine 
(400 μg/kg) was administered intravenously and dynamic airway pressure (cm H20 
× sec) was monitored for 5 min. Following airway measurement, serum, BAL fluid, 
and lung tissue were harvested and processed as described below. 
 
2.12 Bronchoalveolar lavage (BAL) 
Mice were lavaged by flushing the lungs with 1 ml Hanks buffered salt 
solution (HBSS, Gibco) using a 1 mL syringes inserted into the cannula put in place 
during airway measurements (above). Lavage fluids were kept on ice until 
centrifuging for 5 minutes at 500× g, followed by a 1-minute pulse at 5000× g. 





Supernatants were stored in Eppendorf tubes at –80° C. The cell pellet was 
resuspended in ACK buffer for 3 minutes at room temperature to lyse red blood 
cells. 1 mL of 10% fetal bovine serum (FBS) in PBS was added and cells were again 
centrifuged as described. Supernatants were discarded and the pellet re-suspended 
in 200 mL of 10% FBS in PBS. Total cells were determined by trypan blue. Pellets 
were then adhered to slides by centrifuging in a Cytospin and allowed to dry. Slides 
were then processed with Diff-Quick (Siemens, Newark, DE) for differential cell 
counts. 
 
2.13 Serum collection and IgE measurements 
After airway reactivity and BAL collection, the peritoneal cavity was 
exposed and blood collected with a 1 mL insulin syringe from the inferior vena cava. 
Blood was then transferred into serum collection tubes (BD microtainer). Blood was 
allowed to clot at room temperature for 30 minutes, after which tubes were 
centrifuged for 7 minutes at 10,000 rpm. Serum was removed and stored in 96-well 
culture supernatant plates at –80° C. Serum IgE ELISAs were then performed (BD 
Opti IgE kit, BD Biosciences). 
 
2.14 Histology 
To determine the structural alterations of the airways, formalin-fixed lung 
sections were embedded in paraffin wax, cut into 5 μ sections and stained with 





minimum of three airway sections per animal were examined. Examiners were 
blinded. 
 
2.15 Lung tissue collection and flow cytometry 
After serum collection, the pleural cavity was opened and whole lungs were 
excised. One section of the right lung was removed, placed in a cryovial, and stored 
in liquid nitrogen until transfer to -80° C after experiment completion for RNA 
isolation. The remainder of the lung tissue was placed on a 70 m cell strainer in a 6-
well plate containing 6 mL serum-free Roswell park memorial institute medium 
(RPMI) containing 0.5 mg/mL Liberase (Roche, Madison, WI) + 0.5 mg/mL DNaseI 
(Sigma, St. Louis, MO) per well. Tissue was minced and incubated in digestion media 
for 45 minutes at 37°C. After which, the cell strainer was placed on a 50 mL conical 
tube and the tissue homogenized using the flat end of a 3 mL syringe. Cell strainers 
were then rinsed with the media remaining the in 6-well plates, followed by 10 mL 
complete RPMI (10% FBS + 2mmol L-glutamine, 100 U/mL penicillin and 100 
μg/mL streptomycin, c-RPMI). Cell suspensions were centrifuged at 1600 rpm for 6 
minutes and cell pellets re-suspended in 3 mL ACK lysis buffer for 4 minutes. Lysing 
process was stopped by the addition of 10 mL c-RPMI, and cells were again 
centrifuged at 1600 rpm for 6 minutes. Cell pellets were re-suspended in 1 mL c-
RPMI and cell counts determined by trypan blue. Lung single cell suspension was 
plated in a round-bottom 96-well flat-bottom plate for staining. Cell staining was 
performed at 4°C following incubation with mouse FcBlock (BD) for 30 min. Data 





with lasers tuned to 488nm, 633nm, and 405nm. Spectral overlap was compensated 
and analyzed using the FACSDiVa software (BD Biosciences). 
 
2.16 T cell flow 
Lung cells (0.5 × 106) were stimulated with PMA (100 ng/mL) and 
ionomycin (1 μg/mL) for approximately 16 hours, then Brefeldin A and monensin 
(eBioscience) were added for 4 hours. Cells were fixed, permeabilized and stained 
with anti-CD4-PE-Cy7 (RM4–5), anti-TCRβ FITC (H57-597), and anti-IL-13e660 
(eBio13A). 
 
2.17 ILC flow 
Lung-single cell suspensions were plated at a density of 5 × 106 cells in c-
RPMI in a 6-well-flat bottom culture plate. Cells were stimulated with PMA (100 
ng/mL) and ionomycin (1 μg/mL) for approximately 16 hours, then Brefeldin A and 
monensin (eBioscience) were added for 4 hours. ILC2s (Lineage-, CD45+, ST-2+, IL-
13+) were identified using following antibodies. Lineage (Lin) cocktail (PerCPCy5.5) 
contains anti-CD3ε (145-2C11), anti-TCRβ (H57-597), anti-CD11b (M1/70), anti-
CD11c (N418), anti-Gr1 (RB6-8C5), anti-B220 (RA3-6B2), and anti-NK1.1 (PK136). 
Lin- cells were then gated using anti-CD45 (30-F11), anti-ST-2 FITC (T1/ST2) and 
anti-IL-13 PE (ebio13A). 
 





IL-33, IL-8, and IL-6 levels were measured from BEAS-2B culture 
supernatants. IL-33 and IL-13 level were measured from BAL of mice. All the 
cytokine measurements were conducted with ELISA Duo-Sets (R&D). 
 
2.19 Quantitative real-time PCR (RT-PCR) 
Total RNA from mouse lungs and epithelial cell cultures was isolated with 
Trizol according to manufacture’s protocol (Life Technologies). RNA was quantified 
by absorbance at 260 nm and purity determined by 260/280 ratios as measured by 
NanoDrop. 1 μg of RNA (lung tissue) or 500 ng RNA (epithelial cells) was used as a 
template for cDNA synthesis. RT-PCR was performed with iTag Universal Syber 
Green Mix, Hot-Start (BioRad) and specific primers. 
 
2.20 Statistical analysis. 
Analysis of variance (ANOVA) followed by the Dunn’s post test was used for 
analysis of differences among multiple groups. Student's t-test was used for 







Chapter 3: HDM-induced Rapid Increase of Anaerobic Glycolysis Mediates IL-
33 Release from Bronchial Epithelial Cells 
 
3.1  Introduction 
Allergic asthma is a chronic inflammatory disease of the airways that is 
thought to arise as a result of aberrant type-2 immune responses to innocuous 
environmental allergens. Of the allergens, house dust mite (HDM) is the most 
common aeroallergen to which atopic asthmatics are sensitized [375], and 
sensitization to HDM has been shown to be a major risk factor for the development 
of asthma [30, 376]. As a result, dissecting the pathways by which HDM induces 
allergic asthma remains a major goal in asthma research. The pathogenesis of 
allergic asthma has been extensively studied, and the mechanisms as well as factors 
involved in driving the downstream pathology of the disease such as eosinophilia, 
CD4+ Th2 cell infiltration, and bronchoconstriction are well described. However, the 
initiation of allergic asthma remains to be defined.  
It has long been appreciated that airway epithelial cells play critical roles in 
the initiation of innate and adaptive immune responses to diverse environmental 
allergens [377, 378], contributing to the development of allergic asthma [227]. The 
predominant mechanism by which the airway epithelium mediates allergic disease 
initiation and/or progression is by releasing various cytokines that promote type-2 
immune responses [379]. Among these cytokines, the IL-1 like protein IL-33, which 
has a β-trefoil fold in its carboxy-terminus similar to other IL-1 family members for 





to play a central role in allergic inflammation [238]. IL-33 ligation of ST2 has been 
shown to activate Myd88-dependent signaling pathways in target cells expressing 
the ST2/IL-1RAcP receptor complex [238, 239] including ILC2s, mast cells, 
basophils, eosinophils and Th2 cells [380], leading to their production of pro-
inflammatory mediators. IL-33 is constitutively expressed and located mainly in the 
nuclei of tissue structural cells including epithelial cells, endothelial cells and 
fibroblasts [240]. It was originally thought to function as an “alarmin” as it is 
released during cell necrosis, while it is cleaved and inactivated by caspases during 
apoptosis [240-242]. It was also found to be cleaved by calpain as well as neutrophil 
elastase and cathepsin G to generate mature forms from the full-length protein with 
enhanced biological activity [243]. More recently, it has been recognized that IL-33 
is also released upon environmental exposures to allergens, virus infection and 
mechanical stress [244-247]. 
Numerous lines of evidence suggest that IL-33 plays a crucial role in the 
pathogenesis of allergic asthma. The observation that increased expression of IL-33 
in the lung tissue of asthmatic patients [381] as well as the identification of Il33 and 
ST2/Il1rl1 (IL-33 receptor) genes as major asthma susceptibility loci [18] indicate 
its importance in mediating allergic asthma in humans. Meanwhile, a growing 
number of studies in experimental models of asthma have demonstrated its critical 
role in the development of allergen-induced airway hyperresponsiveness, 
eosinophilia and excessive mucus production [240, 382]. It is believed to drive 
initial activation of both innate and adaptive aspects of type-2 immune responses via 





For example, IL-33 contributes to DC activation and migration [255]. It also supports 
macrophage transition to the M2 subset and amplifies the M2 responses [261]. It 
promotes mast cell and granulocyte activation as well as pro-inflammatory cytokine 
release [266, 278]. Most importantly, IL-33 induces IL-5 and IL-13 production by 
ILC2s and CD4+ T cells [383]. As a result, IL-33 in the lung is always linked to 
inappropriate activation of immune responses against environmental allergens and 
local allergic inflammation. 
Despite the importance of IL-33 to allergic disease, the mechanisms by 
which allergens drive its secretion remain incompletely understood. As discussed 
earlier, it was initially thought to be released as a result of cellular damage/injury 
and death for its main location in the nucleus [248]. However, several groups have 
recently proved that allergens and environmental stimuli can also induce live cell 
release of pre-formed IL-33 within minutes from vesicular compartments other than 
the nucleus where this cytokine resides [244, 245, 247]. For example, the fungal 
allergen, Alternaria alternata (Alternaria) has been shown to induce IL-33 release 
from airway basal cells without signs of cell death [244] and to be associated with 
IL-33 release and allergic inflammation [249]. Specifically, Kouzaki et al. report that 
Alternaria induces the rapid release of the danger signal, ATP, by airway epithelial 
cells. This ATP then activates the P2 purinergic receptor to induce increases in 
intracellular calcium that are required for IL-33 release [244]. A more recent study 
supports this hypothesis and demonstrates that the elevated intracellular calcium 
may activate NADPH oxidase dual oxidase 1 (DUOX1)-mediated activation of 





process IL-33 into its mature form for release [245]. These studies greatly advanced 
our understanding of the rapid secretion of IL-33 by airway epithelial cells, but the 
exact pathway directly facilitating the release of IL-33 was not addressed. However, 
another group found that release of IL-33 from live cells was dependent on 
cytoskeleton and cytosolic vesicles-mediated translocation [247].  
As the exact pathway mediating IL-33 release is unknown, the involvement 
of ATP and cytoskeleton suggests that IL-33 live cell secretion is potentially 
dependent on appropriate energy or substrates generated in the cells during 
metabolism. In fact, emerging evidence also suggests that cellular glucose 
metabolism regulates many vital pathways for the release of certain factors such as 
lipid mediators, cytokines, and hormones during the activation of immune cells 
[323-326]. IL-33 release from nuclear and vesicular compartments of live cells upon 
environmental exposure [244, 247] shares many similarities with the release of 
other mediators regulated by cell metabolism: they are all released as pre-formed 
substrates from cells, and membrane formed vesicular structures are likely involved. 
Moreover, recent studies also show that pulmonary resident cells may undergo or be 
affected by metabolic alterations during allergic asthma [369-372]. For example, it 
has been shown that OVA sensitized rats have significantly increased expression of 
proteins related to glycolysis (pyruvate kinase, phosphoglycerate kinase 1, 
glyceraldehyde 3-phosphate dehydrogenase), calcium signaling, and mitochondrial 
activities in the lung [371]. OVA-sensitized mice have more lactate in the BAL [372]. 
Importantly, increased serum lactate levels are observed in humans, which together 





370]. Collectively, these studies suggest that an alteration in the balance of glucose 
metabolism between glycolysis (which generates lactate and acidic environment) 
and OXPHOS (which consumes oxygen and leads to terminal metabolism of glucose 
into CO2 and H2O) is associated with allergic asthma in both experimental asthma 
models and human asthmatics.  
As the association of glucose metabolism with allergic asthma is more 
compelling, we hypothesize that HDM-driven IL-33 release may be facilitated by 
allergen-induced cell glucose metabolism changes in airway epithelial cells. To test 
this hypothesis, we evaluated the IL-33 release pattern and metabolism phenotype 
(live cell respiration and glycolytic flux, lactate production, glucose uptake) in the 
human transformed airway epithelial cell line, BEAS-2B, following treatment with 
HDM and blockade modulation of the glycolytic pathways.  
In the present study, we observed rapid live cell secretion of IL-33 by HDM 
independently of de novo protein synthesis. This is concomitant with an immediate 
increase in glycolytic flux. When the enhanced glycolysis was inhibited by DCA, IL-
33 release was also reduced. These results confirmed our hypothesis that HDM-
induced rapid increase of glycolytic flux associated with IL-33 release in airway 
epithelial cells. 
 
3.2  Results 






We first sought to understand the concentration-response relationship 
between HDM exposure and IL-33 production by airway epithelial cells. To 
determine the optimal concentration of HDM for the analyses, BEAS-2B cells were 
seeded at 20,000 cells/well and serum starved overnight. The cells were then 
treated with HDM at varying concentrations (50 μg/mL, 100 μg/mL and 200 
μg/mL) for 2 hours, and IL-33 levels in the supernatants were measured with ELISA. 
We found that HDM induced significant increases in IL-33 release at all the tested 
concentrations, with a trend suggesting that the release of IL-33 peaked when at a 
dose of 100 μg/mL of HDM. At concentrations lower than 100 μg/m, IL-33 levels 
were around the detection limit of ELISA (data not shown). Moreover, a previous 
study published by our group found that 100 μg/mL HDM exposure was the optimal 
concentration for analyzing HDM-induced release of CCL20 [233], a chemokine 
likely playing important roles in allergic asthma by recruitment of immature DCs 
through its receptor CCR6 [384]. Taken these data together, we used 100 μg/mL 
HDM in the subsequent analysis for both technical and biological reasons. To 
understand the temporal pattern of HDM-induced IL-33 production, BEAS-2B cells 
were seeded at a density of 20,000 cells/well and then serum starved for 24 hours 
followed by treatment with either media control or HDM (100 μg/mL) for varying 
lengths of time (30 minutes, 2 hours, 4 hours, 8 hours and 24 hours) [233, 384]. IL-
33, IL-6 and IL-8 were measured by ELISA in the cell culture supernatants. 
Consistent with previous reports, we found that HDM induced a time-dependent 
rapid increase in IL-33 release. IL-33 was released as early as 30 minutes and 





not observed in the supernatants until 2 hours post-HDM exposure, and peaked at 
24 hours after the beginning of HDM treatment (Fig. 3C – D). 
To determine whether HDM-induced IL-33 release resulted from cell death, 
cell viability was determined using WST-8. Specifically, WST-8 is reduced by cellular 
dehydrogenases to an orange formazan product that is directly proportional to the 
number of living cells, so live cell number was reflected by the absorbance at 450 
nm after a 2 hour incubation with WST-8. The viability of cells didn’t significantly 
differ between cells treated with HDM and media (Fig. 3E). To investigate whether 
the secreted IL-33 was newly synthesized or released pre-formed from an 
intracellular store, we treated cells with cycloheximide, an inhibitor of eukaryotic 
cell protein translation [385]. Following the same culture protocol described above, 
BEAS-2B cells were pre-treated with 0.5 μM cycloheximide for 30 minutes followed 
by HDM (100 μg/mL) treatment for 5, 10, 50 and 100 minutes. As expected, HDM 
exposure induced the rapid release of IL-33, and cycloheximide did not inhibit IL-33 
secretion (Fig. 3F), indicating that the rapidly secreted IL-33 was from pre-formed 
intracellular storage of the protein. 
 
3.2.2 HDM exposure caused rapid concomitant increases in glycolysis and 
IL-33 release in airway epithelial cells. 
As discussed above, alterations in glucose metabolism have been associated 
with the rapid induction of immune cells and cytokine release, and we hypothesize 
that HDM also induces rapid metabolic alteration, likely increased glycolysis, that is 





pathways, one molecule of glucose is metabolized to pyruvate, which is then either 
converted via glycolysis to lactic acid (1 molecule of lactate and 1 proton) in the 
cytosol, or fully oxidized to CO2 and H2O via oxidative phosphorylation (OXPHOS) in 
the mitochondria in the presence of O2 [330]. To investigate whether allergen 
exposure of epithelial cells is associated with changes in cellular glucose 
metabolism, we measured the production of extracellular protons (extracellular 
acidification), oxygen consumption, lactate production and glucose uptake in BEAS-
2B cells. Specifically, cells were seeded at a density of 12,000 cells/well. They were 
cultured overnight, and then placed in a closed chamber with controlled air 
exchange in an extracellular flux analyzer (Seahorse), which monitored culture 
media pH and calculated the glycolytic flux by extracellular acidification rate (ECAR) 
as well as O2 partial pressure changes to calculate the rate of OXPHOS as oxygen 
consumption rate (OCR). Cells were measured every 7 minutes for a total of 70 
minutes. Once the baseline respiration rate was obtained after the first 3 
measurements, media or HDM (final concentration of 100 μg/mL) was injected into 
the cell chamber before the 4th measurement. Compared to cells injected with 
media, there was a significant immediate increase in glycolysis (ECAR) in HDM 
injected cells (Fig. 4A), while OXPHOS remained relatively stable (Fig. 4B). To 
determine whether similar changes were observed in lactate production, lactate 
levels in the culture supernatants of BEAS-2B cells treated with HDM were 
measured by colorimetric assays. Similarly, glucose levels in the HDM-treated cell 
supernatants were calculated to reflect glucose uptake. Consistent with the ECAR 





significantly increased after 2 hours of HDM exposure as compared to that 
measured in media-treated cells (Fig. 4C). Likewise, the calculated glucose uptake 
was also significantly increased in cells exposed to HDM versus those treated with 
media (Fig. 4D). The concomitantly conducted ELISA revealed that cells treated with 
HDM secreted IL-33, while controls cells did not (Fig. 4E). To determine whether 
our findings in the transformed epithelial cell line (BEAS-2B cells) translated to 
primary human epithelial cells, normal primary human airway epithelial cells 
(NHBE) were seeded at 20,000 cells/well and treated with either media or HDM 
(100 μg/mL) for 2 hours. Consistent with our findings in BEAS-2B cells, we 
observed that HDM exposure resulted in significantly increased lactate production 
and IL-33 release by NHBE cells (Fig. 4G). 
To determine whether these metabolic changes were unique to HDM or 
were a common feature of allergenic stimuli, we compared the effects of HDM (100 
μg/mL), LPS (500 ng/mL), peanut extract (100 μg/mL), Alternaria (25 μg/mL) and 
cockroach (25 μg/mL) extracts on extracellular lactate levels. We observed that 
while HDM exposure induced significant increases in lactate production as 
compared to media controls, none of the other stimuli induced lactate production in 
airway epithelial cells (Fig. 4F). Taken together, our results showed that HDM 
exposure caused rapid increases in glycolytic flux, concomitant with IL-33 release. 
Whether these two events are linked is currently unknown.   
 
3.2.3 Inhibition of anaerobic glycolysis diminished HDM-induced IL-33 





Given that we observed significant increases in glycolysis along with IL-33 
release from airway epithelial cells over the same timeframe, we hypothesized that 
the two events are linked and that changes in glycolysis may regulate IL-33 release 
from airway epithelial cells. To assess the effect of blockade of glycolysis on IL-33 
release, we utilized sodium dichloroacetate (DCA), a small molecule inhibitor of 
pyruvate dehydrogenase kinase which increases glucose oxidation by inhibiting 
mitochondrial pyruvate dehydrogenase kinase 1 (PDK1), thereby decreasing lactate 
production and glycolytic flux [386]. Specifically, we determined the effects of DCA 
on lactate and IL-33 levels in HDM-exposed cells. To determine the concentration of 
DCA that modulated lactate without causing cellular toxicity, BEAS-2B cells were 
seeded at 20,000 cells/well and treated with varying concentrations of DCA (0.2 
mM, 2 mM, and 20 mM) for 1 hour. Lactate levels in the supernatants were 
measured. It was observed that as the concentration of DCA increased, the level of 
lactate in the media was decreased (Fig. 5A). To determine whether DCA was toxic 
to these cells, the cells were treated with the highest concentration of DCA at 20 mM 
for 4 days, and cell viability was determined everyday at the same time using the 
WST-8 assay. We confirmed that DCA treatment had no cytotoxic effects, as the 
viability of cells treated with DCA did not differ from those in media alone (Fig. 5B). 
Based on these data, we utilized 20 mM of DCA to pre-treat HDM- and media-treated 
BEAS-2B cell 1 hour prior to HDM exposure, and conducted the same assays of 
cellular metabolism and IL-33 measurement as described in 3.2.2.  
As shown in Fig. 5C, DCA inhibits PDK1, a natural regulator of OXPHOS, to 





the Seahorse experiments, cells were seeded and treated with 20 mM DCA for 1 
hour before loading onto Seahorse for ECAR and OCR measurements. Again, we saw 
a significant increase in ECAR immediately after HDM (100 μg/mL) injection into 
the cell culture. However, cells pre-treated with DCA had significantly lower HDM-
induced ECAR (Fig. 5D) due to a shift of glucose metabolism pathways towards 
OXPHOS (Fig. 5E). To determine whether lactate, glucose and IL-33 levels changed 
in concert with the ECAR and OCR changes, these mediators were measured in 
BEAS-2B cells pre-treated with either DCA or media, following by media or HDM 
(100 μg/mL) treatment for 2 hours. DCA treatment of cells significantly reduced the 
HDM-induced increases in lactate production (Fig. 5F), glucose uptake (Fig. 5G) and 
IL-33 release (Fig. 5H). To confirm that DCA did not cause cell death in the presence 
of HDM, the viability of these cells was determined by trypan blue exclusion. DCA 
treatment did not cause cell death in the presence of HDM (Fig. 5I). As the inhibition 
of anaerobic glycolysis with DCA significantly reversed allergen-stimulated 
increases in glycolytic flux and IL-33 release, our results suggest that that the rapid 
increase of glycolysis by HDM exposure was associated with its induction of IL-33 
release by airway epithelial cells. 
  To confirm that inhibition of anaerobic glycolysis reduced HDM-induced IL-
33 release, we modulated glycolysis with another inhibitor oxamate to analyze its 
effects on IL-33. Similarly, to determine the concentration of oxamate that 
modulated lactate without causing cellular toxicity, BEAS-2B cells were seeded at 
20,000 cells/well and treated with varying concentrations of oxamate (12.5 mM, 25 





that as the concentration of oxamate increased, lactate production was decreased 
(Fig. 6A). To determine whether oxamate was toxic to these cells, live cell numbers 
were determined using trypan blue. We observed no significant cell death after 
treatment with oxamate (Fig. 6B). Based on these data, we utilized 50 mM of 
oxamate to pre-treat BEAS-2B cells for 1 hour followed by 2 hours HDM exposure. 
Similar as DCA treatment, as HDM consistently induced IL-33 release by BEAS-2B 
cells, oxamate treatment significantly reduced IL-33 in the media (Fig. 6C). 
 
3.3  Discussion 
  As IL-33 has been shown to be critical in the initiation of allergic 
inflammation [240], our finding that allergens induce the rapid release of IL-33 from 
the cells lining the airways through a novel mechanism involving alterations in 
cellular metabolism represents an important advance in our understanding of the 
mechanisms by which allergens initiate the inflammatory responses associated with 
the asthma phenotype. Specifically, we showed that HDM exposure led to early IL-
33 release from airway epithelial cells within 30 minutes (Fig. 3B), and confirmed 
that this release is independent of cell viability changes (Fig. 3E). Unlike the 
previous hypothesis that IL-33 is mainly released from the damaged nucleus upon 
cell necrosis, our results have provided additional support for the contention that 
IL-33 can be released from live cells in response to external stimuli such as certain 
allergens [244-247]. One potential limitation of the current study is the lack of a 
comprehensive concentration-response analysis of HDM-induced IL-33. In the 





authors showed that the levels of IL-33 released by primary human cells were 
increased with greater doses of HDM (within 0 – 30 μg/mL), and cells from 
asthmatic individuals produced more IL-33 compared to those from healthy 
individuals [245]. In our studies, we used a higher concentration at which HDM 
could induce significant release of both IL-33 and CCL20, the important epithelial-
derived cytokines playing roles in asthma, as we intent to mimic the possible 
condition in the airway in which multiple cytokines can be induced by 
environmental stimuli [387]. Moreover, in a theoretical analysis of the physiological 
relevant concentrations of HDM in the airways, it was acknowledged that while no 
direct evidence was available to translate the epidemiological measurements of 
HDM levels in the ambient into concentrations for in vitro analysis, normal exposure 
could lead to very high concentrations of HDM allergens depending on the closeness 
of individuals to dust-rich areas, accumulative exposures, and the anatomical 
conditions of the airways. As a result, it was concluded that physiological relevant 
concentrations of HDM could range from nanogram level to milligram level [28]. 
The fact that the IL-33 release is independent of de novo protein synthesis 
(Fig. 3F) suggests a mechanism of rapid translocation of pre-formed proteins from 
stores in the cell to the extracellular milieu. This is consistent with a recent report 
showing that HDM exposure induces the early release of IL-33 independently of 
changes in message expression [245]. Taken together our studies have confirmed 
the new concept that IL-33 is secreted by live cells under stress, and provide a 
potential mechanism for the link between HDM exposure and allergic asthma. 





epithelial cells, the current data highlights the uniqueness of IL-33 secretion 
induced by HDM, suggesting the importance of understanding its regulatory 
mechanisms. 
Our study has provided several lines of evidence to support a novel 
mechanism by which dust mite exposure at the airway surface triggers the release 
of the type-2 promoting cytokine, IL-33, namely through induction of changes in 
cellular metabolism, resulting in a shift towards anaerobic glycolysis for energy 
production. Indeed, we analyzed the metabolic phenotype of airway epithelial cells 
post-HDM exposure and reported for the first that HDM caused a rapid increase in 
glycolysis in airway epithelial cells. Using the advanced extracellular flux analyzer, 
we showed that HDM exposure led to a rapid increase in glycolysis within minutes 
(Fig. 4A), and confirmed this finding with increased lactate production (Fig. 4C) and 
glucose uptake (Fig. 4D) by the cells. Normally, after cells take up glucose molecules, 
they will first go through a few steps to convert one molecule of glucose into two 
molecules of pyruvate. Following this, a large portion of the pyruvate will be 
metabolized into Acetyl-CoA, the substrate for the TCA cycle that occurs in the 
mitochondria (OXPHOS), and the rest of the pyruvate will remain in the cytosol to be 
converted into lactic acid (lactate and proton) [327]. Thus, under normal 
physiological conditions, glycolysis and OXPHOS are balanced. However, although 
HDM induced significant increases in the amount of glucose taken up by the cells, 
instead of both glycolysis and OXPHOS being increased, only glycolysis was 
significantly induced, while the OXPHOS remained relatively stable (Fig. 4B). We 





glycolysis and OXPHOS, resulting in increased glycolytic flux. This tenet is supported 
by our observation that HDM exposure resulted in elevations in the end product of 
glycolysis namely lactate, as well as an increased demand for its substrate, glucose. 
However, this finding is restricted to the earlier phase (within 2 hours) post-HDM 
exposure. Although IL-33 release peaks at the earlier time point, the live cell 
respiration data also suggested that HDM-induced glycolytic flux persisted for at 
least 70 minutes (the maximum length of time that cells could be maintained under 
the experimental conditions required for Seahorse measurements) (Fig. 4A). These 
data pose new questions for future investigation: do HDM-induced early metabolic 
alterations persist for longer than 70 minutes? Does HDM induce different 
metabolic phenotypes in cells after different lengths of exposure? Whether a later 
(maybe also different) metabolic phenotype is associated with IL-33 release? Do 
metabolic alterations contribute to epithelial response to HDM exposure via 
mechanisms other than mediating IL-33 release? Answering these questions will 
provide insights into HDM-induced physiological and pathological changes in the 
airway epithelium. 
Although this is the first report showing that HDM exposure induces 
metabolic changes in airway epithelial cells, our finding is consistent with previous 
reports of altered metabolism in asthma patients, which may contribute to the 
acidic airway lining fluids observed in asthmatic individuals [369, 370]. Moreover, 
previous reports of alterations in lung glycolytic protein profiles following OVA 





alterations may represent an early response of cells to environmental stimuli and 
accounts for allergic inflammation.  
The concept of exogenous stimuli causing cellular metabolic changes has 
recently garnered considerable interest. Indeed, activation of a wide variety of 
immune cells including granulocytes [333-336], DCs [337, 338], macrophages [339, 
340], T cells [321, 341, 342] and B cells [343, 344] has been shown to be dependent 
on metabolic alterations. Specifically, a recent study reported that LPS exposure 
caused rapid induction of glycolytic activity in DCs that drove cytokine production 
and MHC molecule loading [338]. Although this observation might imply that LPS 
and HDM may activate similar signaling pathways leading to IL-33 release and 
glycolytic flux, both our colleagues (data not published) and a recent study have 
shown that LPS exposure does not induce early IL-33 release from airway epithelial 
cells [245]. Moreover, by measuring lactate production of these cells following LPS 
exposure, we showed that LPS did not induce increased glycolytic flux (Fig. 4F). 
Although the BEAS-2B cells do express the TLR4, which recognizes LPS [388], it is 
reasonable to hypothesize that TLR4 activation may preferentially lead to different 
downstream signaling pathways in epithelial cells compared to DCs. Also, it is 
possible that other portions of HDM regulate the induction of IL-33 and glycolysis. 
Interestingly, our findings further suggest that the induction of IL-33 
through stimulation of glycolysis may be somewhat specific to HDM. In addition to 
LPS, other allergens and contaminants of allergens including peanut, Alternaria and 
cockroach allergens did not increase lactate production (Fig. 4F). This is surprising 





induce IL-33 release from airway epithelial cells. Although these results may appear 
discordant, it is possible that either certain unique component(s) of HDM drive the 
induction of glycolysis, or that IL-33 release by airway epithelial cells is regulated by 
multiple pathways depending upon the nature of the stimulus. Evidence supporting 
such a hypothesis is lacking, as little research has been done comparing the IL-33 
induction capacity of different components from each allergen extract. Likewise, 
none of the studies to date have elucidated the secretion pathways of IL-33 
following allergen exposure besides showing the involvement of calcium signaling 
[244, 245]. Understanding the underlying pathways for IL-33 release, or in this case, 
translocation, would provide some insights. However, the current data should also 
be interpreted with caution. In our study, concentration-response and viability 
analyses for the other stimuli have not been conducted. Although BEAS-2B cells 
were reported to be resistant to LPS toxicity at the tested concentration [390, 391], 
and Alternaria exposure was found to have very low toxic effects on BEAS-2B cells 
[392], a thorough analysis is still needed to provide a clear answer.  
Measuring glycolysis solely as changes in lactate levels also has its 
limitations. Lactate is only an end product of anaerobic glycolysis. Thus our data 
does not rule out the possibility that other allergens also induce metabolic 
alterations under the following circumstances: (1) other allergens induce pathways 
or mechanisms compensating the production of lactate, shadowing the induction of 
lactate; (2) other metabolic alterations are induced which also provides energy, 
signaling substrates, or physiological environment as provided by glycolysis to 





within a different timeframe, making detection of lactate at this moment difficult. As 
a result, the current data should not be taken as the final conclusion that only HDM 
induces metabolic alterations in airway epithelial cells, and further phenotyping of 
airway epithelial cell metabolism after exposure to other environmental stimuli 
should be conduction.  
Overall, our study is successful in attempting to understand whether 
environmental allergen causes cell metabolic changes. Our glycolysis blockade 
studies utilizing the small molecular inhibitor, DCA, further provided a link between 
allergen-triggered changes in glycolysis and IL-33 release for the first time. Our 
results were consistent with a previous study showing that DCA treatment of mice 
abrogates ragweed-induced allergic airway inflammation [26]. More importantly, 
our studies provide a potential mechanism by which allergen-driven alterations in 
glycolysis regulate allergic inflammation, namely through the early induction of the 
type-2 promoting cytokines, IL-33. Moreover, as IL-33 is a pivotal cytokine in type-2 
immune responses with unclear regulation mechanism, our novel finding of cell 
metabolism as a contributor of its release also provides insights into how 
environmental stimuli induce the secretion of IL-33 to initiate allergic inflammation. 
More than providing answers to the scientific questions we are asking, our 
data also supports the possibility of using DCA for the blockade of IL-33. DCA has 
been used as a clinically approved oral therapy for lactic acidosis [393-395], and can 
reverse the Warburg effect in cancer cells to bio-energetically improve prognosis of 
cancer therapies [396, 397]. A recent study revealed amelioration effect of DCA on 





description of the effects of DCA on airway epithelial cells. Our study demonstrated 
that while DCA reversed HDM-induced glycolysis enhancement in airway epithelial 
cells, it also reduced the release of IL-33. Considering the potential roles of IL-33 in 
multiple diseases and health conditions, the use of DCA may extend beyond lactic 
acidosis and cancer. 
As we show an association between HDM-induced increases in glycolytic 
flux and IL-33 release, we took one step further and confirmed this using another 
glycolysis inhibitor, oxamate (Fig. 6). More than just reproducing our observation, 
utilizing glycolysis inhibitors targeting different pathways also provides hints to the 
possible mechanism by which glycolysis is linked to IL-33 release. As discussed 
earlier, DCA inhibits PDK1 and leads to the enhancement of OXPHOS. The increase 
in OXPHOS then consumes more pyruvate, the substrate for generating lactate via 
anaerobic glycolysis, and leads to reduced glycolysis activities [398]. Unlike DCA, 
oxamate directly inhibits lactate dehydrogenase (LDH) and thus inhibits the 
production of lactic acid, the very last step in anaerobic glycolysis [399]. While both 
inhibitors block glycolysis, the shared pathway that is blocked is the pyruvate 
conversion into lactic acid, which generates lactate, protons, and promotes the 
generation of glycolysis-derived ATP [330]. As both DCA and oxamate reduced 
HDM-induced IL-33 release, it is thus reasonable to hypothesize that the reduction 
of IL-33 is associated with reductions in glycolysis-derived lactate, proton, or 
glycolytic ATP.  
However, despite the novel observation that HDM-induced glycolysis is 





limitations. Specifically, the transformed airway epithelial cell line BEAS-2B may not 
fully represent the response of epithelial cells in the airway. Our data with NHBE 
cells suggest that HDM exposure also causes concomitant increases in glycolysis and 
IL-33 release in normal primary airway epithelial cells. Although this observation 
supports the importance of metabolic changes in allergen-driven IL-33 release in 
normal cells, studies assessing the metabolic responses of primary airway epithelial 
cells from asthmatics and healthy controls exposed to HDM is still needed. Both our 
colleagues and a recently published study revealed that airway epithelial cells 
isolated from asthmatics produce more IL-33 after HDM exposure compared to cells 
from normal individuals [245]. Whether glycolysis increases induced by HDM are 
also greater in asthmatics compared to healthy subjects remains to be determined. 
Moreover, the current culture system may also limit the generalizability of our 
results, as they are only 2-dimensional, whereas epithelial cells reside in a 3-
dimensional structure in the airway lumen. To better emulate the epithelium in vivo, 
an air-liquid interface culture system that allows cells to differentiate into the multi-
cellular layer seen in vivo would be utilized for future studies. 
Overall, our data strongly supports the hypothesis that HDM induces 
metabolic changes in airway epithelial cells that are associated with IL-33 secretion. 
Further studies are needed to elucidate the underlying mechanisms/pathways 






3.4  Figures 
Figure 3: HDM induced rapid live cell release of IL-33 independently of de 
novo protein synthesis. BEAS-2B cells were seeded in flat-bottom 96-well plates at 
a density of 20,000 cells/well and then serum starved for 24 hours followed by 
treatment with either media control or HDM (50 μg/mL, 100 μg/mL, and 200 
μg/mL) for 2 hours. (A) IL-33 levels in the supernatant were determined. To 
understand the temporal pattern pattern of cytokine release induced by HDM, 
BEAS-2B cells were seeded at a density of 20,000 cells/well in flat-bottom 96-well 
plates and serum starved overnight. These cells were then treated with either media 
control or HDM (100 μg/mL). Cell culture supernatants were collected at 30 
minutes, 2 hours, 8 hours and 24 hours post-exposure for (B) IL-33, (C) IL-6 and (D) 
IL-8 measurement. (E) Cell viability was determined at the end of the 2 hours HDM 
exposure. To determine if de novo protein synthesis was required, (F) cells were 
seeded and treated with 0.5 μM cycloheximide for 30 minutes and then 100 μg/mL 
HDM (conducted by Smole) for IL-33 release. Data presented as mean values ± SEM 
for biological replicates n=3-6, *p<0.05, ****p<0.0001 (student’s t test, one-way 
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Figure 4: HDM exposure caused rapid concomitant increases in glycolysis and 
IL-33 release in airway epithelial cells. BEAS-2B cells were seeded in flat-bottom 
96-well plates at a density of 12,000 cells/well for live cell respiration 
measurements (Seahorse), and 20,000 cells/well for lactate production, glucose 
uptake and IL-33 measurements. For Seahorse assays, cells were equilibrated in a 
CO2 free tank with buffer free media for 1 hour and then loaded into the Seahorse. 
(A) ECAR and (B) OCR were then measured for 10 times within 70 minutes 
following the manufacturer’s instructions, HDM (100 μg/mL final concentration) 
was injected before the 4th measurement. For lactate, glucose and IL-33 
measurements, cells were seeded and then serum starved for 24 hours followed by 
treatment with either media control or HDM (100 μg/mL) for 2 hours. Cell culture 
supernatants were collected for (C) lactate, (D) glucose and (E) IL-33 measurement 
(Chapter 2.12 & 2.13). To test whether other environmental stimuli also induced 
increase glycolysis, BEAS-2B cells were exposed to HDM (100 μg/mL), LPS (500 
ng/mL), peanut (100 μg/mL), Alternaria (25 μg/mL) and cockroach (25 μg/mL) for 
2 hours, and (F) lactate levels in the supernatants were determined. To validate 
these data in primary normal airway epithelial cells, NHBE cells were seeded in flat-
bottom 96-well plates at a density of 20,000 cells/well, serum starved and treated 
with either media or HDM (100 μg/mL) for 2 hours. Cell culture supernatants were 
collected for (G) lactate and IL-33 measurements. Data presented as mean values ± 
SEM for biological replicates n=3-6, *p<0.05, **p<0.01, ****p<0.0001 (student’s t 
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Figure 5: Inhibition of anaerobic glycolysis by DCA diminished HDM-induced 
IL-33 secretion by airway epithelial cells. To determine the correlation between 
HDM-induced early IL-33 release and glycolytic flux, BEAS-2B cells were seeded at 
20,000 cells/well and treated with DCA (0.2 mM, 2 mM, 20 mM) for 1 hour. (A) 
Lactate levels in the cell culture supernatants were determined and 20 mM was 
identified as the effective dose of DCA. The cells were then treated with 20 mM DCA 
for 4 days, and (B) cell viability was measured with WST-8 every day at the same 
time. The cells were then seeded as described in Figure 4, pre-treated with 20 mM 
DCA for 1 hour to (C) inhibit glycolytic flux and then exposed to HDM (100 µg/mL) 
for measurements of (D) ECAR, (E) OCR, (F) lactate production, (G) glucose uptake 
and (H) IL-33 release as described in Figure 4. To assess the cell viability changes 
after DCA treatment in the presence of HDM, cells were pre-treated with either 
media or 20 mM DCA followed by HDM (100 µg/mL) exposure for 2 hours, (I) and 
the numbers of live cells were assessed with trypan blue. Data presented as mean 
values ± SEM for biological replicates n=3-6, *p<0.05, **p<0.01, ***p<0.001, 
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Figure 6: Inhibition of anaerobic glycolysis by oxamate diminished HDM-
induced IL-33 secretion by airway epithelial cells. BEAS-2B cells were seeded in 
flat-bottom 96-well plates at a density of 20,000 cells/well and then serum starved 
for 24 hours. They were then treated with 12.5 mM, 25 mM, 50 mM and 100 mM 
oxamate for 1 hour for (A) supernatant lactate level measurement and (B) cell 
number determination (Trypan blue). According to these data, 50 mM was chosen 
as the effective dose of oxamate. BEAS-2B cells were then seeded at 20,000 
cells/well, serum starved for 24 hours, pre-treated with media or 50 mM oxamate 
for 1 hour followed by treatment with either media control or HDM (100 μg/mL) for 
2 hours. Cell culture supernatants were collected for (C) IL-33 measurement. Data 
presented as mean values ± SEM for biological replicates n=6, **p<0.01, 
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Chapter 4: Allergen driven rapid increases in glycolytic flux facilitates 
cytoskeleton dependent IL-33 translocation and release. 
 
4.1  Introduction 
In Chapter 3 we demonstrated an early rapid increase of glycolysis in 
airway epithelial cells in response to HDM that facilitates secretion of type-2 
promoting cytokine IL-33. However, the signaling pathways regulating allergen-
induced glycolysis and IL-33 release remain unclear. Although IL-33 was originally 
thought to be released during cellular damage/injury due to its localization inside 
the nucleus [248], several recent studies have revealed that exposure to endogenous 
extracellular danger signals or exogenous environmental stimuli could also lead to 
rapid live cell release of pre-formed IL-33 from both the nucleus and vesicular 
compartments in which this cytokine resides [244-247]. Researchers found that IL-
33 was located both in the nucleus and membrane-bound cytoplasmic vesicles, and 
underwent dynamic nuclear-cytoplasmic flux in fibroblasts [247], indicating its 
intracellular inter-organelle translocation. However, IL-33 does not have a 
traditional secretion signal sequence [251]. The current data suggests that its 
release is likely through some unconventional mechanism depending on the nuclear 
pore complex [247] and intracellular calcium mobilization [244].  
Unconventional release of cytokines that do not have a signaling peptide 
such as IL-1β [400] is not rare. Our understanding of the processes governing 
unconventional release of proteins is still limited, but an intact cytoskeletal network 





cytoskeleton forms tracks for vesicle and organelle transport, as well as providing 
expelling or stabilizing forces for secretory compartments when needed [402-404]. 
Since intracellular calcium mobilization plays an important role in cytoskeleton 
rearrangement [405], taken together with the published data on IL-33 release, it is 
likely that IL-33 secretion is mediated by intracellular calcium regulated cytoskeletal 
rearrangement. 
As we show that inhibition of cellular glycolysis with DCA and oxamate 
inhibits IL-33 release (Chapter 3), we argue based on their respective targets that 
either ATP and/or lactic acid produced as a result of glycolysis may contribute to 
HDM-induced IL-33 release. Further support for a role for ATP in IL-33 release is 
suggested by its known role in facilitating motor protein function and activities 
[406]. ATP is mainly generated in the cells from glucose via glycolysis and OXPHOS. 
Although OXPHOS is the central pathway in generating ATP in the presence of 
sufficient O2, cells may preferentially use glycolysis for ATP generation even without 
oxygen deprivation based on certain needs [331]. One example is that glycolysis 
derived ATP fuels the demand of membrane associated actions (e.g., protein 
translocation) in a timely manner compared to OXPHOS derived ATP, as it is 
generated in the cytosol and is in closer proximity to membrane compartments 
[332]. As a result, we hypothesize that HDM-induced rapid increases in glycolysis 
may provide glycolytic ATP to facilitate the energy demands for the rapid 
translocation and secretion of IL-33 from epithelial cells. Specifically, the cells may 
undergo energy deprivation after HDM exposure due to the increased energy 





extracellular transport. This energy deprivation would lead to the activation of 
AMPK, a well known regulator of cellular glucose metabolism that is able to promote 
pathways producing ATP [353] such as GLUT1-mediated glucose uptake [354] and 
glycolytic flux [407].  
While we hypothesize that glycolysis provides the necessary energy for 
epithelial cell responses to HDM exposure, the contribution of glycolysis-generated 
lactate and extracellular acidity to IL-33 release is also worthy of further analyses. 
Although no direct evidence has linked IL-33 production with extracellular acidity 
or lactate, an earlier study has reported that extracellular acidosis could function as 
an endogenous danger signal to induce cytokine release by macrophages [408]. 
Considering that extracellular acidification occurs during glycolysis, it may play a 
role in glycolysis-associated IL-33 release. Lactate is also known as a signaling 
molecule recognized by GPR81 to regulate cell proliferation and survival [348]. 
Understanding whether such signaling is related to IL-33 secretion is needed.  
Although our data suggest that HDM induces IL-33 through metabolic 
alterations in the epithelium, the HDM specific receptors or pathways initiating 
these events remain unknown. Airway epithelial cells recognize external stimuli 
through a wide array of PRRs. It is proposed that airway epithelial cells initiate 
allergic airway responses by recognizing specific allergenic components which drive 
the release of endogenous danger signals [409]. Despite the current understanding 
that epithelial cells express various TLRs that recognize viral antigens and allergenic 
proteins to induce the release of inflammatory cytokines such as tumor necrosis 





the receptor(s) that mediate HDM-induced IL-33 release. Previously, several studies 
have demonstrated a potential correlation between TLR signaling and Il33 
expression by showing that agonists to TLR3, TLR4 and TLR5 increased mRNA 
expression of Il33 [410-412]. Moreover, the MyD88 independent TLR downstream 
signaling molecule TBK1 has been implicated in TLR4 agonist induced rapid 
induction of glycolysis and cytokine secretion [338]. However, such studies only 
focused on the regulation of Il33 transcription, rather than live cell secretion. 
Recently, two groups of researchers have shown that IL-33 secretion from live cells 
was mediated by extracellular ATP released from epithelial cells in response to 
fungal allergen-derived proteases [244, 245]. These results suggest that P2 
purinergic receptor signaling may be important in IL-33 release, and that protease 
properties of allergens may account for IL-33 secretion by airway epithelial cells 
[249, 389]. Although direct evidence for HDM-induced ATP release is lacking, the 
observations that ATP is elevated following in vivo exposure to HDM in mice [245] 
and that HDM is reported to contain protease activity [224] supports the hypothesis 
that these pathways/mechanisms might account for HDM induction of IL-33 and 
glycolytic flux.  
Moreover, PRR mobilization of intracellular calcium might be involved in 
HDM-induced IL-33 and glycolytic flux as calcium signaling has been shown to play a 
critical role in epithelial cell release of IL-33 [244, 245]. In fact, formyl peptide 
receptor 2 (FPR2), a widely expressed G-protein coupled receptor [413], has been 
shown to function as a pattern recognition molecule through its ability to recognize 





allergic airway inflammation [416]. As FPR2 mediates Ca2+ mobilization, immune 
cell migration and mediator release [413], it might be a potential candidate for the 
mediation of HDM-induced IL-33 release and glycolytic flux.  
To address these issues, we asked the following questions: (1) how does 
glycolysis contribute to the release of IL-33? (2) What are the pattern recognition 
receptors mediating HDM-induced IL-33 and glycolytic flux? 
   
4.2  Results 
4.2.1 HDM-induced rapid release of IL-33 was dependent on cytoskeleton 
activity and Rac1 signaling. 
To test the proposed hypothesis that HDM-induced IL-33 release is 
dependent on cytoskeleton-mediated translocation, we first examined the pattern of 
IL-33 translocation induced by HDM. To capture the dynamic processes involved in 
HDM-induced IL-33 release, we treated BEAS-2B cells with HDM (100 μg/mL) for 15 
minutes, collected the supernatants and isolated proteins from nucleus, cytosol and 
cytoskeleton attached compartments. We found that under unstimulated conditions, 
IL-33 resided in both the cell nucleus and cytosol (Fig. 7A). Proportionally speaking, 
more IL-33 resided in the nucleus (about 57%), with less residing in the cytosol 
(about 33%). HDM exposure resulted in a rapid export of IL-33 from both the 
nucleus and cytosol (Fig. 7B), consistent with the recently pulished data that IL-33 
translocated from the nuclear to cytosolic compartments and then to the 
extracellular milieu [247]. Interestingly, when cells were pre-treated with 20 mM 





Thus, the significant reduction in IL-33 in the supernatant caused by DCA was due to 
the significant increase of IL-33 attached to the cytoskeleton (Fig. 7C).  
To further explore the role of the cytoskeleton in IL-33 release, we pre-
treated BEAS-2B cells with the inhibitor of Rac1, a small molecule Rho-GTPase that 
plays an essential role in actin rearrangement and exocytosis [419], followed by 
either media or HDM (100 μg/mL) treatment for 2 hours. Based on the initial study 
showing that the chemical compound NSC23766 inhibited Rac1 activity by more 
than 90% at a concentration of 100 μM [420], we treated cells with two different 
concentrations of the inhibitor at 50 μM and 0.5 μM, and 50 μM was expected to 
inhibit Rac1 activity by 50% [420]. We found that HDM-induced IL-33 release by 
BEAS-2B cells was significantly reduced following treatment of cells with 50 μM 
Rac1 inhibitor (Fig. 7D) independently of cell viability changes (Fig. 7E). Similarly, 
the increase in lactate secretion in HDM-exposed cells was reduced by Rac1 
inhibition (Fig. 7F), indicating that cytoskeleton rearrangement may be upstream of 
the induction of glycolysis. To confirm the effects of the Rac1 inhibitor, we showed 
that siRNA knockdown of Rac1 (Fig. 7G) inhibited IL-33 release (Fig. 7H). Changes in 
intracellular calcium have been shown to induce the activation of Rac1 [419] and to 
mediate IL-33 release [244, 245]. Thus, we asked whether calcium chelation with 
EDTA [421] could alter allergen-driven IL-33 release. Based on the previously 
published data that 0.1 mM EDTA was sufficient to chelate extracellular calcium and 
1.0 mM was required to inhibit intracellular calcium [422], we treated BEAS-2B cells 





(100 μg/mL) treatment for 30 minutes. Consistent with the literature, calcium 
chelation reduced the level of IL-33 release (Fig. 7I).  
 
4.2.2 HDM-induced rapid release of both full-length and cleaved IL-33 that 
was dependent on endoplasmic reticulum (ER)-Golgi trafficking. 
In addition to the involvement of cytoskeleton activities, IL-33 secretion is 
also likely mediated by intracellular vesicle trafficking from the nucleus to the 
cytosol, and then to the extracellular milieu [247]. To confirm this, the effects of ER-
Golgi vesicular trafficking inhibition with Exo1 [423] on IL-33 release was 
determined. BEAS-2B cells were treated with DMSO as a control or 20 μM Exo1 (the 
half minimal inhibitory concentration, or IC50, of Exo1 [423]) for 30 minutes, 
followed by media or HDM (100 μg/mL) exposure for 2 hours. While HDM exposure 
significantly induced IL-33 release from airway epithelial cells, Exo1 treatment 
significantly reduced the IL-33 release (Fig. 8A), suggesting the participation of ER-
Golgi trafficking in IL-33 release.  
A recent study analyzing IL-33 live cell secretion induced by HDM exposure 
suggests that IL-33 is processed into the mature form by calpain-2 [245], a process 
considered to occur in the ER-Golgi complex [424]. The participation of ER-Golgi 
trafficking we observed indicates the potential requirement of proteolytic 
processing for IL-33 release. To confirm this hypothesis, we then concentrated the 
cell culture supernatants to obtain total secreted proteins and analyzed the secreted 
forms of IL-33 by western blot. Both full-length IL-33 and the cleaved isoform were 





secreted full-length protein of IL-33 was reduced (Fig. 8B – C). This data confirmed 
the observation that DCA treatment reduced HDM-induced IL-33 release by BEAS-
2B cells, while its limited effects on the secretion of cleaved IL-33 suggest 
potentially different mechanisms for the release of full-length and cleaved IL-33. 
 
4.2.3 HDM-induced increase of anaerobic glycolytic flux provided glycolytic 
ATP to facilitate cytoskeleton-mediated IL-33 release. 
  Since IL-33 release from airway epithelial cells was likely mediated by 
cytoskeleton-dependent translocation over a very short time frame, we 
hypothesized that ATP derived from glycolysis rather than, or in addition to, that 
generated through OXPHOS would be required to fuel cytoskeleton-mediated IL-33 
release. To address the hypothesis that HDM-induced glycolysis provides glycolytic 
ATP for the release of IL-33, we first defined the roles of intracellular ATP from 
different sources on IL-33 release. Specifically, BEAS-2B cells were seeded at 20,000 
cells/well and cultured overnight in media supplemented with a direct substrate of 
glycolysis – glucose, or the direct substrate of OXPHOS – pyruvate. 24 hours later, 
the cells were treated with media or HDM (100 μg/mL), and IL-33 levels in the 
supernatants were determined. HDM induced significant release of IL-33 in cells 
supplemented with glucose, whereas those bathed in pyruvate-supplemented media 
secreted significantly lower levels of IL-33 (Fig. 9A). To further manipulate the 
intracellular ATP from different sources, we pre-treated the cells overnight with 
dimethyloxaloylglycine (DMOG) (1mM), an inducer of anaerobic glycolysis by 





increased glycolytic ATP production. These cells were then treated with HDM (100 
μg/mL) for 2 hours for IL-33 measurement. We saw that increasing glycolytic ATP 
production by DMOG enhanced HDM-induced release of IL-33 (Fig. 9B). Direct 
inhibition of glycolytic ATP and OXPHOS ATP was performed respectively using the 
LDH inhibitor oxamate (50 mM) and the mitochondrial ATPase inhibitor oligomycin 
(4 μM) followed by 2 hours HDM (100 μg/mL) exposure. Our data demonstrated 
that only the inhibitor of glycolytic ATP production (oxamate) had any effect on the 
early release of IL-33 driven by HDM treatment (Fig. 9C – D).  
To understand whether AMPK accounts for the rapid induction of glycolysis 
to fuel the need of cells for IL-33 release, pharmacological inhibition and siRNA 
knockdown of AMPK were carried out. We first utilized the potent AMPK inhibitor 
compound C (AMPKi). Compound C has been widely used in blocking AMPK at the 
concentration of 20 μM [426, 427]. Based on these data, blockade AMPK blockade 
with Compound C at various concentrations (10 μM and 0.1 μM). 10 μM compound C 
pre-treatment resulted in significant reduction of HDM-induced IL-33 release, while 
the reduction caused by 0.1 μM compound C was smaller, suggesting a 
concentration-response relationship between these 2 concentrations. Significant 
reduction of HDM-induced lactate production was also observed. (Fig. 9E & G), 
which was independent of cell death (Fig. 9F). However, compound C has also been 
reported to have other potential targets including bone morphogenetic protein 
(BMP) and mTOR signaling [428, 429]. To validate the effects of AMPK blockade on 
IL-33 release, we then conducted the siRNA knockdown of AMPK. The same 






4.2.4 Extracellular acidity or lactate did not play regulatory roles in HDM-
induced IL-33 release. 
The current study shows that the HDM-induced immediate increase of 
glycolysis facilitates the rapid release of IL-33 from airway epithelial cells. To 
further understand the contribution of other micro-environmental changes 
resulting from increased glycolysis (e.g., extracellular acidification and lactate) to IL-
33 release, we tested the involvement of extracellular acidity n HDM-induced IL-33 
release by manipulating the extracellular microenvironment with a series of lower 
pH values in the presence of HDM. We used acetic acid, a weak acid that slightly 
modulated extracellular pH without introducing other ions or damaging cells, to 
reduce extracellular pH and mimic the slight acidification resulted from increased 
glycolysis. The cells were serum starved, bathed in media with different pH values 
(pH at 7.5 of the media was adjusted to 6.7, 5.8, 5.4 and 4.6) for 30 minutes, and 
then treated with either media or HDM (100 μg/mL) for 2 hours for IL-33 
measurement. As the extracellular pH slightly decreased from pH 7.5 to pH 5.8, IL-
33 release was enhanced. However, such an increase in IL-33 release was also seen 
in cells under normal culture conditions, indicating a general increase of baseline 
release of IL-33 independently of the presence of environmental stimuli (Fig. 10A).  
To determine whether extracellular lactate played a role in IL-33 release, 
BEAS-2B cells were treated with different concentrations of lactic acid (2.5 mM, 5 
mM, 10 mM, 20 mM and 40 mM) in addition to HDM (100 μg/mL) for 2 hours. The 






4.2.5 HDM-induced rapid release of IL-33 and glycolytic flux was likely 
mediated by FPR2 signaling. 
To investigate the PRRs involved in HDM-induced IL-33 and glycolysis, we 
first examined the effects of blocking TLR signaling, as TLR4, TLR3 and TLR5 have 
been shown to contribute to Il33 expression [410-412]. As the downstream 
signaling of these TLRs can be either MyD88-dependent or MyD88-independent 
[430], we utilized a specific inhibitor of MyD88 (Pepinh-MYD), to block the MyD88-
dependent signaling, and an inhibitor of TBK1 which is downstream of TLR 
activation, but not MyD88 [431], to block the MyD88-independent signaling. 
Specifically, BEAS-2B cells were seeded at 20,000 cells/well and treated with 10 μM 
Pepinh-MYD or its control peptide Pepinh-Control for 30 minutes. Pepinh-MYD 
contains a peptide sequence from the MyD88 TIR homodimerization domain and 
has been engineered to enable its translocation through the cell membrane to 
intracellularly block MyD88 [432]. Treatment of cells with Pepinh-MYD at 10 μM has 
been previously shown to effectively block MyD88 dependent TLR signaling by 
multiple studies [433, 434]. The cells were then treated with media or HDM (100 
μg/mL), and IL-33 and lactate were measured in the supernatants after 2 hours of 
HDM treatment. We observed a consistent induction of both IL-33 and lactate by 
HDM stimulation as compared to the media controls. However, there was little 
reduction of HDM-induced IL-33 and lactate by MyD88 inhibition (Fig. 11A – B). We 
then treated BEAS-2B cells with either DMSO as a control or 5 μM TBK1 inhibitor, 





induced IL-33 and lactate by HDM exposure, which were both significantly reduced 
in the presence of the TBK1 inhibitor (Fig. 11C – D). However, the reduction of IL-33 
was not reproduced in TBK1 siRNA-treated cells, suggesting that the effects of the 
inhibitor were not specific (Fig. 11E – F).  
Extracellular ATP and its receptor, the P2 purinergic receptor, have been 
shown to mediate epithelial cell secretion of IL-33 induced by Alternaria [244, 245], 
but the evidence for this pathway in HDM-induced IL-33 secretion is lacking. To 
address the role of extracellular ATP and its receptor in our model, we first 
measured ATP release from 16HBE cells after 2 hours exposure to HDM (100 
µg/mL). We did not observe a significant induction of extracellular ATP following 
HDM exposure in these cells (Fig. 12A). To further examine this pathway, we 
analyzed the effect of blocking the P2Y2 receptor with the inhibitor suramin [435]. 
According to initial studies analyzing the effects of suramin in blocking extracellular 
ATP induced signaling, researchers found that suramin inhibits activities of P2 
purinergic receptor at concentrations above 10 µM [436], and the blocking efficiency 
reaches 80% at 100 µM [437]. Based on these data, BEAS-2B cells were treated with 
100 µM suramin, 50 µM ATP, or 100 µM suramin combined with 50 µM ATP for 30 
minutes followed by 2 hours of exposure to media or HDM (100 μg/mL). We found 
that neither suramin nor ATP treatment had any effect on HDM-induced release of 
IL-33 (Fig. 12B).  
Earlier studies identifying extracellular ATP as a regulator of IL-33 release 
claimed that the protease activity of the fungal allergen Alternaria was the cause of 





activity played a role in HDM-induced IL-33 release. We heated HDM at 60˚C for 30 
minutes to deactivate its protease activity and compared its induction of IL-33 to 
that of non-heated HDM. BEAS-2B cells were treated with both heated and non-
heated HDM. IL-33 levels in the supernatants were determined after 2 hours 
exposure. Notably, we did not see any differences in the capability of HDM to induce 
IL-33 release after heating (Fig. 12C), suggesting that HDM likely does not induce 
extracellular ATP release through its proteolytic activity.  
As we observed that IL-33 release was regulated by intracellular calcium 
mobilization, PRRs that induce the intracellular calcium flux might be potential 
candidates that mediate HDM-induced IL-33 release. As FPR2 was found to 
contribute to allergic airway inflammation [416], and to mediate Ca2+ mobilization, 
immune cell migration and mediator release [413], we hypothesize that FPR2 may 
regulate HDM-induced IL-33 release and glycolysis. To test this hypothesis, we 
utilized the FPR2 antagonist WRW4, which specifically inhibits the extracellular 
binding of FPR2 to its peptide agonist [438]. BEAS-2B cells were first treated with 
DMSO control or 20μM FPR2 antagonist WRW4 (based on the published effective 
concentration for more than 90% inhibition of FPR2 agonist binding [438]) for 30 
minutes followed by either media control or HDM (100 μg/mL). Cell culture 
supernatants were collected at 30 minutes post-exposure for IL-33 measurement. 
Cells were then seeded at a density of 12,000 cells/well for live cell respiration 
measurement (Seahorse). They were pretreated with 20 μM WRW4 for 30 minutes. 
Glycolysis was then monitored as ECAR following the manufacturer’s instructions, 





significantly reduced HDM-increased IL-33 release (Fig. 13A). Consistently, the 
HDM-induced enhancement in glycolytic flux was significantly reduced upon 
inhibition of FPR2 signaling pathways. These data suggest that FPR2 signaling 
pathways play an important role in HDM-mediated IL-33 release (Fig. 13B). 
 
4.3  Discussion 
4.3.1 Allergen induces cytoskeleton-mediated IL-33 translocation, which is 
also dependent on post-translational modification of the protein.  
In the present study, we made the novel observation that HDM-induced 
rapid increases in glycolysis was at least partially responsible for the rapid, early 
release of IL-33 from epithelial cells. Moreover, our data demonstrated that IL-33 
was rapidly translocated from its primary storage site in the nucleus to the 
cytoplasm following exposure to environmental allergens (Fig. 7B). Our findings that 
inhibition of glycolysis led to IL-33 trapping within the cytoskeleton confirms the 
role of the cytoskeleton in IL-33 release [247], and demonstrates for the first time 
that glycolysis may regulate this process in the context of IL-33 release.  
Our studies provide a potential mechanism of how allergen regulates the 
movement of IL-33 from the cytoplasm to the extracellular milieu in that we 
demonstrated that both Rac1 and calcium were required for IL-33 release (Fig. 7D, 
E, G – H). Considering that these molecules are part of the same pathway in 
regulation of cytoskeleton activity, it is possible that certain signaling induce 
mobilization of intracellular calcium, resulting in increased Rac1 activation and then 





IL-33 live cell secretion was dependent on Rac1 signaling. This appears to be 
contrary to published literature showing that Rac1 inhibition induced Il33 
expression [439]. However, previous studies did not examine the role of Rac1 in 
HDM-induced live cell secretion of IL-33, which may be due to very different 
regulatory mechanisms than Il33 transcription. More importantly, the fact that HDM 
exposure did not induce Il33 mRNA expression in airway epithelial cells in published 
studies [245, 439] supports our argument that HDM might induce Rac1 activation 
and then release of pre-formed IL-33 in the cells. Taken together, we suggest that 
HDM induces increases in intracellular calcium levels, which activate Rac1, leading 
to rapid cytoskeleton rearrangement and the translocation of IL-33 out of the cells.  
In addition to proving that the cytoskeleton is required for HDM-induced IL-
33 release, we further showed that inhibition of ER-Golgi trafficking blocked IL-33 
secretion (Fig. 8A). This is surprising since it was proposed that cytokines lacking a 
conventional signaling peptide, such as IL-33, may utilize secretory pathways 
independently of ER-Golgi-mediated trafficking [440]. However, ER-Golgi trafficking 
allows protein quality control, surface molecule export as well as post-translational 
modifications. Multiple lines of evidence have suggested that IL-33 undergoes post-
translational modification prior to secretion [243, 252]. Specifically, IL-33 requires 
proteolytic processing by calpain for maturation [243], which has recently been 
found to be involved in HDM-induced IL-33 release [245]. Ex vivo analysis revealed 
more possible isoforms that could be generated from full-length IL-33 [89] in 
addition to mature and immature forms. As a result, cleavage of IL-33 mediated by 





forms of the protein. The fact that blockade of ER-Golgi trafficking did not fully 
inhibit IL-33 release would support this contention. Our data showing that both full-
length and cleaved forms of IL-33 were present in the cell culture supernatants after 
HDM treatment further suggested that multiple forms of IL-33 were generated 
during HDM-induced release. 
However, the biological activity of the cleaved IL-33 in our model remains 
unclear, as different processing mechanisms, which generate either inactivated or 
activated forms of IL-33 have been reported [243, 252]. Our current data is not 
sufficient to draw a conclusion on the biological activity of the cleaved IL-33. The 
fact that DCA treatment reduced the levels of only the full-length protein of IL-33 in 
the supernatant (Fig. 8B – C) was unexpected. However, it is reasonable to assume 
that glycolysis affects only part of the total cellular release of IL-33, and the cleaved 
shorter protein is released via a different mechanism. This observation is 
inconsistent with a recent publication reporting that HDM induces only the release 
of the cleaved isoform of IL-33 (18kD) from NHBE cells [245]. The discrepancy 
between our data and the published data might be explained by the differences in 
the cell culture systems used, as we utilized BEAS-2B, not NHBE cells in our studies. 
To address these differences and elucidate the pathways involved in intracellular 
processing of IL-33, future studies analyzing IL-33 release by primary human and 
animal cells, as well as in the BAL of mice are needed. However, even though full-
length IL-33 has been reported to play different roles than mature IL-33 in vivo 
[441], this data does not reduce the significance of our findings. It was reported that 





derived from pro-inflammatory cells during the progression of allergic 
inflammation, generating isoforms with 10-fold greater potency to activate ST2 than 
full-length IL-33 [89]. As a result, inhibition of both full-length and mature cleaved 
IL-33 should confer protective effects against type-2 immune responses in vivo.  
 
4.3.2 The energetic requirement for IL-33 translocation induces rapid 
glycolytic flux. 
Our data suggested that the induction of glycolytic ATP production by HDM 
exposure was likely required to meet the energetic requirements for cytoskeletal 
rearrangement and IL-33 release from the epithelium. This hypothesis was 
supported by the finding that blocking Rac1 signaling inhibited lactate production 
(Fig. 7F), suggesting that HDM-induced glycolytic flux was probably downstream of 
Rac1 activated cytoskeleton rearrangement. As reviewed earlier, cytoskeletal 
rearrangement consumes ATP and may lead to an immediate and transient ATP 
deprivation in the cells. This immediate energy deprivation after HDM exposure 
might cause induction of glycolytic flux, which in turn provides glycolytic ATP and 
satisfies the bioenergetic needs to facilitate IL-33 release. Our data did show that 
enhancement of glycolytic ATP caused an increase in HDM-induced IL-33, and vice 
versa. At the same time, manipulation of OXPHOS ATP did not alter the magnitude of 
HDM-induced IL-33 secretion (Fig. 9A – D), supporting the contention that airway 
epithelial cells required glycolytic ATP for its secretion of IL-33. These data for the 
first time show that the allergen-induced rapid IL-33 release preferentially depends 





belief, but important concept that glycolysis-derived ATP plays different 
physiological roles than ATP generated through OXPHOS [332], and the initial phase 
of cellular secretion depends on glycolytic ATP [442]. 
Since the increase of glycolysis is thought to arise as a result of a rapid 
increased energy demand, AMPK, the molecule sensing shortages of ATP [354, 355, 
407], is likely the inducer of glycolysis in this case. Our data with AMPK inhibition 
using both a pharmacological inhibitor and genetic modification supported this 
hypothesis (Fig. 9E – I). Although details on the phosphorylation status of AMPK 
remain to be identified, the involvement of AMPK in this pathway is strongly 
indicated. Currently, AMPK is mainly implicated in metabolic disorders such as 
obesity and diabetes [443]. Our data for the first time suggests that it may also play 
a role in IL-33 release in the lung, which greatly advances our knowledge of the 
interplay between metabolism and immune function. Although our study has 
provided strong support for a link between glycolysis and IL-33 release, several 
aspects remain to be elucidated. First, the causal links between the identified 
pathways remain to be established. Although IL-33 translocation regulated by Rac1-
mediated cytoskeleton activity is strongly suggested, staining of intracellular IL-33 
in the presence of a Rac1 inhibitor is needed to obtain direct evidence for this 
hypothesis. Also, the mechanism that AMPK induces glycolysis needs to be 
confirmed by (1) demonstrating that the AMP to ATP ratio is transiently increased 
by HDM exposure; and (2) confirming that AMPK phosphorylation leads to 
enhanced glycolytic flux. Moreover, since we propose that glycolysis induction was 





whether the AMPK-mediated glycolysis also facilitates intracellular calcium 
dependent release of IL-33 by Alternaria [244, 245]. Although we did not observe an 
increase in lactate levels in the cell culture supernatants after Alternaria exposure 
(Fig. 4F), we cannot rule out the possibility that glycolytic flux was also involved in 
Alternaria-induced IL-33 release. For example, lactate might be abrogated by other 
Alternaria-induced responses (e.g., induction of mechanisms taking up extracellular 
lactate, the protease property interferes with LDH activities, etc.) in BEAS-2B cells, 
rendering lactate undetectable at the time we measured it in the supernatants. 
Besides analyzing the above-hypothesized pathway, we also sought to 
understand whether changes in the cellular microenvironment that occurred 
secondarily to glycolysis played a role in IL-33 secretion, especially since both DCA 
and oxamate treatment inhibited lactic acid, extracellular acidification and glycolytic 
ATP, resulting in reduced IL-33 release. However, extracellular acidity seemed to 
enhance the baseline release of IL-33 rather than promoting HDM induction of IL-33 
(Fig. 9A). This was not unexpected as extracellular acidity has only been reported to 
regulate IL-1β release induced by LPS from macrophages [408], in which the 
regulatory mechanisms are likely very different from that in airway epithelial cells. 
However, it is indeed interesting that increased extracellular acidity within the pH 
ranges from 5.8 – 7.5 caused an overall increase of IL-33 release from cells in both 
media control and HDM. We infer that an extracellular pH lower than 5.8 induces 
cellular stress, interfering in regular processes of host responses or even causes 
apoptosis that deactivates IL-33 [241]. In the meantime, the general increase of IL-





release. It is known that the release of some cytokines depends on secretory 
lysosomes [440], the dual functional organelle conferring degradation and secretion 
in non-professional secretory cells [444]. Considering that both our data and the 
literature suggest that IL-33 may be secreted via vesicle-mediated pathways [247], 
the general increase in IL-33 release by extracellular acidity may imply involvement 
of secretory lysosomes.  
Our findings that pre-treatment of BEAS-2B cells with different 
concentrations of lactic acid did not modulate the magnitude of IL-33 induction by 
subsequent HDM exposure ruled out a role for extracellular lactate in HDM-induced 
IL-33 release. There have been no reports on the role of lactate signaling in the 
mediation of cytokine release. However, lactate has been shown to promote 
proliferation of CD4+ T cells [370], which is consistent with its roles in promoting 
tumor cell survival and proliferation [445], probably by acting as an alternative 
metabolism substrate when glucose accessibility is restricted [446]. In our model, it 
probably should be treated more as a readout of the metabolic state of the cell, 
rather than a direct regulator of epithelial cell function. However, we cannot rule out 
the possibility that it may function as another mediator secreted by airway 
epithelial cells that might contribute to allergic inflammation in vivo by promoting 
the proliferation of other immune and structural cells.  
 
4.3.3 FPR2 signaling likely plays important roles in recognition of HDM 





Although our study provided a potential mechanism by which HDM might 
induce IL-33 release through the regulation of glycolysis, the upstream regulation of 
HDM-induced IL-33 release, e.g., surface receptor on airway epithelial cells that 
recognized HDM to mediate the induction of IL-33 and glycolytic flux, remained to 
be identified. Reports in the literature support the involvement of TLR3, TLR4 and 
TLR5 in exogenous antigen induced Il33 mRNA expression [411, 412], indicating 
that a common pathway downstream of these receptors may play a role in epithelial 
recognition of foreign antigens that drive IL-33 induction. However, we found that 
neither inhibition of MyD88, the common downstream adaptor molecule of these 
receptors [447], nor TBK1, the common MyD88-independent signaling molecule 
downstream of TLR3 and TLR4, had significant effect on HDM-induced IL-33 and 
glycolysis (Fig. 11). These data indicated that TLR signaling was not the major PPR 
pathway involved in HDM-induced IL-33 release. This is not contrary to the 
literature, as there is no direct evidence showing that the activation of TLRs directly 
induces secretion of IL-33. Even though TLR4 signaling on pulmonary structural 
cells was shown to be required for HDM-induced allergic asthma in mice [31], no 
evidence has directly proven that epithelium TLR4 responses were important for IL-
33 secretion or allergic asthma pathogenesis. In fact, our data is consistent with a 
recent publication showing that Alternaria induced BAL levels of IL-33 in mice were 
not affected by genetic depletion of MyD88 [244].  
The inconsistency in our data between TBK1 inhibition with BX795 and 
siRNA was probably due to off-target effects of BX795, as it might also inhibit PDPK1 





metabolism [448]. Overall, our finding of no effects of TBK1 on IL-33 release is not 
inconsistent with the literature, as no one has examined the role of TBK1 in IL-33 
release or allergic asthma pathogenesis despite some evidence that it is required for 
Il33 mRNA expression in murine embryonic fibroblasts [412]. TBK1 was reported to 
regulate LPS-induced rapid induction of glycolysis that mediated IL-6 production in 
DCs [338]. However, they did not specify whether the secreted IL-6 was attributed 
to newly synthesized or pre-formed proteins. Also, considering that LPS did not 
induce glycolytic flux in BEAS-2B cells (Fig. 4F), it is reasonable to conclude that the 
responding mechanisms to exogenous stimuli differ between airway epithelial cells 
and DCs. It is important to know that although TLRs play an important role in 
environmental stimuli-induced expression of Il33, rapid live cell secretion of IL-33 is 
likely mediated by different mechanism(s). As a result, the signaling pathways 
identified to date to play a role in the regulation of Il33 mRNA expression cannot be 
simply generalized to the rapid secretion of this protein.  
According to two recent published studies, environmental allergen-induced 
ATP release and autocrine activation of its P2 purinergic receptor account for the 
induction of IL-33 in airway epithelial cells [244, 245]. According to this hypothesis, 
excessive ATP is expected to enhance IL-33 release from the cells, which would then 
be reduced by the ATP receptor inhibitor suramin. However, we observed no 
induction of extracellular ATP secretion by HDM (Fig. 12A), and no difference in IL-
33 release was seen when extracellular levels of ATP were modulated in the 
presence of HDM (Fig. 12B). The reason for the discrepancy between our data and 





cells, an epithelial cell line that is potentially different from BEAS-2B cells and 
NHBEs that were used in the published studies. A positive control that induces ATP 
release from airway epithelial cells such as Alternaria should be included. Also, our 
studies lack the validation that suramin and/or extracellular ATP are playing the 
desired roles, and we do not have evidence for the expression pattern of P2 
purinergic receptor on BEAS-2B cells compared to NHBEs used in the published 
studies. Nevertheless, there are no previous reports of HDM-induction of ATP 
release in the airway epithelium. The fact that most of their observations were made 
in an Alternaria model actually supports the notion that different allergens might 
mediate IL-33 release through different mechanisms [245]. Most importantly, in 
both our data and the published studies, extracellular ATP was observed at the 
nanomolar level [245]. The recent studies showing a link to extracellular ATP 
utilized much higher concentrations of ATP at micromolar levels, raising the 
question of physiological relevance. However, caution should be taken in 
interpreting our data as thorough analyses of extracellular ATP at different time 
points post-exposure are lacking, and a concentration-response relationship 
between HDM exposure and extracellular ATP levels should also be analyzed. 
Consistent with there being allergen-specific pathways for IL-33 release, 
there is strong evidence that Alternaria, the fungal-derived allergen, induces IL-33 
release through a serine protease dependent pathway [249]. However, when HDM 
was heated to inactivate the protease activity of its contents, the induction of IL-33 
was not affected (Fig. 12C), indicating that HDM-induced IL-33 release was not 





Although the involvement of TLR signaling as well as endogenous ATP and 
its receptor is inconclusive, the involvement of FPR2 in HDM-induced IL-33 and 
glycolytic flux might be worthy of further investigation. We made the novel 
observation that the FPR2 pathway played a role in both IL-33 release and glycolytic 
flux (Fig. 13). This is consistent with the literature that FPR2 mediates Ca2+ 
mobilization, immune cell migration and mediator release [413]. Considering that 
IL-33 release is also dependent on intracellular calcium mobilization, our studies 
support the contention that FPR2 recognizes certain components in HDM, causing 
increased intracellular Ca2+ that is known to regulate IL-33 release by airway 
epithelial cells [244, 245]. Moreover, we demonstrate for the first time that FPR2 
signaling regulates HDM-induced glycolysis (ECAR), suggesting its potential role in 
regulation of cellular glucose metabolism. However, the causal link between FPR2, 
calcium signaling, IL-33 translocation and glycolysis remains to be further 
established. Direct analysis showing that specific activation of FPR2 leads to 
increased intracellular calcium and IL-33 release is needed. Also, the ligands in HDM 
that are recognized by FPR2 are not known at this time. Since FPR2 is capable of 
binding to both lipid and peptide/protein ligands [449, 450] such as the lipid 
mediator lipoxin A4 (LXA4) and the Th2-promoting protein SAA [451-454], a 
comprehensive study of HDM-induced IL-33 release via FPR2 signaling (e.g., the 
potential ligands of FPR2 in HDM) needs to be established. 
 





Despite the existing caveats in the current studies that have been discussed 
above, there are limitations of our data that require further validation and research. 
First of all, the targets of the inhibitors/siRNA used should be validated with 
specific readouts. For all the inhibitors used in our analyses, the concentrations were 
selected based on published manuscripts, and were shown to specifically and 
effectively block the desired targets. However, we do not have direct data supporting 
our contention that their effects were due to the expected specific actions. To do this, 
Rac1-GTP activities and levels should be tested respectively in cells treated with the 
Rac1 inhibitor and siRNA, together with direct visualization of cytoskeleton 
rearrangement alterations in the presence of the Rac1 inhibitor, HDM and DCA. 
EDTA chelation of calcium should also be confirmed with intracellular calcium 
measurement. For the blockade of ER-Golgi trafficking by Exo1, visualizing IL-33 
translocation will provide direct evidence for its effects. To confirm the successful 
blockade of AMPK signaling, the phosphorylation status at threonine 172 (Thr172) 
is the target readout for compound C, while the protein level should be confirmed 
following siRNA knockdown. 
Similarly, the effects of inhibitors and/or siRNA against the PRRs and danger 
molecules should be validated. TBK1 phosphorylation status (serine 172, Ser172) 
and protein levels remain to be tested for validation of cellular response to TBK1 
pharmacologial inhibition and siRNA knockdown. Meanwhile, as extracellular ATP 
and FPR2 signaling likely induce increased intracellular calcium flux, intracellular 
calcium recordings would be a reliable readout to prove specific blockade of FPR2, 





control that induces ATP release should be included for further analyses. The 
expression pattern of P2 purinergic receptors on BEAS-2B cells should also be 
analyzed, as there is a possibility that these cells do not respond well to suramin or 
that extracellular ATP levels are low. 
Another limitation of the current data is the lack of reproduction of our 
results in asthmatic and normal human epithelial cells. As discussed in Chapter 3, 
the current culture system has reduced generalizability for translating the 
observations into human airways. Our data suggested that primary normal human 
airway epithelial cells also exhibit increased glycolytic flux upon exposure to HDM. 
Based on this, we expect that similar mechanisms also mediate HDM induced IL-33 
release in primary cells. Moreover, whether the same pathways account for the 
epithelium response to HDM in an air-liquid interface culture system should also be 
analyzed. 
In summary, the current data, despite the discussed caveats and limitations, 
strongly support a scenario in which HDM induces the early release of IL-33 by first 
activation of FPR2, which then activates intracellular calcium mobilization and 
Rac1-mediated rapid cytoskeleton rearrangement. In turn, this process initiates 
translocation and release of IL-33 from both the nuclei as well as cytosolic 
compartments, and rapidly consumes ATP present in the cytosol, leading to an 
altered AMP/ATP ratio and activation of AMPK signaling. The AMPK signaling leads 
to increased glycolysis, which in turn generates glycolytic ATP to facilitate the early 





release and its role in allergic asthma pathogenesis will reveal the role of cell 





4.4  Figures 
Figure 7: HDM-induced rapid release of IL-33 was dependent on cytoskeleton 
activity and Rac1 signaling. BEAS-2B cells were seeded in flat-bottom 6-well 
plates at a density of 100,000 cells/well and then serum starved for 24 hours 
followed by first treatment with DCA (20 mM) for 1 hour and then treatment with 
either media control or HDM (100 μg/mL) for 15 minutes. (A) – (C) IL-33 levels in 
the supernatant, nuclear, cytosolic and cytoskeleton-attached proteins from BEAS-
2B cells were identified by ELISA. To determine if Rac1 was involved in HDM-
induced IL-33 release, BEAS-2B cells were seeded in flat-bottom 96-well plates at a 
density of 20,000 cells/well, serum starved for 24 hours and then treated with 
either DMSO control or Rac1 inhibitor NSC23766 (Rac1i, doses shown in the graph) 
for 30 minutes followed by HDM (100 μg/mL). (D) IL-33 release, (E) cell viability 
and (F) lactate production were identified in the supernatants. BEAS-2B cells were 
transfected with Rac1 siRNA as described (Chapter 2, 2.15) and then treated with 
HDM (100 μg/mL) for 2 hours. (G) Rac1 gene expression and (H) IL-33 induced by 
HDM exposure were determined. These cells were then treated with calcium 
chelator EDTA (0.5 mM) for 30 minutes followed by media or HDM (100 μg/mL) for 
2 hours. (I) IL-33 levels in the supernatants were measured. Data presented as one 
representation of 3 experiments for (A) – (C), or as mean values ± SEM for biological 
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Figure 8: HDM induced rapid release of both full-length and cleaved IL-33 that 
was dependent on Endoplasmic reticulum (ER)-Golgi trafficking. BEAS-2B cells 
were seeded in flat-bottom 96-well plates at a density of 20,000 cells/well. They 
were then grouped to receive (A) either DMSO control or 20 μM Exo1 for 30 
minutes. These cells were then treated with media control or HDM (100 μg/mL) for 
2 hours. Cell culture supernatants were collected for IL-33 measurements. To 
identify whether the IL-33 proteins secreted were full-length or truncated, BEAS-2B 
cells were seeded in flat-bottom 6-well plates at the density of 100,000 cells/well. 
They were then treated with either media or DCA (20 mM) followed with either 
media control or HDM (100 μg/mL) for 2 hours. Cell culture supernatants were 
collected and concentrated by 100 folds using Amicon Ultra-0.5 mL Centrifugal 
Filters (EMD Millipore). (B) IL-33 in the concentrated supernatants was determined 
by Western Blot using anti-human IL-33 antibody (R&D), and (C) densities of the 
bands were quantified. Data presented as mean values ± SEM for biological 
replicates n=3-6, *p<0.05, **p<0.01, ****p<0.0001 (student’s t test, one-way ANOVA 
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Figure 9: HDM-induced increase of anaerobic glycolytic flux provided 
glycolytic ATP to facilitate cytoskeleton-mediated IL-33 release. BEAS-2B cells 
were seeded in flat-bottom 96-well plates at the density of 20,000 cells/well. To test 
differential effects of glycolytic and OXPHOS ATP on IL-33 release, cells are cultured 
overnight in (A) pyruvate-supplemented, glucose-free media to reduce glycolysis or 
in (B) 1 mM DMOG to enhance glycolytic activities. These cells were then treated 
with HDM (100 μg/mL) for 2 hours and IL-33 levels were measured in the 
supernatants. To directly inhibit glycolytic and OXPHOS ATP production, cells were 
treated with (C) 20 mM sodium oxamate to inhibit LDH or (D) 4 μM oligomycin to 
inhibit mitochondrial ATPase followed by HDM for IL-33 release measurement. To 
determine if AMPK is involved in HDM-induced IL-33 release, cells are treated with 
either DMSO control or AMPK inhibitor compound C (AMPKi, doses shown in the 
graph) for 30 minutes followed by HDM (100 μg/mL). (E) IL-33 release, (F) cell 
viability and (G) lactate production were identified. AMPK siRNA knockdown was 
conducted and resulted (H) expression of Prkaa1, the gene encoding catalytic 
subunit of AMPK, as well as (I) IL-33 induced by HDM exposure were determined. 
Data presented as mean values ± SEM for biological replicates n=3-6, *p<0.05, 
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Figure 10: Extracellular acidity or lactate did not play regulatory roles in 
HDM-induced IL-33 release. To understand whether extracellular acidity 
contributes to HDM-induced IL-33 release, BEAS-2B cells were seeded at a density 
of 20,000 cells/well and serum starved. For modulation of extracellular acidity, 
acetic acid was added into cell culture media. Using the pH meter, the cell culture 
media pH (7.5) was adjusted to 6.7, 5.8, 5.4, and 4.6. Cells cultured in media with 
different pH were then exposed to HDM (100 μg/mL) for 2 hours. Cell culture 
supernatants were collected and (A) IL-33 was measured by ELISA. To test the 
effects of extracellular lactate, BEAS-2B cells were pre-treated with different doses 
of lactic acid (2.5 mM, 5 mM, 10 mM, 20 mM and 40 mM) for 1 hour, after which 
they were exposed to HDM (100 μg/mL). (B) IL-33 levels were determined in the 
supernatants 2 hours later. Data presented as mean values ± SEM for biological 
replicates n=6. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (student’s t test, one-
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Figure 11: HDM-induced rapid release of IL-33 and glycolytic flux was 
independent of MyD88 and TBK1-mediated TLR signaling. BEAS-2B cells were 
seeded at a density of 20,000 cells/well and serum starved overnight. For the 
MyD88 inhibition, cells were treated with 10 μM Pepinh-MYD or its control peptide 
Pepinh-Control for 30 minutes followed by treatment with either media or HDM 
(100 μg/mL) for 2 hours. IL-33 (A) and lactate (B) were determined in the 
supernatants. For TBK1 inhibition, these cells were pre-treated with either DMSO 
control or 5 μM TBK1 inhibitor BX795 followed by 2 hours exposure to media or 
HDM (100 μg/mL) for IL-33 (C) and lactate (D) measurement. To validate the 
inhibitor results, cells were transfected with TBK1 siRNA for 48 hours, serum 
starved and then followed by 2 hours treatment by media or HDM (100 μg/mL). 
Tbk1 expression was assessed by RT-PCR (E), and IL-33 in the supernatants was 
determined (F). Data presented as mean values ± SEM for biological replicates n=3-
6, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (student’s t test, one-way ANOVA 
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Figure 12: HDM-induced rapid release of IL-33 and glycolytic flux was not 
mediated by extracellular ATP. 16HBE cells were exposed to media or HDM (100 
μg/mL) for 2 hours and ATP levels in the supernatants were determined (A). To 
understand whether extracellular ATP contributed to HDM-induced IL-33 release, 
BEAS-2B cells were treated with 100 µM suramin, 50 µM ATP, or 100 µM combined 
with 50 µM ATP for 30 minutes followed by 2 hours exposure to HDM (100 μg/mL). 
IL-33 in the supernatants was determined with ELISA (B). To test whether protease 
activity was involved, HDM was first heated to 60°C for 30 minutes to inactivate the 
enzymatic activities of its protease content. BEAS-2B cells were then exposed to 
regular and heated HDM (100 μg/mL) for IL-33 release measurement (C). Data 
presented as mean values ± SEM for biological replicates n=3-6, *p<0.05, **p<0.01, 
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Figure 13: HDM-induced rapid release of IL-33 and glycolytic flux was likely 
mediated by FPR2 signaling. BEAS-2B cells were seeded in flat-bottom 96-well 
plates at a density of 20,000 cells/well and serum starved. They were then treated 
with DMSO control or 20 μM WRW4 for 30 minutes followed by either media 
control or HDM (100 μg/mL). Cell culture supernatants were collected at 30 
minutes post-exposure for IL-33 measurement (A). Cells were then seeded at the 
density of 12,000 cells/well for live cell respiration measurement (Seahorse). They 
were incubated in a CO2 free tank with buffer free media containing 20 μM WRW4 
for 30 minutes and then loaded into Seahorse. ECAR was then measured following 
manufacture manual (Chapter 2.12) for 10 times within 70 minutes, and HDM was 
injected before the 4th measurement (B). Data presented as mean values ± SEM for 
biological replicates n=3-6, *p<0.05, ***p<0.001, ****p<0.0001 (one-way ANOVA 
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Figure 14: HDM-induced rapid increase of glycolysis facilitates IL-33 release 
by providing glycolytic ATP. When airway epithelial cells are exposed to HDM, 
rapid cytoskeleton rearrangements mediated by Rac1 happened for the 
translocation and release of IL-33. This process rapidly consumed ATP presented in 
the cytosol, leading to altered AMP/ATP ratio and activation of AMPK signaling. The 
AMPK then led to an increase of glycolysis probably by promoting glucose uptake 
and glycolytic enzyme activities. This rapid increase of glycolysis then generates 
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Chapter 5. Changes in cellular metabolism drive HDM-induced allergic asthma 
in vivo. 
 
5.1  Introduction  
  Based on the data presented in Chapters 3 and 4, in which we saw an 
immediate induction of glycolytic flux in cultured airway epithelial cells by HDM 
exposure that led to the release of IL-33, we asked whether allergen-induced 
alterations in cellular metabolism contributed to the allergic phenotype in vivo. 
  Allergic asthma is thought to arise due to the inappropriate induction of 
type-2 immune responses against environmental stimuli [455]. Asthma pathology is 
driven by cytokines associated with this type of immune response, such as IL-4, IL-5 
and IL-13 [134]. Of these cytokines, IL-4 is necessary for the development of 
adaptive Th2 immunity and IgE antibodies against environmental antigens by 
inducing class switching of the immunoglobulins synthesized by B cells [134]; IL-5 
drives eosinophilia in the lung [456]; and most importantly, IL-13 is necessary and 
sufficient for mounting AHR and excessive mucus production through goblet cell 
metaplasia [113]. These cytokines are thought to derive mainly from Th2 cells, but 
numerous recent studies have shown that ILC2s are also potent sources of both IL-5 
and IL-13, but not IL-4. Mast cells and basophils are also potential sources of IL-
5/IL-13. Together, these findings highlight the importance of understanding the 






IL-33, the epithelial cell-produced cytokine [248, 457], has been identified 
to be a crucial driver of allergic asthma through its ability to promote the secretion 
of IL-13 and IL-5 from multiple sources such as Th2 cells, ILC2s, as well as 
eosinophils, basophils, and mast cells [383]. Among these cells, Th2 cells and ILC2s 
are primary producers of IL-13, the dominant cytokine accounting for allergic 
asthma pathology [458]. Together, they serve as both early (ILC2) and late (Th2 
cells) sources of IL-13 to prime initiation of type-2 immune responses, and to 
activate effector cells such as airway smooth muscle cells during an asthma attack. 
The regulatory effects of IL-33 on these cells are mainly through activating its 
receptor ST2. Specifically, IL-33 activates ST2 on ILC2s to expand the ILC2 
population and to induce ILC2 secretion of IL-13 after helminth infection [302]. In 
mouse models of allergic airway inflammation, IL-33 induces potent type-2 immune 
responses mediated by early activation of ILC2s [221, 306-308] independently of 
adaptive immunity [459]. Meanwhile, Th2 cells are found to have inducible 
ST2/Il1rl1 expression in the presence of IL-33 and IL-2 [313]. IL-33 itself induces 
the production of IL-5 and IL-13, but not IL-4, by murine Th2 cells in the presence of 
antigens [314]. As IL-33 induces IL-13 production by both of these primary sources 
of IL-13, targeting IL-33 secretion and its resultant ILC2 and/or Th2 cell activation 
may prove promising for the treatment of allergic asthma. 
  As IL-33 plays a vital role in directing type-2 immune responses, a recent 
study also showed that IL-33 is required for HDM-mediated allergic sensitization 
[460]. We saw a concomitant rapid induction of glycolysis and IL-33 release by HDM 





diminished IL-33 secretion. These data indicate that cellular metabolism facilitates 
HDM-induced early release of IL-33 by airway epithelial cells in vitro, and whether 
modulating cell metabolism affects HDM-induced allergic airway inflammation in 
vivo needs to be investigated. Thus we hypothesized that administration of DCA in 
vivo would dampen HDM-induced allergic airway inflammation by reducing airway 
epithelial release of IL-33, leading to (1) reduced activation of ILC2s or Th2 cells and 
(2) decreased IL-13 production.  
  To test this hypothesis, wild-type (WT) BALB/c mice were given either PBS 
(40 μL) or HDM (100 μg/40 μL) intra-tracheally. In addition, they also received 
systemic treatment with either H2O (50 μL) or DCA (5 mg/50 μL) to assess the 
effects of glycolysis inhibition on allergic inflammation. To understand whether in 
vivo DCA treatment also has effects on effector cells downstream of IL-33 
production, the mice were then treated with intra-nasal administration of PBS (50 
μL) or recombinant IL-33 (rIL-33) (0.5 μg/50 μL) with and without DCA (5 mg/50 
μL) for airway hyperresponsiveness (AHR) measurement.  
  In the present study, we observed a reduction in HDM-induced early 
production of IL-33 in the lung following DCA treatment, which was consistent with 
our in vitro findings. DCA also significantly reduced all aspects of allergic airway 
inflammation, likely via reducing IL-33-dependent production of IL-13 by ILC2s. The 
fact that DCA had no effect on AHR induced by rIL-33 suggested that it did not affect 
the effector cells directed by IL-33, confirming that modulating glucose metabolism 






5.2  Results 
5.2.1 Identification of in vivo effect and kinetics of DCA. 
  As a glycolysis inhibitor utilized for the treatment of lactic acidosis [461] 
and cancer [462], DCA was recently also found to modulate cell metabolism and 
ragweed-induced allergic airway inflammation in mice [370]. To verify our 
observation that DCA reduced HDM-induced IL-33 release in vitro, we sought to first 
determine the appropriate dose and timing of DCA treatment in vivo. To this end, 
wild type BALB/c mice were given an intra-peritoneal injection of H2O (50 μL) or 
DCA (5 mg/50 μL or 10 mg/50 μL). Cheek blood was then collected from these mice 
using serum gel separator tubes at 1 hour, 4 hours and 24 hours after DCA 
treatment. The serum was then separated for determination of the levels of the 
glycolysis end product lactate. 5 mg/50 μL DCA significantly reduced the level of 
lactate in the serum compared to controls at 1 hour post-treatment (Fig. 15A). The 
reduction of lactate was dampened at 4 hours post-treatment (Fig. 15B), and 
disappeared at 24 hours (Fig. 15C). Notably, 10 mg/50 μL DCA did not reduce the 
lactate in the serum, but rather tended to increase lactate at 4 hours (Fig. 15B) and 
24 hours (Fig. 15C) post-treatment. 
 
5.2.2 HDM-induced increase in anaerobic glycolytic flux was associated with 
IL-33 secretion in vivo.  
We then examined whether HDM exposure induced glycolysis and IL-33 
release in the airways in vivo. As IL-33 was induced by HDM within 30 minutes in 





in which glycolysis was inhibited by treatment with DCA. According to the range 
finding experiments discussed in 5.2.1, we identified 5 mg to be an appropriate dose 
of DCA to inhibit glycolysis. The relatively rapid dampening of effects indicated a 
short half-life of DCA in vivo. So we designed the DCA treatment regimen to include 
treatment of mice 1 hour prior to as well as every 8 hours after each HDM challenge 
(Fig. 16A). WT BALB/c mice were administered 40 μL PBS or 100 μg/40 μL HDM 
intra-tracheally with and without intra-peritoneal injection of DCA, and BAL was 
collected 18 hours later (Fig. 16A). We observed that within 18 hours, HDM-induced 
a significant increase in BAL IL-33 levels, which were reduced by DCA treatment 
(Fig. 16B). Lactate production was induced by HDM, and inhibited by DCA (Fig. 16C). 
These data supported the hypothesis that HDM induced increases in glycolysis were 
associated with the induction of IL-33 release in the airways in vivo.  
 
5.2.3 Inhibition of glycolytic flux reduced HDM-induced allergic airway 
response.  
To determine whether DCA-induced suppression of IL-33 was associated 
with alterations in the pathological aspects of asthma, we compared allergic lung 
inflammation in HDM-challenged WT BALB/c mice with and without DCA 
treatment. Specifically, mice received 2 doses of 100 μg/40 μL HDM intra-tracheally 
on day 0 and day 14 according to the previously developed protocol [193]. To 
modulate the early glucose metabolism alterations in airway epithelial cells by HDM, 
5 mg/50 μL DCA was given intra-peritoneally 1 hour prior to and once every 8 





the last HDM challenge, mice were sacrificed to assess allergic airway responses. 
Increases in airway pressure in response to cholinergic agonist (methacholine) 
stimulation (assessed by airway pressure time index, APTI) were significantly 
higher in mice with HDM challenge than PBS controls, while DCA treatment 
significantly reduced airway responsiveness (Fig. 17B). Mice receiving HDM had 
significantly higher levels of IgE in the serum compared with those receiving PBS, 
and DCA treatment reduced the IgE production (Fig. 17C). HDM treatment caused 
eosinophilia in these mice, another hallmark of allergic airway inflammation, which 
was reduced by DCA treatment (Fig. 17D). In contrast, while HDM exposure also 
recruited neutrophils to the lung, DCA treatment further enhanced the infiltration of 
neutrophils (Fig. 17E). We also assessed the airway mucus production by measuring 
the expression of Muc5ac and Muc5b, the genes encoding mucins produced in 
significant quantities in human and mouse airways [463]. As expected, HDM 
significantly increased their expression compared to controls, indicating increased 
mucus production in the airways. However, the mucin gene expression was reduced 
by DCA treatment (Fig. 17F – G). To visualize the thickening and structural changes 
within the airways, we assessed the morphology of the airways by staining lung 
sections with hematoxylin and eosin. We saw that while HDM treatment caused 
obvious thickening and structural changes in the airways, DCA treatment revealed 
significant amelioration of the pathological alterations (Fig. 17H). Despite the effect 
of DCA on the classical type-2-cytokine-mediated features of asthma, flow 
cytometric analysis of Th2 cell prevalence (IL-13+CD4+TCRβ+) did not show a 





treatment alone (Fig. 17I), and the expression of Il13 in the lung was also not 
significantly affected by DCA at this time point (Fig. 17J).  
 
5.2.4. DCA reduced early ILC2 recruitment and BAL IL-13 levels.  
To evaluate whether earlier changes in type-2 cytokines were involved and 
played a role, WT BALB/c mice were treated with DCA and HDM following the 
protocol shown in Fig. 16A. At the end of the experiment, the total lung tissues of 
mice were harvested for flow cytometric analysis of lung ILC2 prevalence (Lin-
CD45+ST2+IL-13+). IL-13 levels in the BAL were also measured. Using the gating 
strategy shown in Fig. 18A, we found a significant increase in ILC2 prevalence in the 
lung after HDM exposure accompanied with IL-13 production compared to PBS 
controls (Fig. 18B – C), consistent with the literature that ILC2s are recruited in the 
presence of IL-33 during allergic inflammation as a relatively small cell population 
but major producers of IL-13 [301]. Consistent with our earlier findings, DCA 
administration to mice in vivo significantly reduced both ILC2 recruitment and their 
IL-13 production induced by HDM treatment (Fig. 18B – C). Taken together with the 
data presented in Fig. 16, our results supported the hypothesis that HDM-induced 
changes in cellular metabolism lead to IL-33 release, ILC2 recruitment and 
production of type-2 cytokines, and subsequent development of allergic 
inflammation.    
 
5.2.5. HDM-induced glycolysis did not influence responsiveness to IL-33 





Although our results suggested that glycolysis regulated IL-33 release, it 
was also possible that glycolysis might regulate processes downstream of IL-33 
production. To explore this possibility, we administered recombinant IL-33 (rIL-33) 
into the mouse airways to induce allergic airway responses, and analyzed the effect 
of DCA treatment. Specifically, WT BALB/c mice received intra-nasal 
administrations of rIL-33 (0.5 μg/50 μL) on day 0, 3 and 6; control mice received 50 
μL PBS at each time point. Some mice were also given intra-peritoneal injection of 
DCA (5 mg/50 μL) 1 hour prior to and once every 8 hours after rIL-33 
administration. Mice were sacrificed to assess allergic airway responses on day 7 
(Fig. 19A). The airway responses to methacholine stimulation were significantly 
higher in mice with rIL-33 challenge than PBS controls, while DCA treatment did not 
affect the AHR (Fig. 19B). We then analyzed the prevalence of Th2 cells and ILC2s. 
rIL-33 caused increased recruitment of these cells to the lung, but DCA treatment 
had no effect (Fig. 19C – D). Consistently, rIL-33 induced significant increases in IL-
13 production in the lungs as compared with those in saline-treated control mice, 
but little modulation of IL-13 was seen by DCA treatment (Fig. 19E). Together these 
data suggested that modulating glucose metabolism had little effect on the 
responsiveness of lung cells to IL-33. These data support our contention that 
allergen-induced changes in metabolism affect allergic inflammation likely through 
the regulation of IL-33, not downstream cellular responses to IL-33. 
 





  Based on our previous in vitro finding that HDM induced a rapid increase in 
glycolysis in airway epithelial cells to facilitate the release of IL-33, we sought to 
determine whether such metabolic changes contributed to the allergic phenotype in 
vivo. Consistent with our in vitro observation, HDM caused increases in glycolysis in 
the lungs of allergen-exposed mice, concomitant with elevations in the IL-33 levels 
in the airway. Our data demonstrate that short-term exposure to HDM leads to a 
significant elevation of in vivo lung lactate levels (Fig. 16C). This is consistent with 
the previous publication that early asthma-initiating responses in allergen-
sensitized rats are associated with increased glycolytic activities [371], suggesting 
the correlation between initiation of allergic inflammation and glycolysis. When 
mice also received DCA, the enhanced glycolysis was reversed in the lung, consistent 
with a previous report that in vivo administration of DCA could reduce glycolytic 
activities in the mouse lung after ragweed challenge [370]. We also saw an early 
increase in IL-33 levels in the lung (Fig. 16B). This is consistent with the recent 
report showing the early induction of IL-33 in vivo by HDM exposure [245], 
highlighting early IL-33 release as an essential mechanism by which HDM induces 
allergic airway inflammation. The fact that modulating glycolysis with DCA also 
reduced IL-33 release confirmed our in vitro observation that HDM-induced early 
increase of glycolysis was required for IL-33 secretion, as well as the novel 
mechanism that glycolysis facilitated IL-33 release. Together, these results support 
the hypothesis that HDM induces increases in glycolysis, which are associated with 





However, we do not have direct evidence that airway epithelial cells are the 
primary sources of either lactate or IL-33 in the lung. Both lactate and IL-33 can be 
produced by multiple other cells including DCs [464], macrophages/monocytes 
[465-467], mast cells [274, 468] and neutrophils [469] that play a role in allergic 
asthma. Although no evidence to date has shown that HDM can induce lactate and 
IL-33 release by these cells at this time point, our data does not rule out the 
contributions of these cells. As a result, direct analysis of the sources of lactate and 
IL-33 at this time is needed. Since we believe that IL-33 live cell secretion is 
mediated by translocation, analyzing the cell type(s) in the airway in which 
intracellular IL-33 is reduced after HDM exposure will provide the answer. To do 
this, future studies utilizing IL-33 reporter mice to determine the location of IL-33-
producing cells in lung biopsies after HDM treatment with and without DCA are 
needed. Direct evidence for the source of lactate might be harder to obtain as lactic 
acid is produced by every cell type in the lung. However, techniques using 
fluorescent glucose analogues allow in vivo monitoring of glucose by positron 
emission tomography (PET) imaging and near-infrared spectroscopy (NIRS) [470, 
471].  
The current study also failed to show that DCA blockade of glycolysis mainly 
affected airway epithelial cells, as systemic DCA administration was likely affecting 
all the cells. However, targeting glycolysis in specific tissues/cells remains difficult. 
For example, pharmacological inhibition of cell metabolism sometimes results in 
activation of compensatory mechanisms, which are likely the case in the current 





lactate (Fig. 15). Also, mice with genetic deficiency of essential glucose metabolism 
regulators often die as neonates. As a result, the best approach to inhibit glycolysis 
in airway epithelial cells might be to use shRNA designed to express specifically in 
the airway epithelial cells to knock down PDK1 (the target of DCA) or LDH (the 
target of oxamate) to moderately reduce glycolytic activity in these cells. 
To determine whether allergen-induced changes in metabolism played a 
role in the allergic phenotype in vivo, we explored the effect of DCA treatment on 
allergic airway inflammation. We observed a reduction in allergic airway responses 
including AHR, eosinophilia, IgE antibody production, mucus production and airway 
structural changes when HDM-induced glycolysis was inhibited (Fig. 17A – H). Our 
studies demonstrate that HDM-induced allergic airway inflammation was reduced 
by DCA, and is consistent with the previous report that DCA treatment reduced 
airway reactivity to methacholine and mucus production induced by ragweed [370]. 
Moreover, the fact that almost all aspects of allergic inflammation were reduced by 
DCA suggested that it diminished the initiation of HDM-induced allergic asthma, 
supporting the importance of cell metabolism in the early phase of allergic asthma 
pathogenesis. 
As IL-13 is the central mediator of allergic airway inflammation, it was 
expected that DCA treatment inhibited IL-13 production. However, although there 
seemed to be slightly fewer Th2 cells and less Il13 expression in the lungs of DCA-
treated mice (Fig. 17I – J), such moderate suppression could not explain the 
significantly reduced pathological features. It was also inconsistent with the 





model [370]. However, there are differences in the compositions [472, 473] of 
ragweed and HDM, indicating that distinct pathways may be induced, especially 
since ragweed has not been shown to induce IL-33 in the airway epithelial cells. 
Also, DCA administration in the ragweed study occurred during the effector phase of 
the response, not at initiation, while in our model it was given both at the time of 
sensitization and challenge, with a focus on the first 72 hours post-HDM exposure. 
The difference in the timing of the DCA treatment suggested that DCA given in the 
ragweed study probably conferred major effects on CD4+ T cells by inhibition of 
their proliferation and cytokine secretion. Their findings were consistent with the 
idea that activated T cells depend on glycolysis for secretion of cytokines [474]. In 
our study DCA probably mainly affected another earlier source of IL-13. Considering 
that another major and earlier source of IL-13 is ILC2, the innate immune cells that 
are recruited by IL-33 and prime HDM-induced type-2 immune responses [221, 
475], we hypothesized that ILC2 recruitment and production of IL-13 were affected 
by DCA treatment.  
Indeed, we showed that the recruitment of ILC2s into the lungs after HDM 
exposure was significantly reduced by DCA treatment (Fig. 18). These data 
suggested that DCA significantly reduced the early source of IL-13, which provided 
evidence that the reduced allergic airway inflammation might be due, in part, to the 
reduction of the earlier effects of IL-13. In fact, a recent study examined the allergic 
airway inflammation induced by HDM in mice with genetic depletion of ILC2s (RORα 
-/-) and found that lung ILC2s played a critical role in priming the adaptive type-2 





Although their study did not examine the role of ILC2s in AHR or Th2 cytokines 
production in the lung [475], the results suggested that Th2 cytokines derived from 
ILC2s were critical for the development of allergic responses. These results support 
our hypothesis that modulating earlier ILC2 production of IL-13 affects allergic 
asthma development.  
Our data provide strong evidence that modulating glucose metabolism 
alters IL-33 production after HDM exposure, interferring with the progression of 
HDM-induced allergic asthma via inhibition of ILC2-mediated priming of type-2 
immune response. However, several limitations of the current studies should be 
considered. First, the importance of ILC2-derived Th2 cytokines in the development 
of AHR still remains to be determined. To do this, follow up studies examining AHR 
induced by HDM in mice deficient of ILC2 will be necessary. Also, we propose that 
IL-13 derived from both ILC2s and Th2 cells likely contributes to allergic asthma 
pathogenesis at different time points, but limited evidence is available yet for the 
detailed kinetics of IL-13 production in vivo following HDM exposure. To prove our 
hypothesis, defining the temporal pattern of IL- 13 production in vivo following HDM 
exposure would be necessary. More importantly, as discussed earlier, DCA was given 
intra-peritoneally in this mouse model of experimental asthma. Such systemic 
administration affects not only airway epithelial cells, but also other cells presented 
at the time of DCA treatment. In fact, it was published that B cell activities were 
dependent on glycolysis, and DCA treatment sharply suppressed B cell proliferation 
and antibody secretion in vitro and in vivo [374]. Consistent with these concepts, the 





attributed to the effects of DCA on B cells. Moreover, whether DCA also affected 
other cells that contribute to allergic airway responses remains unknown, and 
future studies on the effects of specific knockdowns of genes regulating glycolysis in 
epithelial cells on HDM-induced AHR are required.  
Another observation worth further attention was the significantly increased 
neutrophil recruitment in mice treated with DCA (Fig. 17E). Our colleagues have 
shown that depletion of neutrophils with Ly6G following 24 hours HDM exposure 
resulted in significantly elevated IL-8, slightly increased IL-33 and IL-13 in the BAL, 
as well as more ILC2 recruitment to the lung comparing to mice receiving only HDM 
(data not published). These data are consistent with our observation that inhibition 
of IL-33 and early ILC2 activation by HDM occurred concomitantly with the 
increased neutrophilia, suggesting that neutrophils recruited to the lung at this time 
may confer protective effects against allergic inflammation. However, the role of 
neutrophils in allergic asthma remains unclear [476]. Whether the increased 
neutrophils in response to glycolysis inhibition protect against HDM-induced 
allergic asthma, and how inhibition of glycolysis results in increased recruitment of 
neutrophils are questions remain to be studied. 
Since the current in vivo administration of DCA might affect multiple cell 
types involved in allergic asthma pathogenesis, we also attempted to understand 
whether its reduction of allergic airway inflammation was attributed to its actions 
on effector cells downstream of IL-33 by analyzing the effects of DCA on AHR 
induced by rIL-33. Our observation that rIL-33–induced AHR, ILC2s, Th2 cells, and 





that DCA did not affect the activities of effector cells downstream of IL-33 in allergic 
airway responses. These results might seem inconsistent with the earlier ragweed 
study with DCA, in which DCA was thought to inhibit CD4+ T cell proliferation [370]. 
However, no direct evidence for DCA inhibition of Th2 cells in vivo was presented in 
the ragweed study. Moreover, ILC2s are likely the major cell type responding to IL-
33 in our model, which is confirmed by the fact that the prevalence of Th2 cells in 
these mice was very low. These data further indicated that Th2 cells probably 
played only a limited role in this model. Taken together, these data are consistent 
with the literature that IL-33-induced ILC2s are probably sufficient to induce 
allergic airway responses [459] and that allergen-driven changes in metabolism 
likely induce the allergic phenotype through regulating the production of IL-33, 
rather than altering downstream responsiveness to IL-33. 
In conclusion, we demonstrate a novel mechanism by which HDM induces 
the rapid increase of glycolysis in airway epithelial cells to facilitate IL-33 release, 
leading to the recruitment and activation of ILC2s and the development of allergic 
asthma. The current study reproduced our in vitro observation and proved the 
importance of this mechanism in asthma pathogenesis in vivo. While further studies 
addressing the discussed caveats are needed, we conclude that blocking glycolysis 
likely reduces IL-33 release and resultant allergic airway inflammation in vivo. As a 
result, local instillation or systemic ingestion of glycolysis inhibitors such as DCA 
may provide a successful strategy to either prevent or suppress asthma symptoms. 
Moreover, administration of DCA earlier in life may serve as a novel preventive 





5.4  Figures 
Figure 15: Identification of in vivo effect and kinetics of DCA. To determine the 
optimal dose and timeframe for in vivo blockade of glycolysis with DCA, WT BALB/c 
mice were given intra-peritoneal injection of PBS (50 μL) or DCA (5 mg/50 μL and 
10 mg/50 μL). Cheek blood was collected using serum gel separator tubes at (A) 1 
hour, (B) 4 hours and (C) 24 hours after DCA treatment from these mice. The serum 
was then separated, and levels of glycolysis end product lactate were measured by 
colormetric assays. Data presented as mean values ± SEM for biological replicates 












Figure 16: HDM-induced increases in anaerobic glycolytic flux was associated 
with IL-33 secretion in vivo. WT BALB/c mice were given a single dose of intra-
tracheal PBS (40 μL) or HDM (100 μg/40 μL) to induce early production of IL-33 in 
the lung. To inhibit early induction of anaerobic glycolysis, these mice were further 
grouped to receive intra-peritoneal injection of H2O (50 μL) or DCA (5 mg/50 μL) 1 
hour prior to and every 8 hours after HDM treatment (A). After 18 s of exposure to 
HDM, BAL was collected for assessment of (B) IL-33 secretion and (C) lactate 
production. Data presented as mean values ± SEM for biological replicates n=4-5, 






Figure 16: HDM-induced increases in anaerobic glycolytic flux were associated 






Figure 17: Inhibition of glycolytic flux reduced HDM-induced allergic airway 
response. WT BALB/c mice were given intra-tracheal PBS (40 μL) or HDM (100 
μg/40 μL) on day 0 and day 14 to mount the allergic asthma phenotype. They were 
further grouped to received intra-peritoneal injection of DCA (5 mg/50 μL) during 
the phase of early responses to each HDM exposure 1 hour prior to and once over 8 
hours after HDM treatment for 72 hours. The treatment regimen is shown in (A). 72 
hours after the last HDM treatment, mice were euthanized and HDM-induced 
allergic airway response was analyzed by measuring (B) AHR. (C) Serum IgE was 
measured using ELISA. BAL (D) eosinophils and (E) neutrophils were identified with 
May-Grünwald Giemsa staining and counted. Expression of epithelial mucin genes 
(F) Muc5ac and (G) Muc5b was determined by real-time PCR. (H) Lung sections 
(three per experimental group and three sections per animal) were fixed in 
formalin; cut into 10-μm sections; and stained with hematoxylin & eosin for 
histology analysis. Representative sections are shown. Part of the lung tissue was 
processed to make single cell suspension for flow-cytometric analysis of (I) Th2 cell 
prevalence, and (J) Il13 expression in the lung was determined by real-time PCR. 
Data presented as mean values ± SEM for biological replicates n=7-8, *p<0.05, 













Figure 18: DCA reduced early ILC2 recruitment and BAL IL-13 levels. WT 
BALB/c mice were challenged intra-tracheally with PBS (40 μL) or HDM (100 μg/40 
μL) and treated with H2O (50 μL) or DCA (5 mg/50 μL) following the protocol 
shown in Fig. 16A. BAL was collected; mouse lung was harvested and processed into 
single cell suspension for flow-cytometry analysis. (A) ILC2 was gated as Lin-
CD45+ST2+IL-13+. (B) Prevalence of ILC2s recruited to the lung was determined, 
and (C) IL-13 level in the BAL was measured with ELISA. Data presented as mean 
values ± SEM for biological replicates n=4-5, *p<0.05, ***p<0.001, ****p<0.0001 












Figure 19: HDM-induced glycolysis did not influence responsiveness to IL-33 
during allergic asthma pathogenesis. WT BALB/c mice were treated intra-nasally 
with rIL-33 to elicit experimental allergic asthma. The mice received either PBS (50 
μL) or rIL-33 (0.5 μg/50 μL) on day 0, 3 and 6. The mice were then grouped to 
receive H2O (50 μL) or DCA (5 mg/50 μL) treatment 1 hour prior to and once every 
8 hours after rIL-33 administration for 48 hours as shown in (A). 24 hours after the 
last rIL-33 treatment, mice were euthanized and rIL-33 induced airway responses 
was analyzed by measuring (B) AHR. Lung tissues were harvested and processed 
into single cell suspension for flow-cytometric analysis of (C) Th2 cell and (D) ILC2 
frequencies, and (E) IL-13 level in the BAL was determined by ELISA. Data 
presented as mean values ± SEM for biological replicates n=6, **p<0.01, ***p<0.001, 






Figure 19: HDM-induced glycolysis did not influence responsiveness to IL-33 






Chapter 6: Discussion and future research. 
 
6.1  Summary 
  Allergic asthma is a major public health problem affecting approximately 
300 million people worldwide [5]. Currently, individuals suffering from asthma 
primarily receive corticosteroids and β-agonists for immunosuppression and 
bronchodilation during an asthma attack [477]. However, these therapies are not 
effective in many asthmatics, and generally only offer temporary relief from the 
symptoms, rather than modifying the course of disease [478]. As a result, 
understanding the factors driving allergic asthma in susceptible individuals may 
lead to the development of more effective therapeutic approaches that might modify 
the natural history of the disease in all asthmatics. 
During the past few decades, our understanding of the pathogenesis of 
asthma has significantly increased. Substantial evidence suggests that aberrant 
type-2 immune responses to ubiquitous aeroallergens drive disease pathology in 
genetically susceptible individuals. Although the factors leading to such type-2 
cytokine skewed immune responses in asthma are not well understood, recent 
evidence suggests that elevated secretion of the type-2 promoting cytokine IL-33 
from the airway epithelium plays an important role in the initiation of the disease. 
Indeed, several lines of evidence support a major role for IL-33 in allergic asthma 
including the association of SNPs in Il33 and its receptor ST2/Il1rl1 with risk of 
developing asthma, elevated levels of Il33 expression in lung tissues from 





demonstrating the critical importance of IL-33 and ST2 in the development of the 
allergic airway inflammation [240, 382]. 
Despite strong evidence for the role of IL-33 in asthma susceptibility, little is 
known about its induction, especially by environmental stimuli such as allergens. 
Recent studies suggest that allergens may regulate the rapid release of IL-33 from 
airway epithelial cells [245, 249, 460] independently of effects on gene 
transcription. Although it has been postulated that allergens containing proteases 
may induce IL-33 release from the airway epithelium through activation of oxidative 
stress pathways, it is unclear whether all allergens elicit IL-33 release through a 
common mechanism involving proteases.  
The studies reported in this thesis have identified a novel mechanism by 
which the common allergen, HDM, causes the rapid increase of glycolysis in cultured 
airway epithelial cells, which is associated with the early release of IL-33 (Chapter 
3). Taken one step further, we provide substantial new information regarding the 
mechanisms of allergen-driven IL-33 release from epithelial cells and the pathways 
by which glycolysis contributes to this process. We propose that by recognizing 
certain components in HDM, the formyl peptide receptor 2 (FPR2) likely causes 
increased intracellular calcium flux and activation of Rac1, which activates 
cytoskeleton rearrangement and IL-33 release.  
As this process consumes large amounts of ATP, energy deprivation will 
lead to activation of AMPK to induce glycolytic flux, which in turn fuels the IL-33 
secretion process through the production of glycolytic ATP (Chapter 4). To further 





utilize an in vivo model of experimental asthma and demonstrate that inhibition of 
anaerobic glycolysis reduces airway epithelial cell release of IL-33 upon HDM 
exposure, which dampens the early recruitment and activation of ILC2s and 
diminishes allergic airway inflammation (Chapter 5). These in vivo data add 
considerable support for the concept that HDM regulation of cellular glycolytic 
pathways plays a pivotal role in IL-33 release and allergic asthma pathogenesis.  
Taken together, we have identified a novel mechanism by which HDM 
induces IL-33 release and the initiation of allergic asthma (Fig. 20). We confirm that 
HDM causes the rapid release of IL-33 independent of cell death or de novo protein 
synthesis and discover that allergen-driven changes in cellular glycolytic flux and 
glycolytic ATP facilitate IL-33 release. These studies have highlighted a previously 
understudied area-glucose metabolism-as an important direction for future study of 
allergic asthma pathogenesis. As the role of cellular glucose metabolic pathways 
have been recently revisited in many diseases and conditions such as cancer, our 
study provides additional evidence for its importance in human health.  
 
6.2  Caveats and future directions 
  Despite the advances in our knowledge of the mechanisms regulating IL-33 
release by airway epithelial cells reported in this thesis, several unanswered 
questions remain to be addressed. In the remainder of this chapter, we will discuss 
the caveats of our studies, the future directions of the current research, and the 






6.2.1 Detailed phenotyping of HDM-induced glycolytic flux is needed. 
  HDM exposure was found to induce a rapid increase in the glycolytic flux in 
airway epithelial cells. However, little is known about the long-term effects of 
elevated glycolysis on the airway epithelial phenotype. Recent studies have shown 
that PRR ligands induce different immediate and chronic metabolic alterations that 
play different roles in cells. For example, in bone marrow-derived DCs, researchers 
have shown that LPS causes a rapid induction of glycolytic flux, but no suppression 
of OXPHOS, to mediate DC activation [338]. However, exposure for periods longer 
than 12 hours causes the cells to utilize Warburg metabolism, a phenomenon in 
which cells rely mostly on glycolysis for glucose metabolism for their bioenergetics 
demand while OXPHOS is largely inhibited [337]. This begs the question of whether 
similar mechanisms exist in airway epithelial cells. If so, could these metabolic 
alterations be associated with the remodeling of the airway? In fact, studies have 
found that prolonged exposure to HDM resulted in an epithelial-to-mesenchymal 
transition in human bronchial epithelium [479], a process well known to involve 
glucose metabolic changes [480, 481]. In our studies, we have observed significant 
airway remodeling in the mouse lung after HDM exposure, which was significantly 
ameliorated by DCA treatment, supporting the hypothesis that modulating cell 
metabolism may affect the airway remodeling process. Taken together, examination 
of the long-term effects of allergen-induced alterations in glucose metabolism on 






6.2.2 The potential component(s) in HDM that induces IL-33 release and 
glycolysis needs to be identified. 
  Our data strongly suggest that the G-protein coupled receptor FPR2 
recognizes certain components of HDM and induces IL-33 release and glycolysis. 
Our data support a scenario in which FPR2 activation leads to increased intracellular 
Ca2+ levels and subsequent activation of cytoskeleton rearrangement, leading to IL-
33 translocation from the nucleus and secretion from the cells. However, direct 
evidence for this link is not provided in our studies. Studies designed to monitor (1) 
changes of intracellular Ca2+ fluctuation as well as (2) Rac1 activation and 
cytoskeleton rearrangement upon HDM exposure with and without FPR2 inhibition 
are needed to definitively prove this link. Moreover, even if we prove such a link, the 
potential ligands in HDM that activate FPR2 remain to be identified. FPR2 is widely 
recognized to trigger both pro- and anti-inflammatory responses depending on the 
nature of the ligands [416, 450], which can be either host-derived endogenous 
molecules or exogenous substrates. It has different receptor domains that recognize 
lipid and peptide/protein ligands [449, 450], such as lipid mediator lipoxin A4 
(LXA4) and the pro-Th2/Th17 acute phase protein SAA [451-454]. Thus, we 
hypothesize that HDM may contain FPR2 ligands or that HDM induces immediate 
host production of the ligands by epithelial cells, leading to autocrine actions on the 
epithelium and IL-33 release. Our current data suggest that blocking the peptide-
binding domain with WRW4 abrogated HDM induced IL-33 release and glycolytic 
flux. However, such inhibition may affect the conformation of FPR2 and the binding 





on the possible FPR2 ligands in HDM. To understand this, direct mass spectrometry 
analysis of HDM components should reveal the presence of FPR2 ligands or 
structurally similar substances. If we find no direct evidence for FPR2 ligands in 
HDM, the culture supernatants of airway epithelial cells exposed to HDM should be 
analyzed to determine whether HDM induces release of FPR2 ligands for its 
autocrine activation. 
 
6.2.3 The exact mechanisms of IL-33 release remain to be elucidated. 
In addition to the need for a more detailed understanding of the 
mechanisms by which HDM induces metabolic alterations, many questions remain 
regarding the mechanisms controlling IL-33 secretion. The current study strongly 
suggests that a HDM-induced increase in glycolytic flux facilitates IL-33 secretion. 
However, these data are not sufficient to pinpoint the exact pathways and processes 
regulating IL-33 release. Three main questions that remain to be answered are: 
what are the cytosolic compartments in which IL-33 resides? Which organelles 
participate in IL-33 translocation? What post-translational modifications are 
involved in IL-33 secretion? 
  As previously reviewed, IL-33 exhibits multi-compartmental localization 
inside cells [247]. Kakkar et al. reported that newly synthesized IL-33 was initially 
shuttled into the nucleus to associate with euchromatin, these molecules then 
utilized the nuclear pore complex to transit into the cytoplasmic space and reside in 
membrane-bound vesicles upon stress [247]. In our study, we confirmed that IL-33 





of IL-33 storage in the cytosol. Although our data implied that the IL-33 secreted 
from airway epithelial cells was derived from both nuclear and cytosolic 
compartments, direct evidence for the translocation is lacking. Considering these 
limitations and caveats, more detailed analyses of IL-33 intracellular localization 
(e.g. organelle(s) that stores IL-33, and organelle(s) that participates in IL-33 
translocation after HDM exposure) are needed.  
  It is currently proposed that cytokines lacking a conventional signaling 
peptide, such as IL-33, may be secreted by pathways independent of ER-Golgi-
mediated trafficking [440]. However, we were surprised to see that treatment of 
BEAS-2B cells with a specific inhibitor of vesicular traffic from the ER to the Golgi, 
Exo1 [423], also modulated HDM-induced release of IL-33 (Chapter 4). Normally, 
proteins are synthesized and assembled in the ER and then transported to the Golgi 
complex for further processing, sorting and packaging for secretion [482]. This 
process allows protein quality control, surface molecule export as well as post-
translational modifications to happen. Obviously, this process could also play a role 
in HDM-induced IL-33 release. Since IL-33 release is independent of de novo protein 
synthesis (Chapter 3), other functions associated with the ER-Golgi network, for 
example, post-translational modifications (e.g. cleavage) of IL-33 or other molecules 
involved in its translocation, might be required for IL-33 release, For IL-33 itself, 
multiple lines of evidence have suggested that it undergoes post-translational 
modification prior to secretion [243, 252]. Specifically, it has recently been shown 
that IL-33 requires proteolytic processing by calpain for maturation [243], and that 





pose even more questions: is glycolysis-facilitated IL-33 release restricted to the 
mature form of the protein? Since ER and Golgi are also membrane structures that 
may preferentially utilize glycolytic ATP, does increased glycolysis also contribute to 
the post-translational modification of IL-33? Furthermore, are there any other 
signaling molecules that undergo post-translational modifications required for 
HDM-induced IL-33 release? Future studies are required to explore these remaining 
questions.  
IL-33 was reported to undergo shuttling between cytosolic vesicles and the 
nucleus [247], probably because of its role in gene expression regulation. In fact, IL-
33 was considered a dual functional protein with an intracellular role as a 
transcriptional regulator [483] distinct from its extracellular cytokine properties. As 
a transcriptional repressor, studies have suggested that nuclear IL-33 sequesters 
nuclear NF-κB and reduces NF-κB–triggered gene expression [484]. This new 
finding may shed light on another perspective of HDM-induced IL-33 as turning on a 
series of inflammation-promoting signals in airway epithelial cells and contribute to 
allergic inflammation. According to this, the inducible expression of Il33 in immune 
cells such antigen presenting cells, mast cell and granulocytes could play regulatory 
roles that can be disturbed if IL-33 is released in response to external stimulation. In 
general, these data suggests that the release of IL-33 by various cells contributes to 
the development of allergic inflammation not only by its action as an extracellular 
cytokine, but also by activation of NF-κB and downstream signaling. 
 





We have identified a novel mechanism by which HDM induced glycolysis 
contributes to the live cell secretion of IL-33. Although our data strongly support 
this contention, future studies validating the current discoveries are needed. As 
discussed earlier, the specificity and effectiveness of certain inhibitors and siRNA 
used in this thesis remains to be proved. For example, Rac1-GTP activities and levels 
together with direct visualization of cytoskeleton rearrangement alterations should 
be tested respectively in cells treated with Rac1 inhibitors and siRNA. Intracellular 
calcium flux should be measured to reflect the effect of EDTA chelation, suramin 
inhibition of P2 purinergic receptors, as well as extracellular ATP. Analyses which 
allow us to visually track IL-33 translocation are needed in order to understand the 
effects we observed with ER-Golgi blockade. Furthermore, the successful blockade of 
AMPK signaling and TBK1 should be confirmed with the protein phosphorylation 
status and the protein levels.  
In addition, inconsistencies between our results and recent published data 
suggest that differences exist between different cell lines. The results of the current 
study remain to be reproduced in primary normal and asthmatic epithelial cells. 
Moreover, the transformed human airway epithelial cell line (BEAS-2B) that we 
utilized in the current studies limits the generalizability of the observed phenotype 
to human disease as the normal human epithelial layer contains multiple cell types 
[485], in which inter-cellular communication between cells play a critical role in 
airway function. Given this, future studies are needed to confirm the role of altered 
cellular metabolism on IL-33 secretion in more cell culture systems which allow for 





culture of primary human airway epithelial cells from asthmatic and healthy donors, 
and/or mouse epithelial cells. Besides replication of the discoveries in vitro, the 
pathways identified (e.g., Rac1, AMPK, etc.) should be tested for their involvement in 
allergic asthma pathogenesis in vivo using murine models. 
 
6.2.5 Future research for the role of HDM-induced glycolysis and IL-33 in 
allergic asthma in vivo. 
  Aside from the in vitro analysis of HDM-induced IL-33 release, our study 
using a murine model of experimental asthma provided strong evidence that HDM-
induced early increases in glycolysis and IL-33 production contributed to the 
pathogenesis of allergic asthma in vivo. Blocking HDM-induced glycolysis abrogated 
allergic airway inflammation by inhibiting IL-33 recruitment of ILC2s and its 
priming of type-2 immune responses by IL-13. However, we were unable to provide 
direct evidence that the lactate and IL-33 were derived mainly from airway 
epithelial cells. To further understand this, in vivo radioactive labeling of glucose as 
well as pulse labeling of IL-33 may provide some information for the major source 
of lactate and IL-33.  
In our study, DCA was given systemically to mice to inhibit glycolysis. This 
approach did not provide specific targeting of glycolysis in airway epithelial cells, 
and may complicate the interpretation of our data. Although we did show in the rIL-
33 induced allergic airway response experiment that DCA did not exhibit effects on 
downstream responses to IL-33, we cannot rule out the possibility that DCA also 





glycolysis in the airway epithelial cells, future studies using shRNA designed to 
express specifically in the airway epithelial cells to knock down PDK1 or LDH will 
moderately reduce glycolytic activity in these cells, and answer this question.  
Moreover, even though we have observed that IL-33 was sufficient to 
induce allergic airway responses, and recent literature suggest that it is necessary 
for the HDM-induced asthmatic phenotype in mice [486], whether epithelial cell 
derived IL-33 is necessary in our model remains to be proven. In order to determine 
this, the allergic phenotype should be examined in mice conditionally lacking IL-33 
in airway epithelial cells. 
 
6.3  Implications for human disease 
  The current study identifies a novel mechanism by which HDM exposure 
induces IL-33 release and allergic asthma pathogenesis. As previously mentioned, 
the understanding of allergic asthma pathology has grown robustly over the last few 
years, but the initiation of the disease remains poorly identified. Accumulating 
evidence has suggested a dominant role for airway epithelial cells and their release 
of type-2 immune response promoting factors such as IL-33 upon exposure to 
environmental stimuli. However, although many studies of the role of IL-33 in 
allergic inflammation have been conducted, a lot of questions remain to be 
answered: (1) what are the environmental factors inducing IL-33? (2) How is IL-33 
induced? (3) How to modulate the induction of IL-33? 
  We have provided answers to these questions. First, we have confirmed that 





considered causal to allergic asthma pathogenesis [30, 473], and its allergenicity is 
associated with the mites themselves as well as ligands derived from mite-
associated bacterial and fungal products [487]. Some mechanisms by which HDM 
induces allergic airway inflammation include cleavage of intercellular epithelial 
tight junctions by its protease component Der p 1 to allow allergen delivery to 
antigen-presenting cells [224], functional mimicry of Toll-like receptor complex 
protein by its component Der p 2 to confer intrinsic adjuvant activity [320], etc. 
Recent studies also identified that HDM sensitization was associated with Il33 
expression in the bronchial mucosa [488], and a murine model study of 
experimental asthma showed a significant role of IL-33 in HDM-induced allergic 
inflammation [489]. Another recent study also showed rapid induction of IL-33 
release by HDM [245], and our study further confirmed this observation, 
highlighting the potential of targeting HDM-induced IL-33 release in patients. 
  Second, we have identified a novel mechanism for IL-33 release in which 
HDM induces the rapid increase in glycolytic flux thereby facilitating IL-33 release. 
As the induction and secretion mechanisms of IL-33 have garnered great interest 
during recent years, much has remained unknown about the exact pathways. 
Although studies have identified that IL-33 release is mediated by nuclear pore 
complex, cytoskeleton and calcium [244, 245, 247], no conclusion has been made to 
connect these sporadic evidence pieces together, and systemic elucidation of 
secretory mechanism of IL-33 from airway epithelial cells has been lacking. Here we 
attempt to provide some insights from the perspective of cell metabolism, and show 





of cells for IL-33 translocation by cytoskeleton. As mentioned above, our data not 
only suggests potential pathways for IL-33 release, but also confirmed the 
importance of cell metabolism in allergic diseases. In fact, the significance of cell 
metabolism in the field of immunology is gradually being appreciated. Recent 
studies have shown that alterations of cellular metabolism direct essential pathways 
in immunology such as dendritic cell activation [338], macrophage polarization 
[490], and T cell differentiation [341]. Our study extended the knowledge of cell 
metabolism in health and disease to airway epithelial cells, adding to the current 
understanding of their important roles in immune response and allergic asthma 
pathogenesis.  
Most importantly, we showed that modulating cellular glucose metabolism 
was also capable of modulating IL-33 release in vivo, leading to reduced allergic 
airway responses via inhibition of ILC2 recruitment and its production of IL-13. The 
reduction in all aspects of allergic airway inflammation suggested blockade of 
disease initiation. This observation provides a potentially new avenue for the 
treatment of asthma attacks. The inhibitor utilized in the current studies, DCA, has 
been also used for clinical treatment of lactic acidosis [394, 395] and cancer [398], 
indicating its great potential for future clinical application in allergic asthma 
intervention. It is also worth noting that in our studies, DCA is mainly given during 
the initiation phases of allergic airway inflammation. In another study in which DCA 
was delivered throughout the allergen sensitization and challenge periods, DCA also 
reduced ragweed-induced allergic airway inflammation by inhibition of CD4+ T cell 





administration and its modes of action in vivo are still needed, our study suggest 
that DCA may be a potentially promising new therapeutic approach for the 
treatment of asthma. 
Our findings have implications beyond the context of allergic asthma. IL-33 
has been shown to play important roles in many diseases and conditions such as 
obesity, intestinal inflammation, and cancer [491], in which cellular metabolism may 
also play a role. Moreover, the pathways reported herein may apply to structural 
cell secretion of IL-33 in other organs. As such, the mechanisms identified in our 
model could be explored in other diseases and conditions in which IL-33 has been 
shown to play a role, and could be potentially exploited in cases where modulating 






6.4  Figures 
Figure 20: Schematic summary of epithelial cell metabolism in allergic asthma 
pathogenesis. HDM exposure activates FPR2 that is expressed by airway epithelial 
cells. FPR2 activation results in rapid mobilization of intracellular Ca2+ and rapid 
cytoskeleton rearrangements mediated by Rac1 to facilitate translocation and 
release of IL-33. This process rapidly consumed ATP presented in the cytosol, 
leading to altered AMP/ATP ratio and activation of AMPK signaling. The AMPK then 
led to an increase of glycolysis probably by promoting glucose uptake and glycolytic 
enzyme activities. This rapid increase of glycolysis then generates glycolytic ATP to 
facilitate the early release of IL-33. IL-33 recruits and activates ILC2s, the major 
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